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PERINATAL AND MATERNAL MORTALITY REVIEW COMMITTEE: 12th ANNUAL REPORT 1
The Health Quality & Safety Commission (the Commission) welcomes the 12th 
report of the Perinatal and Maternal Mortality Review Committee (the PMMRC). 
In this report, data on mortality of babies and infants from 2007 to 2016 
is presented, on mothers from 2006 to 2016, and on morbidity relating to 
neonatal encephalopathy from 2010 to 2016.
Once again the PMMRC has produced a comprehensive overview of maternal and neonatal deaths in 
this country. The death of a mother or a baby is a devastating loss, and this work to inform efforts to 
minimise the number of these tragic events is very important.
It is reassuring to see that the rate of stillbirth continues its downward trend, and the rate for maternal 
deaths has dropped, with a significant reduction over the past 10 years; however, there is still inequity 
in mortality outcomes for Māori, Pacific and Indian mothers. 
Sadly, there was no change in the overall neonatal death rate in New Zealand from 2007 to 2016, 
and, again, there is significant inequity in outcomes for Māori babies. 
The report highlights several areas that need to be addressed relating to the persistent inequities 
in relation to deprivation, ethnicity, and age. The PMMRC will work on better understanding these 
inequitable outcomes, to inform efforts by the health sector to address them.
The PMMRC has highlighted areas where mortality or morbidity were considered to be potentially 
avoidable – it is in these areas that the PMMRC can and will influence change through robust, practical 
and evidence-based recommendations to the health sector. 
This report would not be possible without the substantial contribution of a dedicated team of people: 
the local coordinators across the country who provide these data; Dr Sue Belgrave and the PMMRC 
members; the National Coordination Service, Auckland University; the New Zealand Mortality Review 
Data Group, Otago University; and the Mortality Review Committee staff at the Commission.
On behalf of the Commission, I sincerely thank the PMMRC Chair Dr Belgrave for leading this 
committee’s important work.
Foreword
Professor Alan Merry ONZM FRSNZ
Chair, Health Quality & Safety Commission
2
We acknowledge the grief of families and whānau who have lost babies and mothers in 2016. Each of 
the deaths reported represents the tragic loss of a loved child or mother. 
We report on perinatal deaths from 2007 to 2016, maternal deaths from 2006 to 2016, and babies 
with neonatal encephalopathy from 2010 to 2016. It is no longer possible to publish a comprehensive 
review of perinatal and maternal mortality on a yearly basis due to budget constraints. The PMMRC 
has decided to focus on a special topic each year with the publication of basic tables and figures with 
limited commentary on areas outside the special topic. Maternal mortality will be reviewed in depth 
every three years. We acknowledge the Accident Compensation Commission for their support of the 
Neonatal Encephalopathy data reporting to allow this to be presented as in previous years.
In 2016 there were two maternal deaths in New Zealand. For the first time since the PMMRC began 
reviewing maternal death in 2006 we report a statistically significant reduction in maternal mortality.  
Suicide continues to be the leading single cause of maternal death. The PMMRC welcomes the Ministry 
of Health extended funding for the Suicide Mortality Review Committee; however further work with the 
Ministry of Health is required to establish a Maternal and Infant Mental Health Network. It is imperative 
that mothers are able to access maternal mental health services that they need and that the care and 
services are equitable across the country. The UK has increased its funding of maternal mental health 
after considering the emotional and financial implications of maternal mental health on the health and 
outcome for the child (Bauer et al 2014), and we in New Zealand require the same level of commitment 
to tackle the issue of maternal mental health.
The perinatal related mortality rate in 2016 was 10.1 per1000 births. The statistically significant 
reduction in stillbirths reported in previous years continues.
In the PMMRC 12th Report the focus has been on neonatal mortality and neonatal encephalopathy 
(NE).
We have further explored neonatal deaths as it was noted in the 11th report that there had been no 
change in the overall neonatal death rate in New Zealand from 2007, while other countries had 
reported reductions in their neonatal death rates. 
This analysis of all neonatal deaths has highlighted inequity of outcome for babies born to women aged 
less than 20 years and to women of Māori, Pacific and Indian ethnicities especially for babies born at 
20 to 24 weeks gestation. This significantly higher rate of neonatal deaths persists after accounting for 
the effects of age, body mass index (BMI), socioeconomic status, parity, smoking, multiple pregnancy, 
baby sex, and year of birth. Inequity of outcomes by ethnicity will be explored further in the 13th 
report. 
Chair’s Introduction 
This is the 12th annual report of the Perinatal and Maternal Mortality Review 
Committee (the PMMRC) and my last as Chair. It has been a privilege to Chair 
the PMMRC over recent years. I strongly believe that it is only with complete 
accurate data of perinatal and maternal death with informed analysis that we  
 can make recommendations for change and monitor outcomes for women and 
their babies over time.
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Birth in a tertiary centre is known to be associated with improved outcomes for early preterm babies. 
The PMMRC has recommended that strategies be developed to address inequities in care, and in 
access to tertiary care, for all women in early preterm labour, or who require delivery prior to 25 
weeks, to achieve equity in outcome. 
This year the babies diagnosed with Neonatal Encephalopathy (NE) were matched to their National 
Maternity Collection (MAT) record, which allowed for further analysis of associations of NE with 
smoking, BMI, parity, and customised birthweight centile. This analysis showed a relationship between 
parity and NE rates, an increase in risk of NE with increasing BMI and an increase in risk of NE for 
babies born small for gestational age. 
The findings of a review of NE associated with acute peripartum events, completed for 47 babies 
diagnosed with NE from 2013 to 2015, are presented. In two-thirds of the cases, the mortality 
or severity of the morbidity were considered potentially avoidable. This highlights the need for 
multidisciplinary education on the prevention and recognition of NE and regular neonatal resuscitation 
training for all health care professionals involved in providing peri-partum care. The PMMRC 
acknowledge the support of ACC which contributed funding for the case review of NE associated with 
acute peripartum events.
As well as acknowledging the grief of the families and whānau, we would also like to acknowledge 
how difficult it is for clinicians who are impacted by the deaths of the women and babies they have 
cared for.
Dr Sue Belgrave




It is my great honour to be asked to be the voice on behalf of bereaved parents, families and whānau 
as a member of the PMMRC. My name is Lisa Paraku. I hail from the beautiful Hauraki and I stand on 
behalf of my daughter Jasmine Lee, who was born perfect and still in 2006, her four siblings who died 
in early pregnancy, and my two sons who lived. I have been part of the Sands whānau since 2006, first 
as a consumer of Sands support services and later as a committee member and provider of the same 
services that my whānau remains grateful for.
To my fellow bereaved parents, families and whānau, can I offer the following mihi (greeting) to you: 
Me mihi aroha nui ki a koe me tō whānau whānui – My love to you and to your entire family. 
E ngā pēpē, moe mai rā – I acknowledge our precious babies, our grief and our journey.
I stand proud on behalf of your voice and I thank you for having me. I trust I represent you when I 
say that our hope following the loss of our precious pēpē or māmā is ‘to be seen’ – to be listened to, 
understood and cared for in the way that we need, so that our grief journey can be a little more gentle. 
To you, the good people of our New Zealand health system, I salute you and thank you for serving us. 
We are grateful and we would like to continue connecting with you so that our mutual experience is 
positive. 
It is my greatest hope that the incredible work delivered by the collective expertise of the PMMRC and 
our wider support network is acknowledged and that their recommendations are actioned with priority 
by the government agencies that exist to serve the health and wellbeing of our New Zealand people. 
I ask this so that we, the parents, families and whānau, can experience a grief journey that is more 
gentle or so the resulting changes may save the lives of some of our pēpē and māmā.
The PMMRC report and its recommendations have been available since 2009 and we have seen some 
really positive change; however, an area that is particularly close to my heart is being highlighted 
again and again by our data. Along with the very valuable health practice point recommendations 
that this report delivers, there remains an alarming pattern of inequities in health care outcomes for our 
Māori, Pacific and Indian māmā and those who are under 20 years of age. 
In my humble opinion, these priority populations need ‘to be seen’. Can I be so bold as to ask on 
behalf of parents, whānau and families, that all of us who serve within our health system ask a simple 
question: Does this practice, policy, process serve this person(s)? Do I understand this person’s world 
view and circumstance? If the answer is no, then let’s reach out, start a conversation and continue 
to learn. Let’s ask that cultural competency training in all priority populations is made a priority, that 
training and guidance is provided to all of us to identify implicit and explicit bias that shapes how we 
serve within our own systems, and when we are clear, then we, within our own sphere of influence, 
effect change, and together we shape our health system so that the ultimate goal can be achieved: 
equitable health outcomes for all. 
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I continue to tautoko (support) my predecessors’ tono (requests):
I tautoko the voice of Linda Penlington (PMMRC 2016) regarding the value of post-mortem information, 
which has helped us at the PMMRC make recommendations that have seen positive change. We 
continue to see our Māori and Pacific people being less likely to agree to post-mortem for a variety of 
reasons. I wonder what we could do to make this process agreeable to our Māori and Pacific peoples 
and I remain hopeful that their voices, some of which are documented within the body of this report, 
are listened to and change is made so that post-mortem information in these priority populations can be 
gathered and shared to assist our grief journey and also to help others in similar situations.
I reiterate the voice of Vicki Culling (PMMRC 2012) that support service availability and access for our 
bereaved parents, families and whānau is so incredibly important during our grief journey. The deep 
grieving that is inevitable when we lose our most precious taonga, our pēpē and sometimes our māmā, 
can be made more gentle with support service guidance. Part of Vicki’s request remains relevant today:
a. A more active connecting of bereaved mothers and families to support agencies (such as Sands) 
by health and caring professionals would be beneficial, rather than leaving families to do this on 
their own. 
b. A maternity service that is reliant on the unpaid voluntary services in the community to provide 
the majority of quality support to bereaved parents, families and whānau is a sad indictment 
on our attitudes towards perinatal loss. Perhaps this first step towards understanding the impact 
of such a loss, in the form of the Bereaved Mothers Survey, will lead to better support and 
information for this vulnerable part of our population. 
I close with a simple ask, that we all consider the guidance of my elders and achieve ‘kanohi kitea’, 
for our people to be seen, connected and empowered. To my bereaved parents, families and whānau, 
I trust the voice in these words in some way connects with you, and to my health professional whānau, 
we are grateful for you and we thank you. Together we can be better. 
Nāu te rourou, nāku te rourou, ka ora ai te iwi. 
With your knowledge and my knowledge, together we will all be well.
Nō reira, tēnā rā koutou katoa,
Lisa Paraku
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68 babies of all babies born from 
2007 to 2016 died from sudden 
unexpected death in infancy (SUDI) 
before they were 4 weeks old.
Babies should sleep in their own 
bassinet, wahakura or Pēpi Pod, on 
their back, with no pillow.
  Please ask your midwife, doctor or 
nurse for a bassinet, wahakura or 
Pēpi Pod if you do not have one for 
your newborn baby.
Information for women, families and whānau about 
deaths of newborn babies in New Zealand 2007–2016
Approximately 70 babies die each 
year in New Zealand from being born 
prematurely from 20 to 24 weeks.
Being born early is the most 
common cause of death of babies.
  New Zealand needs a premature 
birth prevention initiative to help 
women avoid a premature birth. 
3 out of 10 babies born alive 
without a birth defect at 23 weeks 
were alive at 4 weeks of age. 
7 out of 10 babies born alive without 
a birth defect at 24 weeks were alive 
at 4 weeks.
Some babies born at 23 and 24 
weeks may have disabilities.
Of the 729 babies who died from 
2007 to 2016 due to being born 
too early (from 20 to 24 weeks), 119 
babies were born to mothers who 
had already had a baby born early.
Mothers who have already had a 
baby born early are more likely to 
have another early baby in future 
pregnancies.
Babies born from 23 to 26 weeks 
were more likely to be resuscitated 
and to survive if the babies were 
born in hospitals with a neonatal 
intensive care unit.
Mothers who are younger than 20 
years old and Māori mothers were 
more likely to have their babies in 
hospitals or birthing units without a 
neonatal intensive care unit.
  Parents, families and whānau 
need enough information about 
their baby’s chance of survival 
or disability to help them make 
decisions about their baby's care.
  There is treatment that can start 
early in your pregnancy to help 
stop your baby being born early. 
Please ask your midwife what you 
can do to stop your baby being 
born early.  
Sudden unexpected death in infancy (SUDI)
Babies born too early who have died
Please call your midwife, doctor 
or local hospital if you have signs 
and symptoms of early labour so 
you can receive care and transfer to 
a hospital with a neonatal intensive 
care unit if required.
Findings from 
the Committee
What women, families 
and whānau need to 
know
Babies born at 23 to 26 weeks 
have the best chance of survival if 
born in a hospital with a neonatal 
intensive care unit eg Auckland, 
Middlemore, Waikato, Wellington, 
Christchurch and Dunedin.
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Executive Summary
Significant changes to the 12th report
The 12th report has a new format from previous reports. It addresses neonatal mortality and neonatal 
encephalopathy in depth. The perinatal mortality section includes a slightly reduced selection of tables 
and figures compared to previous years. Maternal mortality includes a core selection of tables and 
figures only. Both of these sections include limited commentary that aims to address any new data or 
issues of particular importance in the current year. The PMMRC plans to analyse and report maternal 
mortality in detail every three years. Specific topics will be chosen each year for in-depth analysis 
and commentary. Maternal morbidity is reported in a separate document, which will be published on 
the Health Quality & Safety Commission website (www.hqsc.govt.nz/our-programmes/mrc/pmmrc/
publications-and-resources/publication/3369/). 
Limited methods and definitions have been included in this document in appropriate chapters. A key 
to the datasets and mortality rates can be found in "Appendix D: Key datasets and definitions in the 
PMMRC 12th report". A comprehensive methodology and definitions document can be accessed at 
www.hqsc.govt.nz/our-programmes/mrc/pmmrc/publications-and-resources/publication/3367/.
Definitions used by the PMMRC
Fetal death is the death of a fetus at 20 weeks gestation or beyond (≥20 weeks) or weighing at least 
400g if gestation is unknown. Fetal death includes stillbirth and termination of pregnancy.
Termination of pregnancy includes any interrupted ongoing pregnancy from 20 weeks (whether the 
baby was stillborn or live born).
Neonatal death is the death of any baby showing signs of life at 20 weeks gestation or beyond or 
weighing at least 400g if gestation is unknown that occurs up until midnight of the 27th day of life. 
Early neonatal death is a death that occurs up until midnight of the sixth day of life. Late neonatal 
death is a death that occurs between the seventh day and midnight of the 27th day of life.
Perinatal mortality is fetal and early neonatal death from 20 weeks gestation (or weighing at least 
400g if gestation is unknown) until midnight of the sixth day of life.
Perinatal related mortality is fetal deaths (including terminations of pregnancy and stillbirths) and 
neonatal deaths (up to midnight of the 27th day of life) per 1000 total babies born at 20 weeks or 
beyond, or weighing at least 400g if gestation was unknown.
A maternal death is the death of a woman while pregnant or within 42 days of termination of 
pregnancy (miscarriage, termination or birth), irrespective of the duration and site of the pregnancy, 
from any cause related to or aggravated by the pregnancy or its management. It does not include 
accidental or incidental causes of death of a pregnant woman.
Maternities are all live births and all fetal deaths at 20 weeks or beyond or weighing at least 400g if 
gestation is unknown. The maternal mortality ratio is calculated per 100,000 maternities.
Neonatal Encephalopathy is a clinically defined syndrome of disturbed neurological function within 
the first week of life, manifested by difficulty in initiating and maintaining respiration, depression of 
tone and reflexes, subnormal level of consciousness and often seizures.
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12th report highlighted findings
Special topic: Neonatal mortality
Neonatal mortality has not reduced in New Zealand in the last 10 years as it has in other countries we 
compare our outcomes to such as the UK and Australia. The neonatal death rate was 2.6/1000 live 
births in 2007 and 2.5/1000 live births in 2016.
The majority of the analyses in the neonatal mortality chapter excluded babies born with congenital 
anomalies. 
At 23 weeks gestation, resuscitation was attempted for 59 percent of live born babies without 
congenital anomalies and of these, 50 percent survived to 28 days. At 24 weeks gestation, 
resuscitation was attempted for 96 percent of live born babies without congenital anomalies and of 
these, 73 percent survived to 28 days.
Survival to 28 days of live born babies without congenital anomalies was 30 percent at 23 weeks and 
70 percent at 24 weeks gestation.  
Antenatal corticosteroids were less often given to mothers of babies who died after birth at 23 weeks 
than at 24 weeks. 
Survival of live born babies from 23 to 26 weeks gestation was statistically significantly higher for 
babies born at tertiary units than babies born at secondary units, and significant differences were found 
in survival between tertiary units in New Zealand. 
There were significantly higher neonatal death rates for babies without congenital anomalies of Māori, 
Pacific and Indian mothers compared to mothers of Other Asian, Other European and New Zealand 
European ethnic groupings.
After accounting for the effects of maternal age, body mass index (BMI), socioeconomic status, parity, 
smoking, multiple pregnancy, baby sex, and year of birth, there remained a higher risk of death after 
birth at 20 to 24 weeks gestation among babies of Māori, Pacific and Indian mothers, which suggests 
that there were other factors increasing risk for these women. The most common cause of neonatal 
death at 20 to 24 weeks gestation, responsible for almost 600 deaths in the 10 years from 2007 to 
2016, was extreme prematurity. 
More babies of Māori, Pacific and Indian mothers are born extremely preterm and so these ethnic 
groups are disproportionately affected by suboptimal care for mothers and babies at these gestations. 
This is compounded if there are also inequities in provision of care by ethnicity.
The in-depth analysis identified inequities by ethnicity and by maternal age (<20 years) in a number 
of care areas affecting neonatal survival. These related to access to antenatal care, access to tertiary 
neonatal facilities, treatment with antenatal corticosteroids, and attempted resuscitation at extreme 
preterm gestations. An analysis of care pathways was not undertaken. However, inequities by ethnicity 
are increasingly found in health care both in New Zealand and overseas, and are associated with 
implicit bias and racism. Therefore, the PMMRC has tried to address this issue in its recommendations 
along with trying to promote improvement strategies that might engage with priority population service 
users and their needs.
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Neonatal encephalopathy
The PMMRC has been reporting data related to babies with moderate and severe neonatal 
encephalopathy (NE) since 2010. Fewer term babies were diagnosed with NE in 2016 (1.0/1000 
term births) than in 2010 (1.4/1000), however this was not a statistically significant difference.
The Neonatal Encephalopathy Working Group (NEWG) has been encouraging district health board 
(DHB) local review of babies diagnosed with NE, and a survey of 2016 cases found 75 percent of 
cases were reviewed, although only 64 percent were reviewed with a multidisciplinary methodology. 
A multivariable analysis is planned for 2018-2019 to investigate the independent predictors of NE 
among babies born at term now that data on NE cases have been merged with data from the national 
maternity collection (MAT).
Acute peripartum events, such as placental abruption and shoulder dystocia, were reported in 22 
percent of babies diagnosed with NE from 2012 to 2016. In 2016, the NEWG reviewed a series of 
47 babies with NE from 2013 to 2015 following an acute peripartum event. In two-thirds of the cases 
reviewed, the mortality or severe morbidity were considered potentially avoidable. Further detail of the 
review findings is provided in the neonatal encephalopathy chapter.
In 2016, 79 percent of babies born at term with moderate or severe NE were treated with induced 
cooling, and of those cooled, 77 percent were cooled within six hours of birth as recommended 
for maximal benefit. Of the 12 babies not cooled in 2016, two may have benefitted from cooling. 
Neonatal observation of babies with risk factors for NE and increased assessment of babies identified 
with probable asphyxia at birth were highlighted to optimise care. 
Perinatal mortality
The perinatal related mortality rate, which includes all deaths from 20 weeks gestation to 27 days of 
life, was 10.1/1000 total births in 2016. While there has been no statistically significant reduction in 
perinatal related mortality overall since 2007, there has been a significant reduction by 11 percent in 
stillbirth rate from 5.7/1000 births in 2007 to 5.1/1000 births in 2016. 
The PMMRC were able to define denominator data for small for gestational age babies (using 
customised birthweight centiles) for the first time this year using the New Zealand Maternity Collection 
(MAT) dataset. There was a statistically significant reduction in small for gestational age babies born 
from 2008 to 2016 and a statistically significant reduction in perinatal related mortality among small 
for gestational age babies.
Of note, the number of mothers aged under 20 giving birth in New Zealand has reduced by 50 
percent from 2007 to 2016. However, in this time, there has been a significant increase in perinatal 
related mortality among mothers aged under 20 giving birth. Mothers under 20 years of age are at 
higher risk of perinatal related death from spontaneous preterm birth, antepartum haemorrhage, and 
perinatal infection than any other age group. 
Maternal mortality
There has been a statistically significant reduction in maternal mortality in New Zealand from 2006 to 
2016.
The maternal mortality ratio for the three years from 2014 to 2016 was 9.4/100,000 births at 20 
weeks or beyond. This is the lowest ratio for a three year period since the PMMRC began reviewing 
maternal deaths in 2006. 
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Maternal suicide is the leading cause of maternal mortality in New Zealand. The rate of maternal 
suicide in New Zealand is seven times the rate in the United Kingdom. Māori women are over-
represented among maternal suicides. Between 2006 and 2016, 16 (57 percent) of 28 women who 
died by suicide in pregnancy or within six weeks of pregnancy were Māori.
Following review of maternal mortality, emerging themes and practice points are identified to support 
clinical improvement. In this report, an emerging theme is the need for a consistent approach to the 




1. The PMMRC recommends the Ministry of Health establish a multidisciplinary working group to 
review current evidence for implementation of a preterm birth prevention program such as that 
implemented in Western Australia, taking care to:
a. identify and adequately resource evidence-based solutions 
b. ensure equitable access to screening and/or treatment for priority populations
c. ensure that priority populations have a voice in the development of health policy, process and 
practice in order to achieve equitable health outcomes
d. ensure that the outcomes of any implemented program, including equity of access, are 
evaluated.
2. Women with a previous preterm birth at less than 34 weeks are at increased risk of neonatal death. 
The PMMRC recommends that LMCs and DHBs employ strategies to reduce preterm birth by 
targeting this high-risk group, including:
a. counselling at the time of a preterm birth to outline the strategies likely to be recommended for 
their next pregnancy, and advice to present for antenatal care as soon as they know they are 
pregnant
b. ensuring that antenatal care is available to allow women to register as early as possible, and 
ensuring that early antenatal care includes attention to modifiable risk factors such as smoking, 
sexually transmitted infections, and urinary tract infections 
c. ensuring referral for specialist consultation in the first trimester to facilitate discussion of 
treatment options, which might include cervical cerclage or vaginal progesterone treatment and 
monitoring of cervical length using transvaginal ultrasound 
d. counselling around signs and symptoms of preterm birth and how to respond to these to optimise 
outcome.
3. Birth in a tertiary centre is associated with improved outcomes for preterm babies at the lower limits 
of viability (prior to 25 weeks gestation). 
The PMMRC recommends the Ministry of Health leads the development of a national consensus 
pathway for the care of women in preterm labour or requiring delivery prior to 25 weeks gestation. 
The PMMRC recommends this pathway includes:
a. ensuring that all groups of women (irrespective of ethnicity, age, socioeconomic status or place of 
residence) are offered and provided the same level of care
PERINATAL AND MATERNAL MORTALITY REVIEW COMMITTEE: 12th ANNUAL REPORT 11
b. strategies for secondary units for management of women in threatened or early preterm labour, 
or who require delivery, prior to 25 weeks gestation. Including:
i.  administration of corticosteroids and magnesium sulphate 
ii. timely transfer from primary and secondary units to tertiary units 
iii. management of babies inadvertently born in their units at the lower limits of viability
c. ensuring that priority populations have a voice in the development of health policy, process and 
practice in order to achieve equitable health outcomes
d. guidance on monitoring that care provision is equitable by ethnicity, age, socioeconomic status 
and place of residence.
4. The PMMRC recommends DHBs make available appropriate information, including appropriate 
counselling, for parents, families and whānau about birth outcomes prior to 25 weeks gestation to 
enable shared decision making and planning of active care or palliative care options. 
5. The PMMRC recommends that DHB maternity services audit the rates of antenatal corticosteroid 
administration, including repeat doses when indicated, to mothers of neonates live born at less than 
34 weeks gestation, including auditing whether administration is equitable by ethnicity, DHB of 
residence, and maternal age. 
6. The PMMRC recommends that tertiary obstetric and neonatal intensive care units investigate and 
address the difference between units in survival rates amongst infants born at 23 to 26 weeks 
gestation as part of their benchmarking and quality and safety initiatives. 
7. The PMMRC recommends that regulatory bodies require cultural competency training of all 
individuals working across all areas of the maternity and neonatal workforce. Training should 
address awareness of, and strategies to reduce and minimise the impact of, implicit bias and racism.
8. The PMMRC recommends that the Ministry of Health and DHBs have a responsibility to ensure that 
midwifery staffing ratios and staffing acuity tools: 
a. enable active observation of mothers and babies who are undertaking skin-to-skin contact in the 
postnatal inpatient period 
b. allow for the identification of, and additional needs of, mothers who have increased risk factors 
for sudden unexpected death in infancy (SUDI).
9. The PMMRC recommends that lead maternity carers (LMCs) and DHBs ensure that every baby will 
have access to a safe sleep place on discharge from the hospital or birthing unit, or at home, that is 
their own place of sleep, on their back and with no pillow. If they do not have access to a safe sleep 
place, then a wahakura or Pēpi-Pod®1 must be made available for the baby’s use prior to discharge 
from hospital. 
Neonatal encephalopathy recommendations
10. The PMMRC recommends that DHBs with rates of neonatal encephalopathy significantly higher than 
the national rate review, or continue to review, the higher rate of neonatal encephalopathy in their 
area and identify areas for improvement.
1  A Pēpi-Pod® is a plastic box with a well-fitting mattress in the bottom. As well as the sleep space, these devices are always provided with safe sleep messaging.
12
Perinatal mortality recommendations
11. Maternity and primary care providers need to be aware of the increasing risk of perinatal mortality 
for mothers under 20 years of age in New Zealand. Inequity in perinatal mortality for babies born 
to mothers under 20 years of age needs to be actively addressed. 
The PMMRC recommends the Ministry of Health and DHBs:
a. develop, in consultation with young mothers, acceptable and safe methods for mothers under 20 
years of age to access and engage with care in order to achieve equitable health outcomes
b. identify and adequately resource evidence-based solutions to address risks for mothers under 
20 years of age, paying attention to smoking cessation, screening and treatment for infections, 
screening for fetal growth restriction, and providing adequate information about the causes and 
symptoms of preterm labour
c. consider how they can support LMCs caring for mothers aged under 20 years.
12. The PMMRC recommends that DHBs with rates of perinatal related mortality significantly higher than 
the national rate review, or continue to review, the higher rate of mortality in their area and identify 
areas for improvement. 
Maternal mortality recommendations
Maternal and Infant Mental Health Network 
The 10th PMMRC report recommended that a Maternal and Infant Mental Health Network be 
established to provide an interdisciplinary and national forum to discuss perinatal mental health issues 
(PMMRC 2016). This work has progressed to development of service specifications for the network. We 
strongly reiterate the previous recommendation:
13. The PMMRC recommends that a Maternal and Infant Mental Health Network is funded by the 
Ministry of Health and that the network then determine an achievable work stream by the end of 
2018 detailing work to be completed by the end of 2020, to include as potential areas of priority: 
a. a stocktake of current mental health services available across New Zealand for pregnant and 
recently pregnant women to identify both the strengths of services and gaps or inequity in 
current services and skills in the workforce 
b. a national pathway for accessing maternal mental health services, including: 
i.  cultural appropriateness to ensure of service access and provision
ii. appropriate screening 
iii. care for women with a history of mental illness
iv. communication and coordination.
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Summary of Key PMMRC 11th Report Recommendations and Progress
Recommendation (PMMRC 11th report) Progress to date (updated 2018)
Epidemiology
The Mortality Review Committees’ Māori Caucus reiterate, ‘As 
a matter of urgency, the Ministry of Health update the National 
Maternity Collection (MAT), including the ethnicity data as 
identified by the parents in the birth registration process.’ (PMMRC 
recommendation ninth report 2015)
The Ministry of Health has updated the MAT with ethnicity data as 
identified by parents during the birth registration process (sourced 
from Births, Deaths and Marriages (BDM)) for babies born in 2016 
and 2017. The Ministry expects to complete the updating of live born 
baby records for babies born from 2012 to 2015 by June 2018.
Update 2018
The PMMRC recommends the Ministry of Health:
a. urgently require DHBs to provide complete and accurate 
registration data to the MAT dataset (as required of LMCs 
providing services to pregnant women in order to receive 
funding for those services). Specifically this should include 
women who present for birthing at DHB facilities without 
previous antenatal LMC registration and women who are 
provided primary maternity care by DHB maternity services
b. require that the MAT dataset include complete registration 
and antenatal data on live and stillborn babies from 20 
weeks gestation (including terminations of pregnancy).
Ministry of Health 
The Ministry of Health has advised it is looking to extend the National 
Maternity Record to feed all information into the MAT. The National 
Maternity Record includes antenatal, postnatal and neonatal care. 
To ensure maternity care records are consistent and completed across 
different care providers and regions, the Ministry is reviewing the 
Health Information Standards Organisation (HISO) standard set in 
relation to maternity care. This will be defined and agreed by the end 
of 2018. 
The Ministry is working with DHBs on the BadgerNet Maternity system 
to transfer data collected as part of the DHB primary maternity service 
to the MAT. This will improve the data completeness for women who 
receive primary maternity care from DHBs.
National Maternity Monitoring Group (NMMG)
The NMMG has asked the Ministry of Health to help prioritise and 
implement recommendations regarding the MAT dataset, and has 
written to DHBs asking that they take all steps possible to support the 
implementation of the recommendations.
Update 2018
Perinatal mortality
The PMMRC investigate why there has been no reduction in 
neonatal mortality in New Zealand.
Neonatal mortality is the focus of the special topic in this report.
The PMMRC supports the development of a national 
interdisciplinary clinical practice guideline on the indications and 
timing for induction of labour, to guide clinicians to offer induction 
when appropriate (that is, where evidence shows that benefit to 
mother and/or baby outweighs risk) and to avoid induction when 
not appropriate.
An interdisciplinary guideline for the indications and timing of 
induction of labour is currently in development. 
The group is using the Appraisal of Guidelines for Research and 
Evaluation (AGREE) tool to guide the guideline development and 
will ask the NMMG to ratify the guideline as a national one upon 
completion.
The Ministry of Health will consider their decision and, if accepted, 
publish the guideline on the Ministry website as national guidance.
Update 2018 
That district health boards with rates of perinatal related mortality 
and neonatal encephalopathy significantly higher than the national 
rate review, or continue to review, the higher rate of mortality or 
morbidity in their area and identify areas for improvement.
Counties Manukau DHB – significantly higher rate of perinatal 
related mortality, significantly higher rate of stillbirth and neonatal 
death than the national rate. 
Waikato DHB – significantly higher rate of neonatal death and 
neonatal encephalopathy than the national rate. 
Perinatal related mortality rates
Counties Manukau 
Counties Manukau Health is committed to ensuring women get early 
access to quality maternity care. The Maternity Quality Workplan 




Counties Manukau DHB continues to highlight the impact the 
upstream determinants (such as income, education and housing) 
have on a range of health outcomes and continue to work with the 
Ministry of Health to explore these relationships more fully. 
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Recommendation (PMMRC 11th report) Progress to date (updated 2018)
Neonatal mortality rates
Waikato 
A multi-disciplinary team reviews each neonatal death. The team note 
learning points from the death and make individual recommendations 
for the women. This case review session forms the basis of information 
for:
• the follow-up appointment with the family/whānau
• presentation to the monthly mortality meeting of health care 
professionals
• reporting to the DHB mortality meeting.
As appropriate, any teaching topics or contributing factors to the case 
are added to the ‘Sharing the Learning’ electronic newsletter.
Each case is added to a database so the team can identify themes 
and link to a programme of work or identify a new programme of 
work in the DHB Maternity Quality and Safety Programme.
The multi-disciplinary team continues to review all cases of NE cared 
for in the Neonatal Intensive Care Unit.
Update 2018 
Maternal mortality 
The PMMRC recommends the Health Quality & Safety Commission 
establish a permanent Suicide Mortality Review Committee.
The Ministry of Health has agreed to extend its funding for the Suicide 
Mortality Review Committee.
Neonatal encephalopathy 
That district health boards with rates of neonatal encephalopathy 
significantly higher than the national rate review, or continue to 
review, the higher rate of morbidity in their area and identify areas 
for improvement.
Taranaki 
Taranaki DHB reviews all unexpected admissions to the neonatal 
unit; this includes cases of NE. 
Current quality improvement initiatives include:
• improvements to the obstetric emergency call system 
• multidisciplinary training in obstetric emergencies for all 
clinicians at both Taranaki Base and Hawera hospitals
• Royal Australian and New Zealand College of Obstetricians 
and Gynaecologists (RANZCOG) fetal surveillance training
• newborn life support training (New Zealand Resuscitation 
Council) 
• local NE workshop on 27 April 2017
• education on recognition of NE and cooling management
• Growth Assessment Protocol (GAP) on recognition and 
management of small for gestational age babies.
Taranaki DHB will continue to monitor and review all NE cases and 
implement quality improvements where indicated.
Capital & Coast 
Capital & Coast DHB continues to review all term infants diagnosed 
with NE in 2016.
Update 2018
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Recommendation (PMMRC 11th report) Progress to date (updated 2018)
Recommendations from the Mortality Review Committees’ Māori Caucus
Māori Maternal Death by Suicide
Improved awareness and responsiveness to the increased risk for 
Māori women
Primary care (general practitioners (GPs), Family Planning 
Association (FPA)), LMCs, termination of pregnancy (TOP) services, 
alcohol and drug services, and secondary and tertiary providers 
of maternity, obstetric, mental health, and maternal mental health 
services should improve their systems, guidelines and professional 
development to ensure that they are responsive to the identified 
increased risk for Māori women.
Risk assessment 
Comprehensive assessment of risk factors for Māori women 
should be undertaken at diagnosis of pregnancy and/or on first 
presentation for antenatal care. This should be undertaken for all 
Māori women, regardless of age, including those who are seeking 
termination of pregnancy.
Management
Where Māori women exhibit symptoms suggesting serious mental 
illness or distress, an urgent mental health assessment, including 
consultant psychiatrist review and consultation with perinatal mental 
health services, on the same day these symptoms are first noted 
should be undertaken.
Māori women who have a history of serious mental illness and are 
currently well should be referred to specialist mental health services 
for a mental health birth plan, and monitored closely by their 
maternity care provider +/- mental health services. Where such a 
woman has a miscarriage, the GP should be notified immediately 
and an explicit process for early follow up that includes a review of 
mental health status agreed with the GP.
The referring doctor of women who undergo a TOP is expected to 
provide a free post-TOP follow-up consultation 10–14 days after 
the procedure (Abortion Supervisory Committee 2009, Standard 
79). The referring doctor should actively follow up Māori women 
referred for TOP to ensure this consultation is completed and review 
mental health status during this consultation.
Communication and coordination 
Communication and coordination between primary care (GPs, FPA), 
LMCs, TOP services, alcohol and drug services, and secondary 
providers of maternity, obstetric, mental health, and maternal mental 
health services should be improved and enhanced using a variety 
of means including but not limited to case management, integrated 
notes systems, and electronic transfer of information.
New Zealand Nurses Organisation, Te Rūnanga o Aotearoa further 
supports the 11th report recommendations, and believes these issues 
still remain relevant: 
1. An explicit recommendation is required to ensure health 
professionals have a higher level of cultural awareness and 
competence.
2. Risk assessment is imperative. Professionals doing this must have 
an understanding of Māori models of wellbeing, including social 
context.
3. Management is a complex situation. It should not be the sole 
responsibility, or expected of, professionals who may have 
limited time and may not be the most culturally appropriate. 
4. Communication is an imperative area for ongoing development. 
The College of Nurses Aotearoa (NZ) further endorses the 11th report 
recommendations and supports the development of much needed 
guidelines based on current evidence to reduce these worrying 
statistics. The College will disseminate the PMMRC findings further 
throughout the nursing workforce, and promote them with college 
members and on their website, to inform members of the importance 
of the PMMRC recommendations in supporting nursing care and 
support for Māori women.
The Royal New Zealand College of General Practitioners The College 
team responsible for updating the General Practice Education 
Programme curriculum development has been alerted about the 
increased risk of maternal suicide for Māori women, and are 
considering adding the Eleventh report to the online learning platform 
for GP registrars.
The College acknowledges the need to raise awareness among GPs 
about the increased mental health risk for Māori women. However, 
their standard 15-minute consultation, does not allow sufficient time 
to discuss pregnancy-related medical issues and mental health; 
some DHBs and PHOs do have funded extended GP appointments 
for patients identified as experiencing serious mental illness or 
addiction. It may be useful to explore whether fully funded extended 
appointments should be introduced to support routine mental health 
screening for all pregnant Māori women. There is a variability in 
the experience of GPs when referring women to an appropriate 
health provider; some of our members generally have good access 
to maternal mental health team and other secondary care services, 
others highlight poor access and delay in accessing the secondary 
care. Women in all areas should have access to necessary care and 
would support any initiative to improve the access to secondary care.
Free post-TOP consultation - there is a variability in women returning 
to the referring doctor for a free post-termination of pregnancy 
(TOP) consultation; not many women return for a post termination 
check-up which indicates the need to actively follow up with women 
who undergo a TOP; also, the timeframe to provide the post TOP 
consultation is narrow, which limits the opportunity to review mental 
health status of Māori women.
Monitoring Māori women with a history of serious mental illness - GPs 
can be unaware that a patient is pregnant if she seeks care directly 
from an LMC midwife. The College agrees that GPs should be notified 
when a woman has a miscarriage, however the process of notification 
is not very consistent at present and a lack of communication with 
midwives has been noted by some College members.
The College supports the recommendation that the communication 
and coordination between service providers should be improved and 
enhanced. Options for information sharing include LMCs requesting 
access to shared electronic records from general practices and LMCs 
using electronic systems that GPs can interact with (eg hMAELTM, 
which is a secure communication channel for the health sector that 
uses a closed messaging system).
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Recommendation (PMMRC 11th report) Progress to date (updated 2018)
Recommendations from the Mortality Review Committees’ Māori Caucus continued... 
Royal Australian New Zealand College of Psychiatrists strongly 
support the principles outlined in the ‘Practice Points on Māori 
Maternal Suicide’ which covers the salient facts regarding screening 
and managing pregnant women with potential mental illness and 
other co-morbidities; referral to secondary mental health services 
is required for those pregnant women who may have a history of 
mental illness and if a woman presents with a range of symptoms 
indicating serious mental illness. In our view, a comprehensive mental 
health assessment is critical to ensure early intervention occurs and 
appropriate treatment and care plans are in place for all at risk 
pregnant women.
We support all clinicians sharing relevant information to provide the 
pregnant women with the best care possible. An integrated model 
of care, across maternity and mental health services, is at the core 
of best practice service delivery ensuring the woman’s mental and 
physical wellbeing are addressed concurrently.
Increasing awareness of risk through education and developing 
greater communication and integration across the key health sector 
services are critical. Research from Australia indicates that increasing 
awareness of maternal mental illness in the community and amongst 
the non-mental health workforce can enhance the understanding of 
the mental health issues experienced during the perinatal period and 
improve the referral pathways for at risk women.
The appropriate management of Māori women with potential mental 
health problems requires specialised skills and expertise that are 
dependent upon a well-resourced workforce. Developing a culturally 
responsive workforce must be a priority to ensure Māori maternal 
health is  effectively managed within a kaupapa Māori context. The 
RANZCP strongly support the development of targeted strategies to 
improve the awareness and responsiveness to the increased risks 
experienced by Māori women. We strongly recommend that the key 
strategic aspects of this work are led by  Māori to ensure a Te Ao 
Māori perspective is woven into any proposed approaches. There 
should be a greater  collective focus on how the whānau are highly 
likely to be part of the solution in working to improve a woman’s 
wellbeing.
The RANZCP supports a comprehensive assessment of risk factors 
for Māori women being undertaken at the time the pregnancy is 
diagnosed and/or on first presentation for antenatal care.
As long-term use of alcohol can exacerbate mental  disorders, 
pregnant women with substance abuse disorders must have timely 
and appropriate access to treatment in order to reduce the negative 
impact on their wellbeing.
The RANZCP strongly suggests that maternal mental health is 
discussed more often than every three years, as it is demonstrated in 
both this Report and literature that mental illness during the perinatal 
period is a complex issue and it is unlikely to decrease significantly 
in the short term. Specific applied cultural competency related to 
Māori concepts in pregnancy must form a fundamental part of any 
Midwifery certification.
Update 2018
Child and Youth Mortality Review
Child and Youth Mortality Review Committee (CYMRC) consider 
including information about whether female suicide cases were 
pregnant in the 12 months prior to their deaths in addition to the 
pregnancy status information currently collected.
The Otago Database Group have included this question on their form: 
1.20 Was the deceased pregnant in the 12 months prior to their 
death?
1.20.1 Pregnant in prior 12 months – options: yes, no, unknown, not 
applicable
Update 2018
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1 Births in New Zealand 2016
Figure 1.1: Births in New Zealand* 2006–2016
* Source of data: New Zealand Maternity Collection (MAT). 
Note: Data relates to Table 4.1.
Figure 1.2: Trends in gestation at birth (36 weeks and beyond) among births in New Zealand 2007–
2016






























36 37 38 39 40 ≥41 weeks
18
Figure 1.3: Trends in maternal age among births in New Zealand 2007–2016
Figure 1.4: Trends in maternal prioritised ethnicity among births in New Zealand 2007–2016
Note: Data relates to Table 4.9.
Note: Data relates to Table 4.14.
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2 Special Topic: Neonatal Mortality 2007–2016
There was no change in the overall neonatal death rate in New Zealand from 2007 to 2016. The 
neonatal death rate was 2.6 per 1000 live births in 2007 and 2.5 per 1000 live births in 2016. There 
have been reductions in neonatal death rates in Australia, the United Kingdom and Scandinavia and so 
for the 12th report the PMMRC focused on this area.
2.1 Key Findings
There was no change from 2007 to 2016 in the neonatal death rate excluding deaths with congenital 
anomalies from 20 to 24 weeks and from 25 to 34 weeks gestation. However, there was a significant 
reduction for babies born from 35 weeks gestation.
Ethnic differences in neonatal death of babies with congenital anomalies
Pacific mothers had significantly higher rates of neonatal death of babies with congenital anomalies 
than mothers of Māori, Other Asian, Other European and New Zealand European ethnic groupings. 
Māori, Indian, and New Zealand European mothers had significantly higher rates than Other 
European, and significantly lower rates than Pacific mothers. 
For Pacific women, higher neonatal death rates with congenital anomalies may be at least partly 
related to lower rates of late termination leading to more stillbirths and neonatal deaths with lethal 
congenital anomalies. However, Pacific mothers had higher stillbirth and neonatal death rates and 
higher overall perinatal related death rates from congenital anomalies compared to Māori and Other 
European mothers who had similar (or higher) rates of termination of pregnancy. Further investigation 
is required to understand the reasons for this. Some of this ethnic difference for Pacific mothers and the 
differences in neonatal death rates for Māori, Indian, and New Zealand European mothers may be due 
to differences in care and/or differences in decisions to treat versus palliation. Further analysis of these 
differences requires data on babies surviving with congenital anomalies. 
Ethnic differences in neonatal death of babies without congenital anomalies
There were significantly more neonatal deaths without congenital anomalies among babies of Māori, 
Pacific and Indian women than among women of Other Asian, Other European and New Zealand 
European ethnic groupings (Figure 2.6). Neonatal death rates were lower among Other Asian and 
Other European mothers than among mothers of all other ethnic groupings.
Neonatal deaths of babies of Indian mothers
Babies of Indian mothers had high neonatal death rates with and without congenital anomalies. 
Sociodemographic factors associated with increased risk of neonatal death at 20 to 24 weeks 
gestation excluding death from congenital anomalies
The significantly higher neonatal death rate (without congenital anomalies) among babies of Māori, 
Pacific and Indian mothers compared to babies of Other Asian, Other European and New Zealand 
European mothers was most obvious at 20 to 24 weeks gestation. 
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A multivariable analysis was used to find which sociodemographic factors were associated with death 
at 20 to 24 weeks gestation after accounting for the effect of related factors. This analysis found that 
after adjustment for age, body mass index (BMI), socioeconomic status, parity, smoking, multiple 
pregnancy, baby sex, and year of birth, there remained a higher risk of death after birth at 20 to 24 
weeks gestation among babies of Māori, Pacific and Indian mothers, which suggests that there were 
other factors increasing risk for these women. 
Maternal age under 20 compared to 20 to 24 years, BMI of 35 and above, multiple pregnancy, 
smoking, increasing socioeconomic deprivation, and mothers having their first baby compared to 
mothers having their second baby were all associated with increased neonatal death independent of all 
the other factors. This analysis included sociodemographic factors and not important clinical risk factors 
such as medical illnesses and previous preterm birth because the data were not available.
The most common cause of neonatal death at 20 to 24 weeks gestation, responsible for almost 600 
deaths in the 10 years from 2007 to 2016, was extreme prematurity.
If the inequity in neonatal deaths at 20 to 24 weeks gestation among Māori, Pacific, and Indian women 
compared with other ethnic groupings was eliminated, 31 excess neonatal deaths would have been 
prevented from 2007 to 2016. 
Neonatal deaths among babies born at 23 to 26 weeks gestation without congenital anomalies 
At 23 weeks gestation 29.5 percent of live born babies without congenital anomalies born in New 
Zealand at any unit or at home survived to 28 days, and at 24 weeks gestation 70 percent survived to 
28 days. 
Resuscitation was attempted at 23 weeks gestation for 59 percent of live births, of whom 50 percent 
survived to 28 days. 
Among deaths of live born babies at 23 weeks gestation, only 11 percent of mothers had completed 
a course of antenatal corticosteroids to mature babies’ lungs. At 24 to 31 weeks gestation 33 to 43 
percent of mothers had completed a course of antenatal corticosteroids.
Inequities in survival of babies born at 23 to 26 weeks gestation without congenital anomalies 
Survival of live born babies from 23 to 26 weeks gestation was statistically significantly higher for 
babies born at tertiary units than babies born at secondary units. 
Babies of Māori, Pacific and Indian mothers are more likely to be born at extremely preterm gestations 
when survival is low. This contributes to the higher rate of neonatal deaths for babies of these mothers.
Inequities were also found in access to antenatal and neonatal care for extremely preterm births. For 
babies born alive at 23 to 26 weeks gestation:
• Babies were more likely to receive an attempt at resuscitation if they were born at a tertiary unit 
than if they were born at a secondary unit.
• Māori mothers were less likely to birth at a tertiary unit compared to mothers of all other ethnicities.
• Mothers under 20 years of age were less likely to birth in a tertiary unit compared to mothers who 
were 20 years and older. This applies to Māori and mothers of Other (predominantly European 
and Other Asian) ethnic groupings but has a greater impact on Māori because they are more likely 
to be mothers at under 20 years of age. Almost all Pacific mothers birth in a tertiary unit and there 
were no Indian mothers under 20 years of age among the live births at 23 to 26 weeks. 
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• Babies of Māori, Pacific and Indian mothers were less likely to receive an attempt at resuscitation 
and less likely to survive to 28 days. This has a disproportionate effect on Māori, Pacific and Indian 
mothers as they are more likely to birth at 23 to 26 weeks gestation than mothers of other ethnic 
groupings.
• Although not statistically significant, Māori, Pacific and Indian mothers were less likely to have 
received a completed course of antenatal corticosteroids than mothers of other (predominantly 
European) ethnic groupings.
Neonatal deaths among babies born at 25 to 34 weeks gestation without congenital anomalies 
From 25 to 34 weeks gestation, 56 percent of deaths were associated with spontaneous preterm birth.
Babies of Pacific mothers had a significantly higher rate of neonatal death from perinatal infection and 
from antepartum haemorrhage than babies of mothers of Māori and Other (predominantly European 
and non-Indian Asian) ethnic groupings. Babies of Māori mothers had a significantly higher neonatal 
death rate from spontaneous preterm birth than babies of mothers of Indian and Other (predominantly 
European and non-Indian Asian) ethnic groupings (Figure 2.16).
Sudden unexpected death in infancy (SUDI)
SUDI death is the second most common category of death of live born babies without congenital 
anomalies born after 35 weeks gestation. Among the 68 neonatal deaths from SUDI from 2007 to 
2016, 45 (66 percent) mothers were Māori and 12 (18 percent) were Pacific.
At the time of death only six of the 68 babies who were identified as SUDI deaths were in a 
recommended low-risk sleeping place; that is, in their own place of sleep, on their back and with no 
pillow. For two babies the place of sleep was unknown.
2.2 Recommendations
1. The PMMRC recommends the Ministry of Health establish a multidisciplinary working group to 
review current evidence for implementation of a preterm birth prevention program such as that 
implemented in Western Australia, taking care to:
a. identify and adequately resource evidence-based solutions 
b. ensure equitable access to screening and/or treatment for priority populations
c. ensure that priority populations have a voice in the development of health policy, process and 
practice in order to achieve equitable health outcomes
d. ensure that the outcomes of any implemented program, including equity of access, are 
evaluated.
Justification
Approximately 60 live born non-anomalous babies died from prematurity per year in New Zealand 
from 2007 to 2016; almost all of these after birth from 20 to 24 weeks gestation. Prematurity is the 
most common reason for neonatal death in New Zealand. New Zealand has seen no improvement in 
neonatal mortality rate over the past 10 years. 
The PMMRC has identified inequities in health care throughout their analyses that specifically impact 
Māori, Pacific and Indian ethnic groupings, young mothers under 20 years of age, and those living in 
areas of high deprivation. 
22
If the inequity in neonatal deaths at 20 to 24 weeks gestation among Māori, Pacific, and Indian women 
compared with other ethnic groupings was eliminated, 31 excess neonatal deaths would have been 
prevented between 2007 and 2016. 
Currently New Zealand has no national programme for screening for risk of preterm labour or for 
preventive treatment.
Evidence
Screening and prevention of preterm birth
Western Australia (WA) launched a campaign titled “the whole nine months” in 2014 which included 
adoption and dissemination of new clinical guidelines, a public health campaign, and a new central 
preterm birth prevention clinic for women at the highest risk (The Western Australian Preterm Birth 
Prevention Initiative 2014). The introduction of this programme has been associated with a reduction in 
singleton preterm birth of 7.6 percent in Western Australia (Newnham et al 2017).
Access to continuity of midwifery care and its impact on preterm birth
A Cochrane systematic review (Sandall et al 2016) on midwife-led continuity models of care compared 
with standard models of care for women during pregnancy, birth and early parenting showed that 
women randomised to continuity of midwifery care models experienced fewer  fetal losses at less 
than 24 weeks gestation and fewer neonatal deaths. The groups of women who are more likely to 
experience preterm birth and neonatal death are least likely to register with lead maternity carer (LMC) 
midwives providing continuity of midwifery care (Ministry of Health 2017b).
2. Women with a previous preterm birth at less than 34 weeks are at increased risk of neonatal 
death. 
The PMMRC recommends that LMCs and DHBs employ strategies to reduce preterm birth by 
targeting this high-risk group, including:
a. counselling at the time of a preterm birth to outline the strategies likely to be recommended 
for their next pregnancy, and advice to present for antenatal care as soon as they know they 
are pregnant
b. ensuring that antenatal care is available to allow women to register as early as possible, 
and ensuring that early antenatal care includes attention to modifiable risk factors such as 
smoking, sexually transmitted infections, and urinary tract infections 
c. ensuring referral for specialist consultation in the first trimester to facilitate discussion of 
treatment options, which might include cervical cerclage or vaginal progesterone treatment 
and monitoring of cervical length using transvaginal ultrasound 
d. counselling around signs and symptoms of preterm birth and how to respond to these to 
optimise outcome.
Justification
Women with a history of preterm birth are at significantly higher risk of a further preterm birth, and 
neonatal death (McManemy et al 2007) (Table 2.9).
Of the 729 babies who died after birth at 20 to 24 weeks, 305 were to multiparous mothers of 
singletons, and 119 (39 percent) of these had a history of previous preterm birth, including 64 (21 
percent) who had a history of previous preterm birth between 20 and 28 weeks gestation (Table 2.9).
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There was a significant difference by ethnicity in the trimester at registration with an LMC by ethnicity 
(Table 2.6).
Evidence
The use of vaginal progesterone and cervical cerclage, even in high-risk women, remains controversial, 
but these treatment options should be available to all women for whom preterm birth is a risk (Dodd 
et al 2013; Keelan and Newnham 2017). Meanwhile, strategies to optimise outcome for babies who 
are born preterm, such as antenatal corticosteroids, magnesium sulphate, transfer to a tertiary unit, and 
discussion around the outcomes and choices for babies born prior to 25 weeks gestation, should be 
available to all families/whānau.
There is limited evidence for dedicated preterm birth clinics as a means to reduce preterm birth rates 
(Whitworth et al 2011; Malouf and Redshaw 2017). 
3. Birth in a tertiary centre is associated with improved outcomes for preterm babies at the lower 
limits of viability (prior to 25 weeks gestation). 
The PMMRC recommends the Ministry of Health leads the development of a national consensus 
pathway for the care of women in preterm labour or requiring delivery prior to 25 weeks 
gestation. The PMMRC recommends this pathway includes:
a. ensuring that all groups of women (irrespective of ethnicity, age, socioeconomic status or 
place of residence) are offered and provided the same level of care
b. strategies for secondary units for management of women in threatened or early preterm 
labour, or who require delivery, prior to 25 weeks gestation. Including:
i. administration of corticosteroids and magnesium sulphate 
ii. timely transfer from primary and secondary units to tertiary units 
iii. management of babies inadvertently born in their units at the lower limits of viability
c. ensuring that priority populations have a voice in the development of health policy, process 
and practice in order to achieve equitable health outcomes
d. guidance on monitoring that care provision is equitable by ethnicity, age, socioeconomic 
status and place of residence.
Justification
The relative survival risk from 23 to 26 weeks was statistically significantly higher for babies born in a 
tertiary compared to a secondary hospital, with a relative risk of 1.27 (95% confidence interval (CI) 
1.13–1.42) (p<0.0001). 
Ethnic and age inequities were found in neonatal care, including access to neonatal care for extremely 
preterm births. For babies born alive at 23 to 26 weeks gestation:
• Māori, Pacific and Indian babies were less likely to receive an attempt at resuscitation and less 
likely to survive to 28 days of age.
• Māori mothers were more likely to birth at a secondary unit than a tertiary unit compared to 
mothers of all other ethnic groupings.
• Mothers under 20 years of age were more likely to birth in a secondary unit compared to mothers 
who were 20 years and older. 
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• Babies were more likely to receive an attempt at resuscitation if they were born at a tertiary unit 
than if they were born at a secondary unit. 
These inequities have a disproportionate effect on Māori, Pacific and Indian mothers as they are more 
likely to birth at 23 to 26 weeks gestation than mothers of other ethnic groupings.
Evidence
Boland et al (2015) found improved survival for babies inborn at tertiary neonatal units between 22 
and 27 weeks gestation compared to babies outborn in Victoria, Australia.
4. The PMMRC recommends DHBs make available appropriate information, including appropriate 
counselling, for parents, families and whānau about birth outcomes prior to 25 weeks gestation 
to enable shared decision making and planning of active care or palliative care options (see 
“Practice point: Care for women in preterm labour or requiring delivery at 23+0 to 24+6 weeks 
gestation”).
Justification
Resuscitation was attempted at 23 weeks gestation for 153 (59 percent) of 258 live births, and for 
391 (96 percent) of 406 live births at 24 weeks in 2007–2016 (Table 2.6). Attempted resuscitation 
varied by place of birth (that is, more often at tertiary than secondary hospitals, and more often at some 
tertiary units than others) and by ethnicity and maternal age.
From 2007 to 2016, at 23+0 to 23+6 weeks gestation, half of non-anomalous live born babies 
survived to 28 days when an attempt was made at resuscitation (76 survivors) and almost three 
quarters (73 percent) at 24 weeks (284 survivors). At 23 weeks gestation 30 percent of non-anomalous 
babies live born in New Zealand at any unit or at home survived to 28 days, and at 24 weeks 
gestation 70 percent survived to 28 days. 
Evidence
These national outcomes compare to 46 percent survival of live born babies (inborn and outborn) at 
23 weeks gestation and 77 percent survival at 24 weeks reported in Western Australia 2004–2010, 
where rates of provision of resuscitation are high (Sharp et al 2018).
Babies born alive at 23 and 24 weeks gestation and who survive have a long stay in neonatal units. 
At two years of age 42 percent of babies born at 23 weeks (8 of 19) and 26 percent of babies born 
at 24 weeks (8 of 31) were found to have moderate or severe morbidity such as neurodevelopmental 
disability and respiratory, gastrointestinal and renal complications of prematurity (Berry et al 2017). 
A systematic review estimated the risk of severe disability among children born at 23 weeks to be 20 
percent (95% CI 5 to 52). This meta-analysis included six studies of 125 survivors. The risk of severe 
disability among children born at 24 weeks was between 5 to 44 percent. This meta-analysis included 
eight studies of 299 survivors. However, the certainty of the evidence for these outcomes was low to 
very low (Myrhaug et al 2017). 
This information, along with consideration of the clinical indicators of outcome, may influence the 
decisions family and whānau will face.
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5. The PMMRC recommends that DHB maternity services audit the rates of antenatal corticosteroid 
administration, including repeat doses when indicated, to mothers of neonates live born at less 
than 34 weeks gestation, including auditing whether administration is equitable by ethnicity, 
DHB of residence, and maternal age. 
Justification
Of babies who died in the first 28 days after live birth, 11 percent at 23 weeks, 33 to 34 percent at 24 
to 26 weeks, and 43 percent at 27 to 31 weeks gestation at birth had a complete course of antenatal 
corticosteroids. These data suggest that many babies at 23 weeks, and some at 24 to 26 weeks, were 
not optimally prepared for preterm birth.
Evidence
Planning for location of birth and preparation with administration of corticosteroids should be 
considered at 23+0 weeks gestation. Both overseas and in New Zealand, a 65 percent rate of 
completing a course of antenatal corticosteroids in babies who were live born, resuscitated and 
transferred to the neonatal intensive care unit has been reported, although 80 percent might be an 
appropriate and achievable goal (Kyser et al 2012; Berry et al 2017; Travers et al 2018). This would 
enable best outcomes for the baby if resuscitation is considered appropriate at the time of birth. See 
“Practice point: Care for women in preterm labour or requiring delivery at 23+0 to 24+6 weeks 
gestation” and the Antenatal Corticosteroid Clinical Practice Guidelines (Antenatal Corticosteroid 
Clinical Practice Guidelines Panel 2015).
6. The PMMRC recommends that tertiary obstetric and neonatal intensive care units investigate 
and address the difference between units in survival rates amongst infants born at 23 to 26 
weeks gestation as part of their benchmarking and quality and safety initiatives.
Justification
There were statistically significant differences in survival rate by tertiary unit at gestations of 23 to 25 
weeks (p<0.001; p<0.001; p=0.047 respectively) but not at 26 weeks (p=0.058). The units with the 
highest survival rates at 23 to 25 weeks gestation were Dunedin and Wellington, both of which are 
units known to have had an active approach to resuscitation at 23 weeks (93 percent and 94 percent 
compared to 35 percent to 68 percent in the remaining units; p<0.001).
There was a significant difference in the proportions of babies where resuscitation was attempted 
from 23 to 26 weeks gestation at tertiary units, with rates ranging from 87 percent (232/266) at 
Middlemore Hospital, 93 percent (137/148) at Christchurch, 94 percent (349/370) at Auckland, and 
97 percent (209/215) at Waikato, to 98 percent (311/316) and 99 percent (93/94) at Wellington 
and Dunedin Hospitals (p<0.001). 
Evidence
The finding that birth in the units with an active approach to resuscitation at 23 weeks gestation was 
associated with better survival out to 25 weeks is consistent with findings in previous reports (Smith et al 
2012; Rysavy et al 2015). However, the role of other factors cannot be excluded. 
New Zealand neonatal intensive care units have been aware that there are different approaches to 
resuscitation practice by unit and are working within the New Zealand Neonatal Network (www.
starship.org.nz/for-health-professionals/new-zealand-child-and-youth-clinical-networks/newborn-clinical-
network/) to develop a consensus statement to align practice across the country.
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7. The PMMRC recommends that regulatory bodies require cultural competency training of all 
individuals working across all areas of the maternity and neonatal workforce. Training should 
address awareness of, and strategies to reduce and minimise the impact of, implicit bias and 
racism.
Justification
Māori, Pacific and Indian live born babies were statistically significantly less likely to have an attempt 
at resuscitation than babies of Other ethnic groupings (Table 2.7), and Māori and Pacific babies were 
significantly less likely to survive compared to babies of ‘Other’ ethnic groupings among all non-
anomalous live born babies at 23 to 26 weeks gestation. Māori, Pacific and Indian mothers were less 
likely to have registered, or been able to register, with an LMC in the first trimester of pregnancy. 
Pacific mothers had higher stillbirth and neonatal death rates and higher overall perinatal related death 
rates from congenital anomalies compared to Māori and Other European mothers who had similar (or 
higher) rates of termination of pregnancy. 
While the reasons for these differences by ethnicity have not been elucidated in the analyses in this 
report, previous analysis on inequities by ethnicity in New Zealand suggest that institutional bias or 
implicit biases are likely to play at least some part.
Evidence
There is a large body of work in New Zealand (including this report) describing the inequities in access 
to care, quality of care, and health outcomes experienced by Māori and Pacific peoples. There is also 
a significant body of literature that clearly documents the association between exposure to racism/
ethnic discrimination and adverse health outcomes internationally and in New Zealand (Harris et al 
2006; Harris et al 2012a; Crengle et al 2012). Furthermore, in New Zealand, exposure to ethnic 
discrimination has been associated with lower levels of cervical (adjusted odds ratio (AOR) 0.51; 95% 
CI 0.30–0.87) and mammography screening (AOR 0.37; 95% CI 0.14–0.996) among eligible Māori 
women (Harris et al 2012b). In New Zealand people who report experiencing ethnic discrimination by 
health professionals are significantly more likely (both separately and for all experiences together) to 
report they were not always listened to carefully, their care was not always discussed as much as they 
wanted, and that they were not always treated with respect and dignity (combined AOR 1.57; 95% CI 
1.15–2.14) (Harris et al 2012b). There is also evidence that exposure to discrimination is associated 
with adverse maternal and infant health outcomes (Thayer and Kuzawa 2015; Becares and Atatoa-Carr 
2016; Hobbs et al 2017). The influence of clinicians’ implicit racial/ethnic biases and explicit racial/
ethnic stereotypes on their behaviours, cognition and decision making and the contribution of these 
to producing and maintaining ethnic inequities in health has been discussed for some time (see, for 
example, van Ryn and Fu 2003; van Ryn et al 2011) and more recently has received greater attention. 
In New Zealand, ethnic bias has been observed amongst medical students (Harris et al 2018). 
The contribution that clinicians’ biases per se make to ethnic health inequities is more difficult to 
quantify, as there are many factors that are involved in the development and maintenance of these 
inequities. Nevertheless, there is some evidence that these biases can impact on patient experience 
and clinical outcomes (Hall et al 2015; Ben et al 2017; Dehon et al 2017; Maina et al 2018). 
Cultural competence is one strategy used to improve health outcomes and eliminate ethnicity-related 
health inequities. In New Zealand, the medical colleges, the Medical Council of New Zealand and 
the Midwifery Council all require ongoing evidence of cultural competence training/activities. The 
assessment of cultural competence training and other interventions to address clinician bias is also 
complex. However, there is some evidence of effectiveness for cultural competence training (Horvat et al 
2014; Truong et al 2014; Clifford et al 2015). 
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8. The PMMRC recommends that the Ministry of Health and DHBs have a responsibility to ensure 
that midwifery staffing ratios and staffing acuity tools: 
a. enable active observation of mothers and babies who are undertaking skin-to-skin contact in 
the postnatal inpatient period 
b. allow for the identification of, and additional needs of, mothers who have increased risk 
factors for sudden unexpected death in infancy (SUDI). 
Justification
There were four deaths prior to discharge from hospital among the SUDI deaths from 2007 to 2016 
reviewed for this report.
Evidence
The Ministry of Health’s 2012 consensus statement Observation of the Mother and Baby in the 
Immediate Postnatal Period notes that sudden unexpected neonatal death in the first two days after 
birth is an increasingly recognised problem. Risk factors include unsupervised skin-to-skin contact, 
inexperienced mothers and mothers being left unsupervised in the immediate postnatal period. It also 
notes that mothers are less able to ensure a safe environment for breastfeeding or sleeping when they 
have experienced a long or complicated labour and birth, are under the influence of medications, or 
have some medical conditions. 
Babies are more at risk of respiratory difficulties from a compromised airway where their mother or 
family/whānau have been or are exposed to medications, drugs, alcohol and/or smoking. 
Skin-to-skin contact has been demonstrated to support increased breastfeeding; however, if risk factors 
for sudden unexpected neonatal death in hospital are present (such as smoke-exposed pregnancy, 
maternal tiredness, and the influence of medications) it is important to ensure that women are actively 
observed by someone who is capable of carrying out this responsibility confidently, and have 
immediate access to additional support when required.
9. The PMMRC recommends that lead maternity carers (LMCs) and DHBs ensure that every baby 
will have access to a safe sleep place on discharge from the hospital or birthing unit, or at 
home, that is their own place of sleep, on their back and with no pillow. If they do not have 
access to a safe sleep place, then a wahakura or Pēpi-Pod®2 must be made available for the 
baby’s use prior to discharge from hospital.
Justification
The review of SUDI deaths to 28 days from 2007 to 2016 found that at least 22 (32 percent) of the 68 
babies reviewed who died did not have a usual safe place of their own to sleep. Usual place of sleep 
was not stated for a further 10 babies (15 percent).
Evidence
To keep babies safe while sleeping, all babies need to be in their own place of sleep (bassinet, cot, 
Pēpi-Pod or wahakura), free from adults or children who might accidentally suffocate them (Ministry of 
Health 2016).
A randomised controlled trial with the wahakura found that they were at least as safe as bassinets, and 
in addition encouraged breastfeeding (Baddock et al 2017).
2  A Pēpi-Pod® is a plastic box with a well-fitting mattress in the bottom. As well as the sleep space, these devices are always provided with safe sleep messaging.
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2.3 Introduction
In 2017 the PMMRC decided to explore neonatal mortality in more detail as it was apparent that there 
had been no improvement in neonatal mortality rate in New Zealand from 2007, when the PMMRC 
began mandatory reporting and thus complete ascertainment and review of all perinatal related deaths. 
This was on a background of apparent improvement in neonatal mortality in other developed countries 
(Australia, UK, and Scandinavia) (Manktelow et al 2016; Australian Institute of Health and Welfare 
2016; Heino and Gissler 2016) (Figure 2.1, Table 2.16).
From 2007 to 2016 there were 1,731 neonatal deaths in New Zealand from 20 weeks gestation 
(excluding terminations of pregnancy resulting in neonatal death). 
2.4 Methodology
Neonatal deaths are usually reported per 1000 live births. In some analyses an alternative denominator 
per 1000 ongoing pregnancies is used to estimate risk. A quick reference for definition of rates and 
datasets used is available in “Appendix D: Key datasets and definitions in the PMMRC 12th report”.
The analyses in this chapter use data from the PMMRC data collection, and from a merge of PMMRC 
deaths with denominator data from the National Maternity Collection (MAT). When analyses included 
parity, smoking, BMI, customised birthweight centile, or gestation at registration with an LMC, they 
were limited to mothers registered for care with an LMC (either a midwife, obstetrician or general 
Figure 2.1: Neonatal death rate (per 1000 live births) by gestation and country 2004-2016 
Data sources and definitions
United Kingdom – live birth at ≥ 20 weeks gestation, or birthweight ≥ 400g if gestation is not available, who died before 28 completed days (routine data 
sources) (Manktelow et al 2016).
Australia – live birth at ≥ 20 weeks gestation, or birthweight ≥ 400g, who died before 28 completed days (routine data sources)(Australian Institute of Health and 
Welfare 2017; Australian Institute of Health and Welfare 2018).
Scandinavia – live birth at ≥ 22 weeks gestation who died before 28 completed days (routine data sources) (Heino and Gissler 2016).
New Zealand - live birth at ≥ 20 weeks gestation, or birthweight ≥ 400g if gestation is not available, who died before 28 completed days. Or live birth at ≥ 22 
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Scandinavia ≥ 22 weeks New Zealand ≥ 22weeks
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practitioner (GP)) claiming from the Section 88 Primary Maternity Services Notice from 2008. This 
is because these data were only reliably available for women under LMC care, and the variable for 
LMC was only accurate from 2008. These analyses included 79.9 percent of births in New Zealand in 
2008, increasing to 92.1 percent in 2016.
When analyses used MAT data for the deaths (numerator), the analyses were necessarily limited to the 
deaths which were able to be merged with the MAT dataset, which was slightly fewer than the complete 
cohort in the PMMRC dataset. This was when rates were presented and there was a reason to believe 
that numerator-denominator bias might exist such as for analyses including smoking, BMI, customised 
birthweight centile, and trimester at first registration.
The findings begin with a description of neonatal death from congenital anomalies (n=414). Congenital 
anomalies were then excluded from the remainder of the analyses of neonatal deaths (n=1317).
Neonatal deaths without congenital anomalies were divided into three groups: birth at 20 to 24 weeks 
gestation, 25 to 34 weeks gestation, and 35 weeks and over. These gestation groupings were chosen 
for a priori reasons related to cause of death in the expectation that these categories would be the most 
useful in exploring the potential for improvements in neonatal mortality.
The analyses attempted to look at quality of maternity and neonatal care and to explore inequities in 
neonatal death rates to identify where reductions in neonatal deaths might be possible.
A full description of the methodology, definitions, and abbreviations common to PMMRC reporting 
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Ethnicity






















Māori Pacific peoples Indian Other Asian MELAA Other European NZ European
* Unknown/Other ethnicity is not represented. 
MELAA = Middle Eastern, Latin American or African.
Late termination of pregnancy is the most common mode of death among babies dying with congenital 
anomaly (Figure 2.3). Indian, Other Asian and New Zealand European mothers had the highest rates 
of late termination of pregnancy associated with congenital anomaly, and this led to the highest rates of 
perinatal related death with congenital anomaly in these ethnic groupings.
Pacific mothers had significantly higher rates of stillbirth of babies with congenital anomalies than 
Māori, Other Asian, Other European and New Zealand European mothers. All other ethnic groupings 
have similar rates.
Pacific mothers had significantly higher rates of neonatal death of babies with congenital anomalies 
than Māori, Other Asian, Other European and New Zealand European mothers. Māori, Indian, and 
New Zealand European mothers had significantly higher rates than Other European.
For Pacific women, higher stillbirth and neonatal death rates with congenital anomalies may be at 
least partially related to lower rates of late termination leading to more stillbirths and neonatal deaths 
with lethal congenital anomalies. However, some of this ethnic difference in stillbirth and neonatal 
death rates for Pacific mothers and the differences in neonatal death rates for Māori, Indian, and New 
Zealand European mothers may be due to differences in care and/or differences in decisions to treat 
versus palliation. Further investigation of these deaths, including an analysis of the care pathway, 
and inclusion of data for infants surviving with congenital anomalies are needed to understand these 
findings further.
There is no evidence of a change in perinatal related mortality from congenital anomaly from 2007 to 































Table 2.1: Perinatal death classification (PSANZ-PDC) among neonatal deaths from congenital anomalies by gestational age at birth and place 
of birth 2007–2016
Perinatal death classification 
(PSANZ-PDC)
Total
Gestation (weeks) Place of birth
20–24 25–34 ≥35 Primary* Secondary Tertiary Other/unknown
n=414 n=7 n=129 n=278 n=18 n=101 n=291 n=4
n % n % n % n % n % n % n % n %
Congenital abnormality
Central nervous system 39 9.4  -  -  12  9.3  27  9.7  2  11.1  13  12.9  24  8.2  -  - 
Cardiovascular system 65 15.7  -  -  11  8.5  54  19.4  5  27.8  15  14.9  43  14.8  2  50.0 
Urinary system 41 9.9  1  14.3  20  15.5  20  7.2  4  22.2  11  10.9  26  8.9  -  - 
Gastrointestinal system 12 2.9  -  -  4  3.1  8  2.9  -  -  3  3.0  8  2.7  1  25.0 
Chromosomal 95 22.9  4  57.1  27  20.9  64  23.0  4  22.2  25  24.8  66  22.7  -  - 
Metabolic 24 5.8  -  -  2  1.6  22  7.9  2  11.1  10  9.9  12  4.1  -  - 
Multiple abnormality/non-
chromosomal syndromes
60 14.5  1  14.3  24  18.6  35  12.6  -  -  9  8.9  51  17.5  -  - 
Other congenital abnormality
Musculoskeletal 15 3.6  -  -  5  3.9  10  3.6  -  -  4  4.0  11  3.8  -  - 
Respiratory 4 1.0  -  -  1  0.8  3  1.1  -  -  2  2.0  2  0.7  -  - 
Diaphragmatic hernia 30 7.2  -  -  11  8.5  19  6.8  -  -  5  5.0  25  8.6  -  - 
Haematological 2 0.5  -  -  -  -  2  0.7  -  -  2  2.0  -  -  -  - 
Tumours 6 1.4  1  14.3  4  3.1  1  0.4  -  -  -  -  6  2.1  -  - 
Other 9 2.2  -  -  4  3.1  5  1.8  1  5.6  -  -  8  2.7  -  - 
Unspecified 2 0.5  -  -  1  0.8  1  0.4  -  -  1  1.0  -  -  1  25.0 
Maternal conditions
Diabetes/Gestational diabetes 9 2.2  -  -  3  2.3  6  2.2  -  -  1  1.0  8  2.7  -  - 
Other maternal conditions 1 0.2  -  -  -  -  1  0.4  -  -  -  -  1  0.3  -  - 
* Home, birthing unit, Level 1 hospital
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The most frequent congenital anomalies associated with neonatal death were chromosomal anomalies, 
anomalies of the cardiovascular system, and non-chromosomal syndromes (Table 2.1).
Without the total number of live births with congenital anomaly, it is not possible to know if survival 
with congenital anomaly differs by place of birth. However, the distribution of causes of death among 
neonatal deaths from congenital anomaly was broadly similar in secondary and tertiary units, except 
for a higher proportion of deaths from non-chromosomal syndromes and diaphragmatic hernia at 
tertiary hospitals, which would be consistent with the higher likelihood that these were diagnosed and 
referred prior to birth (Table 2.1).
Thirty-six percent of babies who died with congenital anomalies who were born outside a tertiary 
hospital were transferred to a tertiary hospital after birth (10/18 (56 percent) from primary and 
32/101 (32 percent) from secondary care).
Neonatal deaths excluding deaths with congenital anomalies

























Neonatal deaths Stillbirths Termination of pregnancy Perinatal related deaths
There was a reduction in stillbirth rate from 2007 to 2016 excluding death with congenital anomalies 
(score test for trend p=0.006). There has been an increase in termination of pregnancy rate excluding 
death with congenital anomalies (score test for trend p=0.04), but no change in neonatal death rate 
(score test for trend p=0.8) (Figure 2.4).
From 2007 to 2016 there has been no statistically significant change in neonatal deaths at 20 to 24 
weeks or 25 to 34 weeks but a significant reduction in neonatal deaths from 35 weeks (score test for 
trend p=0.01) (Figure 2.5).
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Figure 2.5: Neonatal death rate (per 1000 ongoing pregnancies) by gestation at birth and year of 
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Māori Pacific peoples Indian Other Asian MELAA Other European NZ European
* Unknown/Other ethnicity not represented.
MELAA = Middle Eastern, Latin American or African.
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There were few late terminations of pregnancy for reasons other than congenital anomaly (Figure 2.6), 
and so these have little impact on non-anomalous perinatal related mortality. 
There were significantly more neonatal deaths and more overall perinatal related deaths among babies 
of Māori, Pacific and Indian mothers than among mothers of Other Asian, Other European and New 
Zealand European ethnic groupings (Figure 2.6). Stillbirth rates were not significantly higher among 
Māori compared to New Zealand European mothers. 
Stillbirth, neonatal death and overall perinatal related mortality was lower among babies of Other 
Asian and Other European mothers than among mothers of all other ethnic groupings.
It is notable that babies of Indian mothers had high perinatal mortality rates with and without congenital 
anomalies (Figure 2.3 and Figure 2.6).
Figure 2.7: Neonatal death rate (per 1000 ongoing pregnancies) by gestation at birth and maternal 
































Gestation at birth (weeks)
Māori Pacific peoples Indian Other Asian MELAA Other European NZ European
* Unknown/Other ethnicity not represented.
MELAA = Middle Eastern, Latin American or African.
There were more non-anomalous neonatal deaths among babies of Māori and Pacific women across all 
gestation groupings, although this was most evident at 20 to 24 weeks. Among babies born at 20 to 
24 weeks gestation, the highest rate of neonatal death was among Indian babies (Figure 2.7). 
Body mass index
There was a strong positive association between maternal BMI and non-anomalous neonatal death rate 
(Figure 2.8) at 20 to 24 weeks and from 35 weeks but the association with deaths between 25 and 34 
weeks gestation is less obvious.
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Figure 2.8: Neonatal death rates (per 1000 ongoing pregnancies) by gestation at birth and BMI 






























Gestation at birth (weeks)
<18.50 18.50–24.99 25.00–29.99 30.00–34.99 35.00–39.99 ≥40.00 BMI (kg/m2)
* MAT data numerator and denominator; limited to mothers who were registered for care with an LMC (either a midwife, obstetrician or GP) claiming from the 
Section 88 Primary Maternity Services Notice.
Maternal age
Figure 2.9: Neonatal death rate (per 1000 ongoing pregnancies) by gestation at birth and maternal 
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Young mothers (under 20 years of age) had significantly higher rates of neonatal death at 20 to 24 
weeks and from 35 weeks gestation than all age groupings, and higher rates than mothers aged 20 
to 39 years old at 25 to 34 weeks gestation (Figure 2.9). The rates of neonatal death did not vary 
significantly by age grouping at any gestation for mothers aged 20 or older.
Socioeconomic deprivation
Figure 2.10: Neonatal death rate (per 1000 ongoing pregnancies) by gestation at birth and 






























Gestation at birth (weeks)
1 (least deprived) 2 3 4 5 (most deprived)
There was a statistically significant increase in neonatal death rate across all gestation groupings with 
increasing quintile of socioeconomic deprivation (chi square test for trend p<0.0001), although the 
gradient is more marked at 20 to 24 weeks gestation than at later gestations (Figure 2.10). 
Parity
Women’s first births were associated with significantly higher neonatal mortality than second to fourth 
births at 20 to 24 weeks and from 35 weeks gestation (Figure 2.11). Fifth births were significantly 
more at risk of neonatal death from 35 weeks than second to fourth births. Parity was not significantly 
associated with neonatal deaths from 25 to 34 weeks gestation. 
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Figure 2.11: Neonatal death rate (per 1000 ongoing pregnancies) by gestation at birth and parity 

































Gestation at birth (weeks)
Primiparous Multiparous 1–3 Multiparous ≥4
* MAT data numerator and denominator; limited to mothers who were registered for care with an LMC (either a midwife, obstetrician or GP) claiming from the 
Section 88 Primary Maternity Services Notice.
Smoking
Figure 2.12: Neonatal death rate (per 1000 ongoing pregnancies) by gestation at birth and smoking 






























Gestation at birth (weeks)
Smoker Non-smoker
 * MAT data numerator and denominator; limited to mothers who were registered for care with an LMC (either a midwife, obstetrician or GP) claiming from the 
Section 88 Primary Maternity Services Notice.
Mothers who smoked were at significantly increased risk of neonatal death at all gestations.
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Table 2.2: Clinical details of neonatal deaths by gestation 2007–2016
Total Congenital abnormalities
Neonatal deaths excluding congenital abnormalities
20–22 23–24 25–27 28–34 35–37 ≥38 weeks
n=1,731 n=414 n=422 n=307 n=148 n=115 n=71 n=254
n       % n       % n       % n       % n       % n       % n       %     n       %
Age at death (days)
0  872  50.4  147  35.5  397  94.1  179  58.3  43  29.1  33  28.7  13  18.3  60  23.6 
1–6  502  29.0  135  32.6  25  5.9  82  26.7  60  40.5  56  48.7  32  45.1  112  44.1 
7–13  187  10.8  79  19.1  -  -  30  9.8  20  13.5  13  11.3  12  16.9  33  13.0 
14–20  77  4.4  22  5.3  -  -  11  3.6  11  7.4  8  7.0  5  7.0  20  7.9 
21–27  93  5.4  31  7.5  -  -  5  1.6  14  9.5  5  4.3  9  12.7  29  11.4 
Level of birth
Home  70  4.0  8  1.9  7  1.7  9  2.9  8  5.4  6  5.2  7  9.9  25  9.8 
Birthing unit  33  1.9  7  1.7  3  0.7  -  -  1  0.7  1  0.9  -  -  21  8.3 
Hospital Level 1  23  1.3  3  0.7  1  0.2  4  1.3  2  1.4  1  0.9  -  -  12  4.7 
Hospital Level 2  487  28.1  101  24.4  140  33.2  64  20.8  20  13.5  29  25.2  29  40.8  104  40.9 
Hospital Level 3  1,094  63.2  291  70.3  262  62.1  225  73.3  114  77.0  78  67.8  33  46.5  91  35.8 
Other  19  1.1  2  0.5  8  1.9  5  1.6  3  2.0  -  -  -  -  1  0.4 
Unknown  5  0.3  2  0.5  1  0.2  -  -  -  -  -  -  2  2.8  -  - 
Place of death
Home  142  8.2  43  10.4  4  0.9  5  1.6  2  1.4  6  5.2  18  25.4  64  25.2 
Hospital  - 
Delivery suite  541  31.3  87  21.0  274  64.9  136  44.3  14  9.5  7  6.1  5  7.0  18  7.1 
Antenatal ward  14  0.8  2  0.5  10  2.4  1  0.3  1  0.7  -  -  -  -  -  - 
Postnatal ward  32  1.8  12  2.9  6  1.4  2  0.7  2  1.4  2  1.7  1  1.4  7  2.8 
Neonatal unit  692  40.0  181  43.7  3  0.7  134  43.6  123  83.1  89  77.4  38  53.5  124  48.8 
Operating theatre  53  3.1  20  4.8  3  0.7  5  1.6  3  2.0  8  7.0  2  2.8  12  4.7 
Emergency department  50  2.9  6  1.4  23  5.5  9  2.9  1  0.7  1  0.9  2  2.8  8  3.1 
Other  174  10.1  53  12.8  91  21.6  11  3.6  1  0.7  2  1.7  3  4.2  13  5.1 
Unknown  5  0.3  3  0.7  1  0.2  -  -  -  -  -  -  -  -  1  0.4 
Other  28  1.6  7  1.7  7  1.7  4  1.3  1  0.7  -  -  2  2.8  7  2.8 
Inter hospital transfer
To Level 2 Hospital  6  0.3  -  -  -  -  1  0.3  -  -  1  0.9  1  1.4  3  1.2 
To Level 3 Hospital  194  11.2  44  10.6  3  0.7  17  5.5  23  15.5  20  17.4  17  23.9  70  27.6 































* not applicable 
Apgar 1 minute
0–3  979  56.6  163  39.4  *  *  204  66.4  62  41.9  71  61.7  38  53.5  130  51.2 
4–5  243  14.0  86  20.8  *  *  57  18.6  35  23.6  15  13.0  3  4.2  12  4.7 
6–7  155  9.0  64  15.5  *  *  15  4.9  37  25.0  12  10.4  8  11.3  13  5.1 
≥8  225  13.0  91  22.0  *  *  7  2.3  7  4.7  14  12.2  19  26.8  86  33.9 
Unknown  129  7.5  10  2.4  *  *  24  7.8  7  4.7  3  2.6  3  4.2  13  5.1 
Apgar 5 minutes 
0–3  812  46.9  105  25.4  *  *  163  53.1  43  29.1  49  42.6  27  38.0  110  43.3 
4–5  164  9.5  61  14.7  *  *  35  11.4  15  10.1  15  13.0  6  8.5  17  6.7 
6–7  227  13.1  89  21.5  *  *  54  17.6  38  25.7  23  20.0  6  8.5  15  5.9 
≥8  369  21.3  144  34.8  *  *  29  9.4  45  30.4  25  21.7  28  39.4  97  38.2 
Unknown  159  9.2  15  3.6  *  *  26  8.5  7  4.7  3  2.6  4  5.6  15  5.9 
Resuscitation at birth 
Yes  873  50.4  223  53.9  *  *  186  60.6  143  96.6  103  89.6  50  70.4  156  61.4 
No  850  49.1  189  45.7  118  38.4  5  3.4  11  9.6  21  29.6  97  38.2 
Unknown  8  0.5  2  0.5  *  *  3  1.0  -  -  1  0.9  -  -  1  0.4 
Outcome of resuscitation
Baby resuscitated and 
transferred to another clinical 
care area
 719  41.5  200  48.3  *  *  135  44.0  122  82.4  89  77.4  42  59.2  128  50.4 
Baby unable to be resuscitated  150  8.7  22  5.3  *  *  50  16.3  20  13.5  14  12.2  8  11.3  27  10.6 
Unknown  4  0.2  1  0.2  *  *  1  0.3  1  0.7  -  -  -  -  1  0.4 
Customised birthweight centile
Small for gestational age  473  27.3  201  48.6  56  13.3  53  17.3  57  38.5  43  37.4  20  28.2  43  16.9 
Appropraite for gestational age  1,076  62.2  172  41.5  309  73.2  228  74.3  80  54.1  56  48.7  42  59.2  189  74.4 
Large for gestational age  174  10.1  38  9.2  55  13.0  26  8.5  11  7.4  15  13.0  9  12.7  20  7.9 
Unknown  8  0.5  3  0.7  2  0.5  -  -  -  -  1  0.9  -  -  2  0.8 
Table 2.2:  Clinical details of neonatal deaths by gestation 2007–2016 (continued)
Total Congenital abnormalities
Neonatal deaths excluding congenital abnormalities
20–22 23–24 25–27 28–34 35–37 ≥38 weeks
n=1,731 n=414 n=422 n=307 n=148 n=115 n=71 n=254
n       % n       % n       % n       % n       % n       % n       %     n       %
* Not applicable.
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Neonatal deaths among babies born at 20 to 24 weeks gestation without congenital 
anomalies 
Of the 729 babies who died without congenital anomalies up to 28 days after live birth at 20 to 24 
weeks gestation, from 2007 to 2016 (approximately 70 per year), 96 were born at 20 weeks, 137 at 
21 weeks, 189 at 22 weeks, 184 at 23 weeks and 123 at 24 weeks. 
Table 2.3: Perinatal death classification (PSANZ-PDC) by neonatal death classification (PSANZ-NDC) 
among neonatal deaths without congenital anomaly at 20–24 weeks 2007–2016
Perinatal death classification 
(PSANZ-PDC)






Infection Neurological Gastro-intestinal Other TOTAL
Perinatal infection  25  -  6  -  -  -  31 
Hypertension  4  2  -  2  -  1  9 
Antepartum haemorrhage  157  10  1  12  2  1  183 
Maternal conditions  15  1  1  -  -  1  18 
Specific perinatal conditions  84  2  4  3  1  1  95 
Fetal growth restriction  1  -  -  -  -  -  1 
Spontaneous preterm  312  32  13  24  6  5  392 
TOTAL  598  47  25  41  9  9  729 
The most common cause of neonatal death at 20 to 24 weeks gestation was extreme prematurity. 
The most common obstetric antecedents were spontaneous preterm labour (312 (52 percent)) and 
antepartum haemorrhage (157 (26 percent)) (Table 2.3).
Of the 157 babies where antepartum haemorrhage preceded death from extreme prematurity 
(Table 2.3), 55 (35 percent) were associated with placental abruption, 54 (34 percent) bleeding of 
undetermined origin, 47 (30 percent) other bleeding, and one placenta praevia.
Specific perinatal conditions contributed to a significant number of neonatal deaths from extreme 
prematurity (84 (14 percent)) (Table 2.3). The antecedent causes in these cases were twin-to-twin 
transfusion syndrome (31 (5 percent)), uterine anomalies (40 (7 percent)), rupture of membranes after 
amniocentesis (4), and other (9).
Perinatal infection was implicated as obstetric antecedent cause (PSANZ-PDC) or primary neonatal 
cause (PSANZ-NDC) of death in 50 (7 percent) deaths from 20 to 24 weeks gestation (Table 2.3). 
These included infections from Group B Streptococcus (10), Escherichia coli (13), other specified 
bacterial (12), unspecified bacterial (7), fungal (2), Cytomegalovirus (1), and other unspecified 
organism (5).
Mothers of 21 babies who died after birth at 23 weeks (11 percent) had a complete course of 
antenatal corticosteroids and 41 (33 percent) at 24 weeks. This compares to 34 percent of mothers 
respectively at 25 and 26 weeks (24/71, 17/50), and 43 percent (43/100) from 27 to 31 weeks. 
These data would suggest that many babies at 23 weeks were not prepared for active management or 
resuscitation over this time period in New Zealand. 
Planning for location of birth and preparation with administration of antenatal corticosteroids should be 
considered at a gestation of 23+0 weeks gestation. Both overseas and in New Zealand, a 65 percent 
rate of completing a course of antenatal corticosteroids in babies who were live born, resuscitated 
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and transferred to the neonatal intensive care unit has been reported, although 80 percent might be 
an appropriate and achievable goal (Kyser et al 2012; Berry et al 2017; Travers et al 2018). This 
would enable best outcomes for the baby if resuscitation is considered appropriate at the time of birth 
(see “Practice point: Care for women in preterm labour or requiring delivery at 23+0 to 24+6 weeks 
gestation”).
Of the 729 babies who died after birth at 20 to 24 weeks, 170 (23 percent) were twins or other 
multiples. Of the 305 multiparous mothers of singletons, 119 (39 percent) had a history of previous 
preterm birth, including 64 (21 percent) who had a history of previous preterm birth between 20 and 
28 weeks gestation. Of babies who died after birth at 20 to 24 weeks, 15 percent of their mothers (18) 
had a cervical suture placed in this pregnancy.
Multivariable analysis
The multivariable analysis was limited to deaths merged with the MAT denominator dataset and to 
mothers who were registered for care with an LMC (either a midwife, obstetrician or GP) claiming from 
the Section 88 Primary Maternity Services Notice and births from 2008. This was because smoking, 
parity, and BMI data were only consistently available in the denominator for this population which 
comprises approximately 87 percent of the birthing population in New Zealand from 2008 to 2016. 
The multivariable analysis (Table 2.4) estimates the independent association of the sociodemographic 
factors included in the model with extreme preterm neonatal death. Factors with a statistically significant 
independent association with neonatal death of non-anomalous babies after birth at 20 to 24 weeks 
gestation included maternal age under 20 years, BMI of 35 and over, multiple pregnancy, smoking, 
Māori, Pacific and Indian ethnicity, increasing deprivation decile, and first birth compared to later 
births.
The increased risk associated with Māori, Pacific and Indian ethnicity reflects unmeasured factors; for 
example, factors relating to access to health services and quality of care, rather than factors related to 
ethnicity per se. More detailed work is required to understand these factors. One important factor that 
contributes to ethnic differences in neonatal mortality at 20 to 24 weeks gestation is the proportion 
of all babies born to Māori (0.27 percent), Pacific (0.28 percent), and Indian (0.27 percent) mothers 
compared to mothers of all other ethnic groupings (0.12 percent) who are born at extremely early 
gestations (20 to 24 weeks) (Figure 2.13). Thus, to address inequity in neonatal mortality, the factors 
that lead to extreme preterm birth need to be identified and addressed. (See “Practice point: Care for 
women in preterm labour or requiring delivery at 23+0 to 24+6 weeks gestation”).
If the inequity in neonatal deaths at 20 to 24 weeks gestation among Māori, Pacific, and Indian women 
compared with other ethnic groupings was eliminated, 31 excess neonatal deaths would have been 
prevented from 2007 to 2016.
Strategies that may reduce these inequities include providing improved access to continuity of midwifery 
care (Sandall et al 2016); early antenatal care for Māori, Pacific and Indian women, who have lower 
rates of registration with an LMC in the first trimester (Table 2.8); and access to obstetric services that 
provide specialised education, offer support and intervention for women with risk factors for preterm 
birth (Malouf and Redshaw 2017). 
Although the Ministry of Health via the Maternity Quality and Safety Programme (Allen + Clarke 2015) 
and the Better Public Service Results 2 (early access to midwifery services) may impact on very preterm 







OR 95% CIN=451,149 n=400 (/1000live births)
Maternal age
<20 26,304 46 1.75 1.62 1.13 2.32 1.45 1.00 2.10
20–24 79,536 86 1.08 1 1
25–29 117,379 102 0.87 0.8 0.6 1.07 0.99 0.73 1.33
30–34 132,713 92 0.69 0.64 0.48 0.86 0.94 0.68 1.3
35–39 77,894 60 0.77 0.71 0.51 0.99 1.13 0.79 1.63
≥40 17,323 14 0.81 0.75 0.42 1.31 1.09 0.6 1.96
BMI (kg/m2)  
<18.50 12,905 10 0.77 1.06 0.56 2 1.01 0.53 1.93
18.50–24.99 225,176 165 0.73 1
25.00–29.99 116,370 109 0.94 1.28 1 1.63 1.17 0.91 1.49
30.00–34.99 57,630 59 1.02 1.4 1.04 1.88 1.21 0.89 1.64
35.00–39.99 25,164 36 1.43 1.95 1.36 2.8 1.65 1.13 2.40
≥40.00 13,904 21 1.51 2.06 1.31 3.25 1.70 1.06 2.72
Baby sex
Female 219,335 187 0.85 1 1
Male 231,814 213 0.92 1.08 0.89 1.31 1.09 0.89 1.32
Plurality
Singleton 440,628 310 0.7 1 1
Multiple pregnancy 10,521 90 8.55 12.3 9.68 15.51 13.9 10.9 17.6
Smoking
Non-smoker 382,881 296 0.77 1 1
Smoker 68,268 104 1.52 1.97 1.58 2.47 1.80 1.39 2.33
Ethnicity (maternal)
New Zealand European 187,256 123 0.66 1
Māori 114,734 139 1.21 1.56 1.27 1.92 1.42 1.08 1.88
Pacific 38,351 54 1.41 1.68 1.26 2.24 2.00 1.41 2.83
Indian 16,122 29 1.8 2.11 1.45 3.08 3.00 1.97 4.55
Other Asian 39,842 30 0.75 0.84 0.58 1.21 1.43 0.95 2.15
Other European 46,478 19 0.41 0.43 0.27 0.69 0.66 0.41 1.08
Other 86,320 6 0.07 0.81 0.36 1.81 1.15 0.51 2.62
Deprivation decile (per unit) 1.11 1.07 1.16 1.06 1.02 1.11
Parity  
Nulliparity (0) 186,131 204 1.1 1.44 1.14 1.8 1.45 1.14 1.83
1 150,628 115 0.76 1 1
2 67,177 50 0.74 0.97 0.7 1.36 0.87 0.62 1.22
3 26,063 15 0.58 0.75 0.44 1.29 0.55 0.32 0.96
4 10,998 5 0.45 0.6 0.24 1.46 0.36 0.15 0.90
≥5 10,152 11 1.08 1.42 0.76 2.64 0.78 0.41 1.48
Year of birth (per year) 1.05 1.01 1.09 1.04 1 1.08
Table 2.4: Multivariable analysis of sociodemographic factors associated with neonatal death among 
babies born at 20–24 weeks gestation without congenital anomalies 2008–2016*
* Limited to deaths merged with the MAT denominator and to mothers who were registered for care with an LMC (either a midwife, obstetrician or GP) claiming 
from the Section 88 Primary Maternity Services Notice.
OR = odds ratio.
CI = confidence interval.
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Figure 2.13: Gestational age at birth by maternal ethnicity among live born babies born at 20–26 
weeks without congenital anomalies 2007–2016
Deaths after birth at 23 to 26 weeks gestation among babies without congenital anomalies
The analyses in Table 2.5 to Table 2.7 and Figure 2.14 and Figure 2.15 are limited to deaths merged 
with the MAT dataset.
Resuscitation
Resuscitation was attempted at 23 weeks gestation for 153 of 258 live births (59 percent), and for 391 
of 406 live births (96 percent) at 24 weeks (Table 2.5).
From 2007 to 2016, at 23+0 to 23+6 weeks gestation, half of non-anomalous live born babies 
survived to 28 days when an attempt was made at resuscitation (76 survivors) and almost three 
quarters (73 percent) at 24 weeks (284 survivors). 
At 23 weeks gestation, 29.5 percent of all non-anomalous live born babies survived to 28 days, and 
at 24 weeks gestation 70 percent survived to 28 days. These data apply to all non-anomalous infants 
born in New Zealand at any unit or at home, irrespective of attempt at resuscitation. These national 
outcomes compare to 46 percent survival to hospital discharge of live born babies (inborn and outborn) 
at 23 weeks gestation and 77 percent survival at 24 weeks reported in Western Australia 2004–2010, 
where rates of provision of resuscitation are high (Sharp et al 2018). 
* Other ethnicity includes New Zealand and Other European; Other Asian; Middle Eastern, Latin American or African (MELAA); Other ethnicities; and unknown 
and not stated.
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Table 2.5: Survival (to 28 days) after birth at 23 and 24 weeks gestation 2007–2016
Total births 
Gestation at birth (weeks)
23 24
n=627 n=629
n % n %
Congenital anomalies who died (SB or TOP or NND) 143 22.8 84 13.4
Non-anomalous stillbirths 177 28.2 116 18.4
Non-anomalous termination of pregnancy 49 7.8 23 3.7
Non-anomalous live birth 258 41.1 406 64.5
 No resuscitation 105 16.7 15 2.4
 Resuscitation attempted* 153 24.4 391 62.2
 Died <28 days 77 12.3 107 17
 Survived to 28 days 76 12.1 284 45.2
Survival to 28 days
Of all births 76 12.1 284 45.2
Of non-anomalous births 76 15.7 284 52.1
Of non-anomalous live births 76 29.5 284 70
Of resuscitated non-anomalous live births 76 49.7 284 72.6
* PMMRC data.
SB = stillborn.
TOP = termination of pregnancy.
NND = neonatal death.
In a recent report from Wellington of births from 2003 to 2012, survival rates at two years of inborn 
live born babies where resuscitation was attempted were 22/38 (58 percent) at 23 weeks and 36/60 
(60 percent) at 24 weeks gestation (Berry et al 2017).
Table 2.6: Resuscitation, survival (to 28 days) and antenatal care by maternal ethnicity for live born 
babies at 23–26 weeks gestation without congenital anomalies 2007–2016
Māori Pacific Indian Other# Chi-
square 
test (p)
n=578 n=244 n=81 n=774
n % n % n % n %
Resuscitation attempted  533  92.2  216  88.5  70  86.4  734  94.8 <0.001
Survival to 28 days – of live births  417  72.1  175  71.7  58  71.6  603  77.9 0.051
Survival to 28 days – of resuscitated live births 417  78.2 175  81.0 58  82.9 603  82.2 0.35
Antenatal care* n=417 n=125 n=55 n=645
First trimester  213  51.1  44  35.2  28  50.9  435  67.4 
Second trimester or no antenatal care  204  48.9  81  64.8  27  49.1  210  32.6 <0.001
* Limited to mothers who were registered for care with an LMC (either a midwife, obstetrician or GP) claiming from the Section 88 Primary Maternity Services 
Notice 2008–2016.
# Other ethnicity includes New Zealand and Other European; Other Asian; Middle Eastern, Latin American or African (MELAA); Other ethnicities; unknown and 
not stated.
Nationally, live born babies of Māori, Pacific and Indian mothers were statistically significantly less 
likely to have an attempt at resuscitation than babies of Other (predominantly non-Indian Asian and 
European) ethnicity mothers (Table 2.6). Babies of Māori and Pacific mothers were significantly less 
likely to survive compared to babies of mothers of other ethnic groupings among all non-anomalous live 
born babies at 23 to 26 weeks gestation (p=0.05). 
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The proportion of women who were able to register with an LMC in the first trimester of pregnancy was 
lower among Māori, Pacific and Indian mothers. The rates of first trimester registration among Māori, 
Pacific and Indian mothers will almost certainly be lower than these data suggest, as the analysis of 
antenatal care in Table 2.6 is limited to the 87 percent of women who engaged with a community 
midwife, private obstetrician or GP for their LMC.
Place of birth
The analysis in this section explores the effect of place of birth, specifically level of neonatal service 
at hospital of birth on survival, at current limits of viability. Transfer may have occurred after birth, but 
this analysis ONLY relates to place of birth. The analysis includes babies born at 25 and 26 weeks 
gestation to provide a broader clinical context. 
Table 2.7: Survival (to 28 days) and level of hospital of birth among babies without congenital 
anomalies by gestation at birth 2007–2016 
Hospital of 
birth
Gestation at birth (weeks)

























Tertiary* 64 126 34 252 101 71 361 51 88 415 39 91
Secondary 12 47 20 28 16 64 29 11 73 58 7 89
Primary/home 0 4 0 1 1 50 4 2 67 11 1 92
Missing place 
of birth
0 5 3 4 7 6 8 3
Tertiary unit only
Middlemore 7 42 14 45 22 67 65 10 87 70 5 93
Christchurch 5 18 22 12 17 41 38 8 83 47 3 94
Dunedin 5 9 36 26 2 93 26 0 100 26 0 100
Waikato 6 13 32 33 17 66 56 14 80 63 13 83
Wellington 31 20 61 72 15 83 74 5 94 90 9 91
Auckland 10 24 29 64 28 70 102 14 88 119 9 93
* Indicates neonatal intensive care available at hospital of birth; secondary unit survivors are transferred after birth.
At 23 weeks gestation, from 2007 to 2016, 190 non-anomalous babies were born at tertiary units (76 
percent), 59 at secondary units, and nine at primary units or at home or birthplace was unknown (Table 
2.7). At 24 weeks gestation, 353 (89 percent) non-anomalous babies were born at tertiary units, 44 at 
secondary units, and nine babies at primary units or at home or birthplace was unknown. Only small 
numbers of babies were born at primary units between 23 and 26 weeks gestation and so these data 
are not included in Figure 2.14. 
The relative risk of survival after birth at 23 weeks for babies born at tertiary compared to those born at 
secondary units was 1.66 (95% CI 0.96–2.85); at 24 weeks, 1.12 (95% CI 0.89–1.42); at 25 weeks, 
1.21 (95% CI 1.00–1.47); and at 26 weeks, 1.02 (95% CI 0.94–1.12). However, when considered 
together the relative risk of survival from 23 to 26 weeks was statistically significantly higher for babies 
born in a tertiary compared to a secondary hospital with a relative risk of 1.27 (95% CI 1.13–1.42) 
(p<0.0001) (Figure 2.14).
Boland et al (2015) also found improved survival for babies inborn at tertiary neonatal units between 
22 and 27 weeks gestation compared to babies outborn in Victoria, Australia.
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Figure 2.14: Survival (to 28 days) of live inborn babies without congenital anomaly by gestation at 
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Survival to one year of live born babies without congenital anomaly after birth from 23 to 26 weeks 
gestation was also statistically significantly higher for babies born in tertiary compared to secondary 
maternity units from 2007 to 2015 (2016 data incomplete at publication; data not supplied) 
(p=0.006).
Figure 2.15: Survival (to 28 days) of live inborn babies by gestation at birth and tertiary unit of birth 
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There were statistically significant differences in survival rate to 28 days by tertiary unit at gestations 
of 23 to 25 weeks (p<0.001; p<0.001; p=0.047 respectively) but not at 26 weeks (p=0.058) 
(Figure 2.15). The units with the highest survival rates at 23 to 25 weeks gestation were Dunedin and 
Wellington, both of which are units known to have had an active approach to resuscitation at 23 weeks 
(93 percent and 94 percent compared to 35 percent to 68 percent in the remaining units; p<0.001) 
(data not given). 
Survival to one year from 2007 to 2015 among live inborn babies without congenital anomaly, after 
birth at 23 to 26 weeks gestation, by tertiary unit of birth, was less than at 28 days but still differed by 
unit (p<0.00001) (data not supplied).
There was a significant difference in the proportions of babies where resuscitation was attempted 
from 23 to 26 weeks gestation at tertiary units, with rates ranging from 87 percent (232/266) at 
Middlemore Hospital, 93 percent (137/148) at Christchurch, 94 percent (349/370) at Auckland, and 
97 percent (209/215) at Waikato, to 98 percent (311/316) and 99 percent (93/94) at Wellington 
and Dunedin Hospitals (p<0.001). The proportion of mothers completing a course of antenatal 
corticosteroids, transferred to the tertiary hospital in utero, and the proportion arriving with birth 
imminent, are all unknown for survivors, and so the contribution of these factors to outcome cannot be 
determined from these data. These factors may be important confounders in the association between 
tertiary unit of birth and survival. In addition, in 2010 and 2011 there were devastating earthquakes in 
Christchurch, which may have had some impact on neonatal outcomes.
The finding that birth in the units with an active approach to resuscitation at 23 weeks gestation was 
associated with better survival out to 25 weeks is consistent with findings in previous reports (Smith et al 
2012; Rysavy et al 2015). However, the role of other factors cannot be excluded. 
New Zealand neonatal intensive care units have been aware that there are different approaches to 
resuscitation practice by unit and are working within the New Zealand Neonatal Network (www.
starship.org.nz/for-health-professionals/new-zealand-child-and-youth-clinical-networks/newborn-clinical-
network/) to develop a consensus to align practice across the country.
Most importantly, the finding that there were differences in survival by unit suggests that further 
improvements are possible. 
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Table 2.8: Characteristics of mothers whose babies were live born at 23–26 weeks by level of hospital 
of birth excluding deaths with congenital anomalies 2007–2016
Births 
23–26 weeks
Level of hospital of birth
Tertiary Secondary Primary^ Missing
n=1,677 n=1,409 n=208 n=24 n=36
n % n % n % n % n % p*
Gestation at birth (weeks)
23  258  15.4  190  13.5  59  28.4  4  16.7  5  13.9 
24  406  24.2  353  25.1  44  21.2  2  8.3  7  19.4 
25  471  28.1  412  29.2  40  19.2  6  25.0  13  36.1 
26  542  32.3  454  32.2  65  31.3  12  50.0  11  30.6 <0.001
Resuscitation attempt
Attempted  1,553  92.6  1,331  94.5  170  81.7  20  83.3  32  88.9 
<0.001
No attempt  124  7.4  78  5.5  38  18.3  4  16.7  4  11.1 
Ethnicity (maternal)
Māori  578  34.5  455  32.3  97  46.6  12  50.0  14  38.9 
Pacific peoples  244  14.5  216  15.3  18  8.7  4  16.7  6  16.7 
Indian  81  4.8  76  5.4  4  1.9  -  -  1  2.8 
non-Māori non-Pacific non-
Indian
 774  46.2  662  47.0  89  42.8  8  33.3  15  41.7 <0.001
Maternal age
<20  196  11.7  151  10.7  33  15.9  3  12.5  9  25.0 
20-34  1,140  68.0  949  67.4  151  72.6  17  70.8  23  63.9 
≥35  341  20.3  309  21.9  24  11.5  4  16.7  4  11.1 0.0053
Deprivation decile
1 (least deprived)  180  10.7  160  11.4  19  9.1  1  4.2  -  - 
2  208  12.4  179  12.7  23  11.1  4  16.7  2  5.6 
3  253  15.1  215  15.3  28  13.5  4  16.7  6  16.7 
4  395  23.6  332  23.6  48  23.1  8  33.3  7  19.4 
5 (most deprived)  626  37.3  521  37.0  90  43.3  6  25.0  9  25.0 0.54
Missing  15  0.9  2  0.1  -  -  1  4.2  12  33.3 
Trimester at first LMC 
registration‡  n=1,112
 Tertiary  Secondary  Primary^  Missing 
 n=913  n=157  n=18  n=24 
First trimester  708  63.7  599  65.6  95  60.5  4  22.2  10  41.7 
0.0031Second trimester  369  33.2  288  31.5  54  34.4  13  72.2  14  58.3 
No LMC antenatal care  30  2.7  25  2.7  5  3.2  -  -  -  - 
Invalid data  5  0.4  1  0.1  3  1.9  1  5.6  -  - 
^ Home, birthing unit, Level 1 hospital
* Statistical testing excludes missing data
‡ limited to mothers who were registered for care with an LMC (either a midwife, Obstetrician or GP) claiming from the Section 88 Primary Maternity Services 
Notice 2008–2016
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Table 2.9: Perinatal death classification, pregnancy management and history of preterm birth by 
ethnicity among neonatal deaths 23–26 weeks without congenital anomalies 2007–2016
Neonatal deaths 23–26 
weeks
Māori Pacific peoples Indian Other* Chi-
square 
test (p)
n=159 n=69 n=26 n=174
n % n % n % n %
Perinatal death classification (PSANZ-PDC)
Perinatal infection  4  2.5  11  15.9  -  -  5  2.9 
Hypertension  7  4.4  -  -  -  -  11  6.3 
Antepartum haemorrhage  32  20.1  17  24.6  8  30.8  32  18.4 
Maternal conditions  1  0.6  2  2.9  1  3.8  7  4.0 
Specific perinatal conditions  15  9.4  5  7.2  2  7.7  20  11.5 
Fetal growth restriction  -  -  1  1.4  -  -  2  1.1 
Spontaneous preterm  100  62.9  33  47.8  15  57.7  97  55.7 0.002
Cervical suture in this pregnancy  11  6.9  5  7.2  2  7.7  3  1.7 0.094
Antenatal corticosteroids  35  22.0  11  15.9  5  19.2  52  29.9 0.093
Multiparous mothers  n=101  n=39  n=12  n=77 
History of preterm birth  44  43.6  18  46.2  2  16.7  23  29.9 0.075
Between 20 and 28 weeks  19  18.8  8  20.5  1  8.3  11  14.3 0.66
Although not statistically significant (p=0.09), Māori, Pacific and Indian mothers whose babies 
died after birth at 23 to 26 weeks gestation were less likely to have received a completed course of 
antenatal corticosteroids than mothers of other (predominantly European) ethnic groupings (Table 2.9). 
Further, a history of prior preterm birth was more common among multiparous mothers of babies who 
died after birth at 23 to 26 weeks if they were Māori (44 percent) or Pacific (46 percent) than Other 
(30 percent) or Indian (17 percent) mothers, although this was not statistically significant (p=0.08).
Non-anomalous babies live born at 23 weeks gestation were more likely to have been born at a 
secondary unit than a tertiary unit; and live born babies at 23 to 26 weeks were more likely to receive 
an attempt at resuscitation if born at a tertiary unit than a secondary unit (Table 2.8). However, the 
reasons for these differences, including potential confounding factors, are not known and require further 
investigation. 
In addition, Māori mothers and mothers under 20 years of age giving birth at 23 to 26 weeks gestation 
were more likely to birth in a secondary unit than mothers of all other ethnic groupings and mothers 
aged 20 years and older (Table 2.8). 
* Other ethnicity includes New Zealand and Other European; Other Asian; Middle Eastern, Latin American or African (MELAA); Other ethnicities; unknown and 
not stated.
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Practice point: Care for women in preterm labour or requiring delivery at 23+0 to 24+6 
weeks gestation
Care for pregnant women at risk of birthing at the lower extremes of gestational age (23+0 to 24+6 weeks) 
remains a complex area of perinatal medicine. 
The clinical care pathway is individualised to reflect individual medical complexity and co-morbidity, parental 
wishes and resource availability. 
All New Zealand tertiary neonatal centres offer resuscitation and neonatal intensive care to infants born at 23 
and 24 weeks gestation. Overall mortality at 23 to 24 weeks is higher than at more mature gestations, but 
high-quality survival is possible.
Care of women with threatened preterm labour or who require iatrogenic preterm birth at 23+0 to 24+6 weeks 
gestation involves consideration of the needs of the mother as well as the baby. Mode of birth is an important 
part of this discussion as a caesarean section at this gestation not only has risks for the mother at the time of this 
birth but also has significant implications for subsequent pregnancies, and may not improve neonatal outcomes.
Integrated care for women in threatened preterm labour or women requiring iatrogenic birth at 23+0 to 24+6 
weeks gestation should include open discussion between the family and the LMC, obstetric, and neonatal 
or paediatric services. Best clinical care may follow a palliative or intensive care pathway, according to the 
specific requirements of each clinical situation. Even if there is a plan for intensive care, at this gestation 
resuscitation of the newborn is not always successful. 
Survival and outcomes for infants born at 23+0 to 24+6 weeks gestation are improved if they deliver in a 
tertiary centre. Early consultation with tertiary obstetrics/neonates is recommended.
Parents, families and whānau should be counselled that babies born at 23 weeks gestation who have not been 
prepared for early birth (eg, antenatal corticosteroids, magnesium sulphate) may appear vigorous at birth. 
Despite this, admission to a neonatal intensive care unit of an unprepared baby is still likely to result in severe 
morbidity and/or mortality.
Points for particular consideration in the context of imminent birth at 23+0 to 24+6 weeks 
gestation
Transfer to a tertiary centre for collaborative discussion and planning is optimal. Transfer is not only for 
those wanting active management but also for all to have a tertiary consultation. Parents, families and 
whānau should be counselled antenatally about the possible range of outcomes for the baby and this should 
be individualised to the clinical setting. These discussions should be led by senior obstetric and neonatal 
staff and should reflect local institutional outcome data as well as current international data on long-term 
outcomes, particularly in relation to neurodevelopmental and cognitive outcomes. Parents, families and 
whānau should be in the centre of decision-making and be aware of the range of possible interventions at 
this gestation.
Appropriate care options as agreed by parents and senior clinical team include:
1. Palliative
a. No maternal corticosteroids or magnesium sulphate
b. No fetal monitoring or operative birth
c. A palliative care pathway for the baby from birth (stay with parents for comfort cares; no neonatal 
intensive care unit admission)
2. Active
a. Maternal corticosteroids and magnesium sulphate
b. Planning with parents, families and whānau, ideally prior to active labour, regarding whether or not 
there will be fetal monitoring and intervention (this should include the agreed plan for mode of birth)
c. Senior neonatal assessment at birth with planned neonatal intensive care unit admission 
3. Interim (for parents, families and whānau who require more time to make this decision)
a. Maternal corticosteroids and magnesium sulphate
b. Further discussion with parents, families and whānau, regarding whether or not there will be fetal 
monitoring and intervention.
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Practice point: Prevention of preterm birth
Prevention of preterm birth requires a multifaceted holistic approach.
In New Zealand, Māori, Pacific and Indian mothers, mothers under 20 years of age, mothers who smoke and 
mothers living in areas of socioeconomic deprivation are at increased risk of preterm birth. Women who have 
delivered a previous preterm baby are at especially high risk.
Prevention strategies include:
1. Provision of services that enable registration with an LMC in the first trimester, including information for 
women on what LMCs are working in their area and how to access these LMCs.
2. Early access to smoking cessation services, recognition and support to address alcohol and substance 
abuse and family violence. 
3. Screening and treating vaginal infections before 20 weeks (Sangkomkamhang et al 2015).
4. Screening for asymptomatic urinary tract infections.
5. Secondary/tertiary obstetric services that provide specialised education and offer support and intervention 
for women with risk factors for preterm birth* (Whitworth et al 2011).
6. Progesterone treatment has been demonstrated to reduce preterm birth in women with a short cervix 
(<25mm) on transvaginal ultrasound between 16 and 24 weeks gestation (Dodd et al 2013; Keelan and 
Newnham 2017).
7. Cervical cerclage for women with a short cervix (<25mm) and a history of previous preterm birth or 
treatment to their cervix (Dodd et al 2013).
* Current literature suggests some benefit of specialist clinics aimed at preventing preterm labour and delivery, but methodological weakness across these 
studies indicates caution, as the most positive reported outcomes are from retrospective cohort studies.
Deaths after birth at 25 to 34 weeks gestation among babies without congenital anomalies
Table 2.10: Perinatal death classification (PSANZ-PDC) by neonatal death classification (PSANZ-NDC) 
for neonatal deaths among births from 25–34 weeks without congenital anomalies 2007–2016
Perinatal death classification 
(PSANZ-PDC)






Infection Neurological Gastro-intestinal Other Total
Perinatal infection  -  -  17  -  2  -  19 
Hypertension  1  9  7  6  3  -  26 
Antepartum haemorrhage  2  9  6  23  3  2  45 
Maternal conditions  -  2  5  7  1  1  16 
Specific perinatal conditions  1  9  2  9  2  11  34 
Hypoxic peripartum death  -  -  -  1  -  -  1 
Fetal growth restriction  -  4  2  1  2  3  12 
Spontaneous preterm  6  33  25  27  8  11  110 
Total  10  66  64  74  21  28  263 
From 25 to 34 weeks gestation, 147 (56 percent) of 263 deaths were associated with spontaneous 
preterm birth, although spontaneous preterm was not always the primary antecedent cause of death, 
as shown in Table 2.10 (that is, spontaneous preterm birth was identified as the secondary or tertiary 
perinatal death classification).
From 25 weeks, some live born babies die from complications of prematurity, most commonly 
respiratory distress syndrome (23) and pulmonary hypoplasia (24). Deaths of babies born from 25 to 
34 weeks often occur in neonatal units and, aside from the direct consequences of preterm birth, are 
most often from infectious and neurological causes.
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Neurological deaths (74) from 25 to 34 weeks were from hypoxic ischaemic encephalopathy (41), 
intraventricular haemorrhage (29), and other causes (4). Twenty-one of these neurological deaths 
occurred after birth at 25 weeks (16 from intraventricular haemorrhage), with 2 to 10 after birth 
at each of 26 to 34 weeks. Intracranial haemorrhage of any type was uncommon after 26 weeks 
gestation.
Of the 41 deaths after birth at 25 to 34 weeks gestation who died of hypoxic ischaemic 
encephalopathy, 27 were born in hospitals with a Level 3 neonatal intensive care unit. Of the 10 born 
in hospitals with a Level 2 neonatal unit, nine were transferred prior to death.
Of the 32 who died from intracranial haemorrhage, 24 were born in hospitals with a Level 3 neonatal 
intensive care unit, six in Level 2, and two at home. 
Deaths with infection (either PSANZ-PDC or PSANZ-NDC) (66) were most commonly due to Group B 
Streptococcus (10), Escherichia coli (11), and Staphylococcus aureus (7). Forty-seven (72 percent) were 
born in hospitals with Level 3 neonatal intensive care units.
Twenty-one babies born from 25 to 30 weeks gestation (at 450 to 1590g) died from necrotising 


















































Perinatal death classification (PSANZ-PDC)
Māori Pacific peoples Indian Other*
Figure 2.16: Cause-specific (PSANZ-PDC) neonatal death rate after birth at 25–34 weeks gestation 
excluding congenital anomalies per 1000 babies in utero from 25 weeks by maternal ethnicity 2007–
2016
* Other ethnicity includes New Zealand and Other European; Other Asian; Middle Eastern, Latin American or African (MELAA); Other ethnicities; unknown and 
not stated.
Babies of Pacific mothers were significantly more likely to die from perinatal infection and from 
antepartum haemorrhage after birth at 25 to 34 weeks gestation than babies of Māori and Other 
ethnic groupings. Babies of Māori mothers were more likely to die from spontaneous preterm birth at 
25 to 34 weeks gestation than babies of Indian and Other ethnic groupings (Figure 2.16). 






































Neonatal death classification (PSANZ-NDC)
Māori Pacific peoples Indian Other*
* Other ethnicity includes New Zealand and Other European, Other Asian, MELAA, Other ethnicities; unknown and not stated.
Babies of Māori mothers were significantly more likely to die after birth at 25 to 34 weeks gestation 
from cardio-respiratory disorders (which are consequences of preterm birth) than babies of Pacific 
and Other (predominantly non-Indian Asian and European) ethnic groupings. Pacific babies were 
significantly more likely to die after birth at 25 to 34 weeks gestation from infection than babies of 
Māori or Other ethnic groupings (Figure 2.17).
These figures demonstrate that spontaneous preterm birth is still a major underlying obstetric problem 
in neonatal death after birth at 25 to 34 weeks gestation, though neonates may ultimately die due to 
failure of different systems – for example, cardio-respiratory, neurological and gastrointestinal – as well 
as from infection.
Deaths after birth from 35 weeks gestation among babies without congenital anomalies
Table 2.11: Perinatal death classification (PSANZ-PDC) by neonatal death classification (PSANZ-NDC) 
among births from 35 weeks gestation without congenital anomalies 2007–2016
Perinatal death classification 
(PSANZ-PDC)




Infection Neurological Gastro-intestinal Other Total
Perinatal infection  -  36  3  -  1  40 
Hypertension  -  -  2  -  -  2 
Antepartum haemorrhage  -  -  11  -  -  11 
Maternal conditions  -  1  7  -  1  9 
Specific perinatal conditions  3  -  13  -  9  25 
Hypoxic peripartum death  3  2  112  -  1  118 
Fetal growth restriction  1  1  14  -  6  22 
Spontaneous preterm  2  3  5  1  6  17 
No obstetric antecedent  2  14  2  -  63  81 
Total  11  57  169  1  87  325 
Figure 2.17: Cause-specific (PSANZ-NDC) neonatal death rate after birth at 25–34 weeks gestation 
excluding congenital anomalies per 1000 babies in utero from 25 weeks by maternal ethnicity 2007–
2016
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The most common cause of death from 35 weeks gestation was neurological death due to peripartum 
injury (neurological death from hypoxic peripartum injury) (Table 2.11). These babies were included 
in the neonatal encephalopathy (NE) dataset and discussed in detail in chapter “3 Neonatal 
Encephalopathy 2016”.
The second most common group of deaths of babies live born after 35 weeks gestation without 
congenital anomalies was SUDI deaths, accounting for 68 neonatal deaths from 2007 to 2016. These 
babies were included in the review of SUDI deaths in New Zealand in 2017 by the Child and Youth 
Mortality Review Committee (CYMRC 2017).
Infection and neonatal death after birth from 35 weeks
There were 61 babies who died due to perinatal or neonatal infection. The most common aetiology 
was Group B Streptococcus (14 congenital and 2 acquired). 
A previous review of early onset neonatal Group B Streptococcal sepsis in New Zealand showed that 
in 31 percent of cases, intrapartum antibiotic prophylaxis was not provided when indicated based on 
maternal risk factors (Darlow et al 2016). Intrapartum prophylaxis should be provided according to the 
national consensus guideline (Darlow et al 2015).
Review of SUDI deaths from 35 weeks gestation
For the purpose of this review SUDI death included babies where the classification of cause of death 
was PSANZ-NDC 7.1 Sudden Infant Death Syndrome (4), PSANZ-NDC 7.31 Trauma – accidental 
(7) and PSANZ-NDC 7.91 Unclassified Sudden Infant death (57). This is in line with the revision of 
the PSANZ classification system in 2018 to report these deaths under the classification of ‘Sudden 
unexpected death in infancy (SUDI)’ (PSANZ 2018).
For these 68 babies identified as SUDI deaths after birth from 35 weeks gestation, the PMMRC Rapid 
Reporting and Classification forms, Coronial post-mortem reports, and where available, Coronial 
findings (62), SUDI liaison reports (26), DHB perinatal mortality reports and correspondence from 
clinicians were reviewed. 
The appointment of SUDI liaison officers during 2009 has improved the information available on SUDI 
deaths considerably. Coroner’s findings were not available for four of the seven SUDI deaths from 2015 
and two of the six deaths from 2016. 
Forty-four (65 percent) of mothers of babies who were SUDI deaths from 35 weeks were Māori and 12 
(18 percent) were Pacific (Table 2.12). Eight deaths occurred in hospital (12 percent). Four babies died 
prior to discharge and were less than 32 hours of age, and four were readmitted and died in hospital 
after events at home. 
The four babies who died in hospital prior to discharge were assessed as well at birth (Apgars 
9 at 1 minute and 10 at 5 minutes) and were found collapsed during skin-to-skin contact or after 
breastfeeding. Most reported similar cases relate to unobserved prone skin-to-skin care, and maternal 
smoking has been reported as an important risk factor (Lavezzi et al 2004; Lavezzi and Matturri 
2012). While there are important benefits from skin-to-skin care for babies born at 35 weeks or more, 
such as improved breastfeeding (Moore et al 2016), prone positioning, even on the mother’s chest, is 
not without risk. Skin-to-skin care in the immediate postpartum period should be practiced according to 
Ministry of Health and multi-disciplinary consensus statement guidelines. Colour, tone, and respiration 
of the baby should be monitored at all times during periods of skin-to-skin contact (Ministry of Health 
2012c).
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Māori  44  64.7 
Pacific peoples  12  17.6 
Other  12  17.6 
Deprivation quintile
1 (least deprived)  4  5.9 
2  7  10.3 
3  5  7.4 
4  20  29.4 
5 (most deprived)  32  47.1 
Place of birth
Home/Born before arrival at birthing unit or hospital  5  7.4 
Hospital level 1 or birthing unit  10  14.7 
Hospital level 2  28  41.2 
Hospital level 3  25  36.8 
Place of death
Hospital  8  11.8 
Own home  52  76.5 
Friend or relative’s home  8  11.8 






The majority of mothers were known to have smoked in pregnancy 48 (71 percent). Smoking status in 
the postnatal period was unknown for 43 mothers as the smoking status was not recorded. However, 
20 mothers were noted to smoke in the postnatal period. Whānau smoking status was unknown in 48 
cases (68 percent). In 17 cases (25 percent), whānau were known to be smoking postnatally in the 
home. 
Twelve caregivers (18 percent) were known to have been consuming alcohol on the night of the baby’s 
death.
Two caregivers (3 percent) were known to use illicit drugs at the time of death. Methamphetamine was 
found on routine toxicology testing of three babies.
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Table 2.13: Sleeping risk factors among SUDI deaths from 35 weeks gestation 2007–2016 by 
maternal ethnicity
Total Māori Pacific Non-Māori non-Pacific
n=68 n=44 n=12 n=12
n % n % n % n %
Location of sleep at event or death
Home 56 82 38 86 8 67 10 83
Family or friend’s home 8 12 6 14 2 17
Hospital 4 6 0 2 17 2 17
Stated place of sleep at event or death
Cot 8 12 4 9 1 8 3 25
Pēpi-Pod® 1 1 1 8 0
Single bed 5 7 4 9 1 8 0
Double/Queen bed 46 68 30 68 9 75 7 58
Couch/Chair 6 9 4 9 0 2 17
Not stated 2 3 2 5 0 0
Other persons sleeping with 
baby at event or death 54 79 35 80 10 83 9 75
Adults 36 53 22 50 6 50 8 67
Adults and siblings 18 26 13 30 4 33 1 8
Other sleep risk factors identified at event or death
Pillow in bed 8 12 7 16 1 8
Rolled blankets in bed 1 1 1 2
Sleep position at time of death
Back 39 57 25 57 8 67 6 50
Side 9 13 3 7 2 17 4 33
Front 2 3 2 5
Not stated 18 26 14 32 2 17 2 17
Usual place of sleep
Own sleeping place 36 53 24 55 5 42 7 58
Cot 31 46 20 45 4 33 7 17
Pēpi-Pod® 3 4 2 5 1 8
Own bed 2 3 2 5
Co-sleeping place 22 32 14 32 6 50 2 17
Bed 20 29 12 27 6 50 2 17
Couch 1 1 1 2 0 0
On pillows 1 1 1 2 0 0
Usual place of sleep not stated 10 15 6 15 1 2 3 25
At the time of the event or death, 56 babies (82 percent) were at home, eight babies (12 percent) were 
at a family or friend’s home, and four babies (6 percent) were in hospital (Table 2.13). Four of the eight 
babies where the event occurred at home were resuscitated and transferred to hospital where they 
subsequently died.
At the time of death (or event leading to death) only six of the 68 babies who were identified as SUDI 
deaths were known to be in a recommended low-risk sleeping place; that is, in their own place of 
sleep, on their back and with no pillow. For two babies the place of sleep was unknown.
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The majority were sleeping with an adult and/or siblings (79 percent), and just over half were reported 
as having their own (unshared) usual sleeping place (Table 2.13). Very few babies had a Pēpi-Pod® 
and no baby had wahakura recorded as their usual place of sleep. Nine babies (13 percent) had 
pillows or rolled blankets in the bed with them as an added risk factor at the time of death or event. 
Family violence was documented in the maternal history of five SUDI deaths, but there was no 
information on screening for family violence for 25 women (37 percent). In four cases, Child, Youth and 
Family/Oranga Tamariki was involved with child protection at the time of death. 
In some cases the mother or caregiver was known to have fallen asleep while feeding the baby (19 
cases (28 percent)), and in a further 12 (18 percent) this was considered to be highly probable.
There were insufficient data available to comment on provision of SUDI prevention information to 
families.
Messages to caregivers 
The PMMRC highlights the guidance from the Ministry of Health on safe sleep (Ministry of Health 
2016).
Make every sleep a safe sleep
Sudden unexpected death is a risk to babies until they are about 12 months old, but most deaths 
can be prevented.
There are things that we can do to protect our babies. Although for some babies the cause of 
death is never found, most deaths happen when the babies are sleeping in an unsafe way.
Always follow these safe-sleep routines for your baby and your baby’s bed.
Make sure that your baby is safe
To keep your baby safe while sleeping, make sure:
• they always sleep on their back to keep their airways clear
• they are in their own bassinet, cot or other baby bed (eg, Pēpi-Pod® or wahakura) – free from 
adults or children who might accidentally suffocate them
• they are put back in their own bed after feeding – don’t fall asleep with them (to protect your 
back, feed your baby in a chair rather than in your bed)
• they have someone looking after them who is alert to their needs and free from alcohol or 
drugs
• they have clothing and bedding that keeps them at a comfortable temperature – one more 
layer of clothing than you would wear is enough; too many layers can make your baby hot 
and upset them
• they are in a room where the temperature is kept at 20°C.
You can check that your baby is warm but not too hot by feeling the back of their neck or 
their tummy (under the clothes). Baby should feel warm, but not hot or cold. Your baby will be 
comfortable when their hands and feet are a bit colder than their body.
Further information is available on this link: www.health.govt.nz/your-health/pregnancy-and-kids/
first-year/first-6-weeks/keeping-baby-safe-bed-first-6-weeks.
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Child and Youth Mortality Review Committee (CYMRC) Recommendations 
The PMMRC supports the recommendations of the CYMRC 2017 report, Sudden unexpected death in 
infancy (SUDI): Special report (CYMRC 2017), as reiterated below.
Child and Youth Mortality Review Committee (CYMRC) Recommendations
Sudden unexpected death in infancy (SUDI): Special report (CYMRC 2017)
Recommendation 1:
The Ministry of Health leads and enables the development of a comprehensive SUDI Prevention Programme 
that includes effective SUDI prevention information and support products and services that are evidence 
based, and delivers equitable health outcomes for Māori and Pacific communities.
Recommendation 2:
The Ministry of Health’s SUDI Prevention Programme incorporates:
• universal approaches that are accessible, culturally appropriate and effective for all pregnant women and 
their babies
• tailored approaches for priority populations most at risk of experiencing a SUDI death, specifically Māori 
and Pacific mothers, mothers under 25 years of age, and mothers who smoke.
Recommendation 3:
The Ministry of Health and DHBs fund and provide universal and targeted smokefree prevention information 
and support products and services that are culturally appropriate and known to be effective for Māori and 
Pacific women and their whānau and families. This includes interventions that:
• discourage people from taking up smoking at all, especially during pregnancy
• support people to stop smoking, especially during pregnancy
• support everyone living with, or caring for, pregnant women and babies to be smokefree.
Recommendation 4:
The Ministry of Health, in its contracts with DHBs, requires DHBs to prioritise, monitor and evaluate a SUDI 
Prevention Programme to ensure equitable benefits for priority population groups identified. This should 
include smokefree support packages and initiatives that support whānau and families to live in warmer, drier 
homes that are free from crowding.
Recommendation 5:
The Ministry of Health works with the Ministry for Vulnerable Children, Oranga Tamariki and other relevant 
government agencies to promote the SUDI Prevention Programme across government. The aim is for all health, 
social and housing agencies and providers in contact with pregnant women, and whānau and families with 
babies, to provide access to effective SUDI prevention interventions that deliver equitable health outcomes. 
These agencies and providers should ensure whānau and families have the income and housing support 
they need to live in warm, dry homes that are free from crowding. Critical contact points include, but are not 
limited to, visits with:
• lead maternity carers
• Well Child/Tamariki Ora providers
• primary care providers, especially for immunisation
• Family Start
• Work and Income services
• social housing services
• Whānau Ora providers.
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Recommendation 6:
The Ministries of Health and Justice, and the Ministry for Vulnerable Children, Oranga Tamariki, the Chief 
Coroner and New Zealand Police work with whānau and families to develop a multi-agency protocol for the 
care of whānau and families after the sudden and unexpected death of a baby. The protocol could build on 
existing services and should:
• commence immediately during the first response of a SUDI investigation
• ensure professional case management and culturally appropriate counselling and support services to 
support bereaved whānau and families is provided during the investigation, and for one year following 
the death
• provide whānau and families with access to a paediatrician to interpret and discuss post-mortem results
• ensure immediate notification to the lead maternity carer, Well Child/Tamariki Ora provider and general 
practitioner, or named primary health provider, so ongoing care and support can be provided, including 
any additional health care and safeguards for subsequent babies
• prioritise timely information sharing between agencies during the investigation, including notification of 
death to all agencies involved with the infant to ensure whānau and families, as well as providers, are not 
further distressed by appointment notifications or home visits after the death of the baby.
The full report is available at: www.hqsc.govt.nz/assets/CYMRC/Publications/CYMRC_SUDI_Report.pdf.
Investigation of neonatal death
Table 2.14: Post-mortem investigation and placental pathology of neonatal deaths by gestation at birth 
(excluding deaths with congenital anomalies) 2007–2016
* Optimum investigation is defined as post-mortem or karyotype confirming congenital anomaly or clinical examination/investigation confirming diagnosis. Note: 
More than one option can be selected.
# No post-mortem; investigations may have included placental pathology, MRI, ultrasound scan or x-ray.
+ No post-mortem, placental pathology, MRI, ultrasound scan or x-ray.
Placental pathology should be routine standard of care for all babies born preterm and/or with 
intrauterine growth restriction, but especially those born at less than 32 weeks gestation. Accurate 
characterisation of placental disease may (i) inform long-term neurodevelopment risk to the baby and 
(ii) inform subsequent pregnancy management and risk of adverse pregnancy outcome.
Gestation at birth (weeks)
20–24 25–34 ≥35
n=729 n=263 n=325
n % n % n %
Adequacy of investigation of perinatal death
Optimum*  131  18.0  94  35.7  240  73.8 
Partial#  436  59.8  143  54.4  44  13.5 
No investigation+  141  19.3  25  9.5  37  11.4 
Unknown  21  2.9  1  0.4  4  1.2 
Placental pathology
No histological examination of placenta  162  22.2  57  21.7  158  48.6 
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Table 2.15: Contributory factors and potentially avoidable death by gestation at birth among neonatal 
deaths without congenital anomalies 2009–2016
* Most of these related to SUDI deaths.




n % n % n %
Any contributory factor
Organisational and/or management factors  31  5.2  24  11.3  47  19.4 
Poor organisational arrangements of staff  4  0.7  1  0.5  6  2.5 
Inadequate education and training  7  1.2  2  0.9  13  5.4 
Lack of policies, protocols or guidelines  8  1.3  3  1.4  13  5.4 
Inadequate numbers of staff  3  0.5  -  -  3  1.2 
Poor access to senior clinical staff  1  0.2  3  1.4  7  2.9 
Failure or delay in emergency response  1  0.2  5  2.3  14  5.8 
Delay in procedure (eg, caesarean section)  1  0.2  6  2.8  11  4.5 
Inadequate systems for sharing of clinical information  6  1.0  2  0.9  4  1.7 
Delayed access to test results or inaccurate results  1  0.2  1  0.5  2  0.8 
Equipment (eg, faulty equipment, inadequate 
maintenance, inadequate quality or lack of equipment)
 3  0.5  5  2.3  6  2.5 
Building and design functionality (eg, space, privacy, 
ease of access, lighting, noise, power failure, 
operating theatre in distant location)
 -  -  -  -  3  1.2 
Other  2  0.3  3  1.4  5  2.1 
Not stated  3  0.5  -  -  1  0.4 
Personnel factors  50  8.3  28  13.1  81  33.5 
Knowledge and skills of staff were lacking  11  1.8  8  3.8  27  11.2 
Delayed emergency response by staff  1  0.2  3  1.4  16  6.6 
Failure to maintain competence  -  -  -  -  3  1.2 
Failure of communication between staff  13  2.2  6  2.8  23  9.5 
Failure to seek help/supervision  6  1.0  5  2.3  7  2.9 
Failure to offer or follow recommended best practice  20  3.3  12  5.6  49  20.2 
Lack of recognition of complexity or seriousness of 
condition by care giver
 15  2.5  3  1.4  23  9.5 
Other  2  0.3  3  1.4  1  0.4 
Barriers to access and/or engagement with care  121  20.2  66  31.0  108  44.6 
No antenatal care  45  7.5  15  7.0  10  4.1 
Infrequent care or late booking  36  6.0  25  11.7  17  7.0 
Declined treatment or advice  12  2.0  12  5.6  14  5.8 
Obesity impacted on delivery of optimal care (eg, USS)  2  0.3  2  0.9  4  1.7 
Substance use  15  2.5  9  4.2  12  5.0 
Family violence  7  1.2  7  3.3  4  1.7 
Lack of recognition of complexity or seriousness of 
condition by the woman and/or family
 22  3.7  20  9.4  13  5.4 
Maternal mental illness  6  1.0  2  0.9  1  0.4 
Cultural barriers  3  0.5  3  1.4  4  1.7 
Language barriers  3  0.5  3  1.4  3  1.2 
Not eligible to access free care  3  0.5  -  -  2  0.8 
Environment (eg, isolated, long transfer, weather 
prevented transport)
 9  1.5  11  5.2  20  8.3 
Other  4  0.7  6  2.8  45*  18.6 
Potentially avoidable deaths 90  15.0 50  23.5 142  58.7 
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Table 2.16: Neonatal death rate (per 1000 live births) by gestation and country 2004-2016
2.6 Neonatal Mortality 2007–2016: Appended Tables
 ≥20 weeks gestation ≥22 weeks gestation
Year United Kingdom Australia New Zealand Scandinavia New Zealand
 rate (/1000 live births)
2004 3.43 * * * *
2005 3.5 * * * *
2006 3.46 * * * *
2007 3.26 2.90 2.58 1.99 2.30
2008 3.18 2.83 2.72 1.96 2.50
2009 3.12 2.92 2.83 1.81 2.50
2010 2.96 2.94 3.23 1.63 2.76
2011 2.95 2.81 2.61 1.65 2.35
2012 2.85 2.38 2.84 1.60 2.39
2013 2.71 2.68 2.56 1.60 2.18
2014 2.71 2.57 3.05 1.67 2.52
2015 2.72 2.25 2.80 1.60 2.51
2016 NA NA 2.51 1.49 2.18
* data not available
Data sources and definitions
United Kingdom – live birth at ≥ 20 weeks gestation, or birthweight ≥ 400g if gestation is not available, who died before 28 completed days (routine data 
sources) (Manktelow et al 2016).
Australia – live birth at ≥ 20 weeks gestation, or birthweight ≥ 400g, who died before 28 completed days (routine data sources)(Australian Institute of Health and 
Welfare 2017; Australian Institute of Health and Welfare 2018).
Scandinavia – live birth at ≥ 22 weeks gestation who died before 28 completed days (routine data sources) (Heino and Gissler 2016).
New Zealand - live birth at ≥ 20 weeks gestation, or birthweight ≥ 400g if gestation is not available, who died before 28 completed days. Or live birth at ≥ 22 
weeks gestation who died before 28 completed days (PMMRC).
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Neonatal deaths Perinatal related deaths
Termination of pregnancy Stillbirths
N=628,529 n=1,155 n=304 n=414 n=1,873
N n Rate n Rate n Rate n Rate
2007  65,202  125  1.92  35  0.54  38  0.58  198  3.04 
2008  65,624  114  1.74  28  0.43  43  0.66  185  2.82 
2009  65,198  111  1.70  30  0.46  43  0.66  184  2.82 
2010  65,445  128  1.96  37  0.57  46  0.70  211  3.22 
2011  63,236  128  2.02  27  0.43  50  0.79  205  3.24 
2012  63,274  130  2.05  35  0.55  38  0.60  203  3.21 
2013  60,133  110  1.83  22  0.37  32  0.53  164  2.73 
2014  60,073  112  1.86  34  0.57  45  0.75  191  3.18 
2015  59,768  88  1.47  25  0.42  45  0.75  158  2.64 





Neonatal deaths Perinatal related deaths
Termination of pregnancy Stillbirths
N=628,529 n=1,155 n=304 n=414 n=1,873
N n Rate LL UL n Rate LL UL n Rate LL UL n Rate LL UL
Māori  159,803  182  1.14  0.97  1.30  73  0.46  0.36  0.57  114  0.71  0.58  0.85  369  2.31  2.07  2.54 
Pacific peoples  70,229  71  1.01  0.79  1.28  53  0.75  0.57  0.99  70  1.00  0.78  1.26  194  2.76  2.37  3.15 
Indian  24,236  71  2.93  2.29  3.70  10  0.41  0.20  0.76  19  0.79  0.47  1.23  100  4.13  3.32  4.93 
Other Asian  54,738  156  2.85  2.40  3.30  24  0.44  0.28  0.65  27  0.49  0.33  0.72  207  3.78  3.27  4.30 
MELAA  12,584  17  1.35  0.79  2.16  7  0.56  0.22  1.15  6  0.48  0.18  1.04  30  2.38  1.61  3.40 
Other European  60,070  97  1.61  1.31  1.97  25  0.42  0.27  0.61  16  0.27  0.15  0.43  138  2.30  1.91  2.68 
NZ European  246,413  561  2.28  2.09  2.47  112  0.45  0.37  0.54  161  0.66  0.55  0.76  834  3.38  3.15  3.61 
Unknown/Other  456  -  -  -  -  -  -  -  -  1  2.19  -  -  1  2.19  -  - 
Table 2.18: Congenital anomaly specific perinatal related mortality rate (per 1000 births) by maternal ethnicity 2007–2016
MELAA = Middle Eastern, Latin American or African.
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Neonatal deaths Perinatal related deathsTermination of 
pregnancy Stillbirths
N=626,718 n=312 n=3,099 n=1,317 n=4,728
N n Rate n Rate n Rate n Rate
2007  65,011  19  0.29  334  5.14  129  2.00  482  7.41 
2008  65,449  31  0.47  351  5.36  134  2.06  516  7.88 
2009  65,018  27  0.42  379  5.83  140  2.17  546  8.40 
2010  65,245  23  0.35  310  4.75  164  2.53  497  7.62 
2011  63,036  43  0.68  305  4.84  114  1.82  462  7.33 
2012  63,079  42  0.67  285  4.52  140  2.23  467  7.40 
2013  59,973  31  0.52  284  4.74  121  2.03  436  7.27 
2014  59,887  38  0.63  293  4.89  137  2.30  468  7.81 
2015  59,614  19  0.32  280  4.70  121  2.04  420  7.05 
2016  60,406  39  0.65  278  4.60  117  1.95  434  7.18 
Table 2.20: Neonatal death rate (per 1000 ongoing pregnancies) by gestation at birth and year of 
birth excluding congenital anomaly deaths 2007–2016
Gestation at birth (weeks)
Year of 
death
≥20 20–24 ≥25 25–34 ≥35 ≥35
N=620,386 n=729 N=617,986 n=263 N=599,205 n=325
N n Risk N n Risk N n Risk
2007  64,275  68  1.06  64,065  24  0.37  62,089  37  0.60 
2008  64,302  62  0.96  64,062  26  0.41  61,935  46  0.74 
2009  64,414  70  1.09  64,169  32  0.50  62,138  38  0.61 
2010  64,685  92  1.42  64,434  32  0.50  62,438  40  0.64 
2011  62,540  67  1.07  62,283  20  0.32  60,388  27  0.45 
2012  62,101  77  1.24  61,868  29  0.47  60,015  34  0.57 
2013  59,608  69  1.16  59,361  30  0.51  57,635  22  0.38 
2014  59,460  91  1.53  59,181  20  0.34  57,485  26  0.45 
2015  59,191  68  1.15  58,989  28  0.47  57,273  25  0.44 
2016  59,810  65  1.09  59,574  22  0.37  57,809  30  0.52 
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Table 2.22: Neonatal death rate (per 1000 ongoing pregnancies) by gestation at birth and maternal ethnicity excluding death with congenital 
anomaly 2007–2016
Gestation at birth (weeks)
Maternal 
Ethnicity
≥20 20–24 ≥25 25–34 ≥35 ≥35
N=620,386 n=729 N=617,986 n=263 N=599,205 n=325
N n Risk LL UL N n Risk LL UL N n Risk LL UL
Māori  157,142  255  1.62  1.42  1.82  156,370  86  0.55  0.44  0.68  151,082  118  0.78  0.64  0.92 
Pacific peoples  69,089  127  1.84  1.52  2.16  68,722  40  0.58  0.42  0.79  66,755  41  0.61  0.44  0.83 
Indian  23,969  57  2.38  1.80  3.08  23,833  11  0.46  0.23  0.83  23,069  6  0.26  0.10  0.57 
Other Asian  54,168  47  0.87  0.64  1.15  54,030  17  0.31  0.18  0.50  52,755  9  0.17  0.08  0.32 
MELAA  12,456  17  1.36  0.80  2.19  12,395  2  0.16  0.02  0.58  12,002  6  0.50  0.18  1.09 
Other European  59,452  28  0.47  0.31  0.68  59,280  9  0.15  0.07  0.29  57,680  16  0.28  0.16  0.45 
NZ European  244,000  198  0.81  0.70  0.92  243,249  98  0.40  0.33  0.49  235,762  129  0.55  0.45  0.64 
Unknown/Other  110  -  107  -  100  - 





Neonatal deaths Perinatal related deaths
Termination of pregnancy Stillbirths*
N=626,718 n=312 n=3,099 n=1,317 n=4,728
N n Rate LL UL n Rate LL UL n Rate LL UL n Rate LL UL
Māori  159,421  61  0.38  0.29  0.49  847  5.31  4.96  5.67  459  2.90  2.63  3.16  1,367  8.57  8.12  9.03 
Pacific peoples  70,022  39  0.56  0.40  0.76  444  6.34  5.75  6.93  208  2.99  2.58  3.40  691  9.87  9.13  10.60 
Indian  24,147  21  0.87  0.54  1.33  177  7.33  6.25  8.41  74  3.09  2.43  3.88  272  11.26  9.93  12.60 
Other Asian  54,545  27  0.50  0.33  0.72  179  3.28  2.80  3.76  73  1.34  1.05  1.69  279  5.12  4.51  5.72 
MELAA  12,548  9  0.72  0.33  1.36  59  4.70  3.58  6.07  25  2.00  1.30  2.96  93  7.41  5.98  9.08 
Other European  59,886  22  0.37  0.23  0.56  172  2.87  2.44  3.30  53  0.89  0.67  1.16  247  4.12  3.61  4.64 
NZ European  245,695  133  0.54  0.45  0.63  1,220  4.97  4.69  5.24  425  1.74  1.57  1.90  1,778  7.24  6.90  7.57 
* One unknown maternal ethnicity
MELAA = Middle Eastern, Latin American or African.

































Gestation at birth (weeks)
≥20 20–24 ≥25 25–34 ≥35 ≥35 weeks
N=484,197 n=449 N=482,627 n=180 N=469,103 n=239
N n Risk LL UL N n Risk LL UL N n Risk LL UL
<18.50  13,812  11  0.80  0.40  1.42  13,767  5  0.36  0.12  0.85  13,360  3  0.22  0.05  0.66 
18.50–24.99  241,362  190  0.79  0.68  0.90  240,670  85  0.35  0.28  0.44  233,925  89  0.38  0.31  0.47 
25.00–29.99  124,559  119  0.96  0.78  1.13  124,129  39  0.31  0.22  0.43  120,777  76  0.63  0.50  0.79 
30.00–34.99  61,584  67  1.09  0.84  1.38  61,381  30  0.49  0.33  0.70  59,604  33  0.55  0.38  0.78 
35.00–39.99  26,867  39  1.45  1.03  1.98  26,743  16  0.60  0.34  0.97  25,960  21  0.81  0.50  1.24 
≥40.00  15,011  22  1.47  0.92  2.22  14,939  5  0.33  0.11  0.78  14,517  15  1.03  0.58  1.70 
Unknown  1,002  1  998  -  960  2 
Table 2.23: Neonatal death rate (per 1000 ongoing pregnancies) by gestation at birth and BMI excluding congenital anomalies 2008–2016*
* MAT data numerator and denominator; limited to mothers who were registered for care with an LMC (either a midwife, obstetrician or GP) claiming from the Section 88 Primary Maternity Services Notice.
Table 2.24: Neonatal death rate (per 1000 ongoing pregnancies) by gestation at birth and maternal age excluding death with congenital 
anomaly 2007–2016
Gestation at birth (weeks)
Maternal age 
(years)
≥20 20–24 ≥25 25–34 ≥35 ≥35
N=620,352 n=729 N=617,952 n=263 N=599,172 n=325
N n Risk LL UL N n Risk LL UL N n Risk LL UL
<20  39,175  96  2.45  1.98  2.99  38,932  33  0.85  0.58  1.19  37,503  37  0.99  0.69  1.36 
20–34  448,166  503  1.12  1.02  1.22  446,520  162  0.36  0.31  0.42  433,683  230  0.53  0.46  0.60 
35–39  107,726  104  0.97  0.78  1.15  107,333  53  0.49  0.37  0.65  103,857  49  0.47  0.35  0.62 
≥40  25,285  26  1.03  0.67  1.51  25,167  15  0.60  0.33  0.98  24,129  9  0.37  0.17  0.71 
Table 2.25: Neonatal death rate (per 1000 ongoing pregnancies) by gestation at birth and socioeconomic deprivation excluding congenital 
anomalies 2007–2016
Gestation at birth (weeks)
Deprivation 
quintile
≥20 20–24 ≥25 25–34 ≥35 ≥35
N=620,386 n=729 N=617,986 n=263 N=599,205 n=325
N n Risk LL UL N n Risk LL UL N n Risk LL UL
1 (least deprived)  87,230  61  0.70  0.53  0.90  86,989  28  0.32  0.21  0.47  84,539  35  0.41  0.29  0.58 
2  94,672  76  0.80  0.63  1.00  94,384  33  0.35  0.24  0.49  91,668  33  0.36  0.25  0.51 
3  113,271  121  1.07  0.88  1.26  112,889  43  0.38  0.28  0.51  109,547  56  0.51  0.39  0.66 
4  143,351  157  1.10  0.92  1.27  142,794  54  0.38  0.28  0.49  138,474  68  0.49  0.38  0.62 
5 (most deprived)  177,481  310  1.75  1.55  1.94  176,593  105  0.59  0.48  0.71  170,813  133  0.78  0.65  0.91 
Unknown  4,381  4  4,337  -  4,164  - 
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Table 2.26: Neonatal death rate (per 1000 ongoing pregnancies) by gestation at birth and parity excluding death with congenital anomaly 
2008–2016* 
Parity
Gestation at birth (weeks)
≥20 20–24 ≥25 25–34 ≥35 ≥35
N=484,197 n=449 N=482,627 n=180 N=469,103 n=239
N n Risk LL UL N n Risk LL UL N n Risk LL UL
Primiparous  199,252  228  1.14  1.00  1.29  198,504  81  0.41  0.32  0.51  192,161  114  0.59  0.48  0.70 
Multiparous 1–3  262,236  201  0.77  0.66  0.87  261,501  91  0.35  0.28  0.43  255,151  106  0.42  0.34  0.49 
Multiparous ≥4  22,678  20  0.88  0.54  1.36  22,591  8  0.35  0.15  0.70  21,761  19  0.87  0.53  1.36 
Unknown  31  -  31  -  30  - 
* MAT data numerator and denominator; limited to mothers who were registered for care with an LMC (either a midwife, obstetrician or GP) claiming from the Section 88 Primary Maternity Services Notice.
Table 2.27: Neonatal death rate (per 1000 ongoing pregnancies) by gestation at birth and smoking excluding congenital anomaly deaths 
2008–2016*
Smoking
Gestation at birth (weeks)
≥20 20–24 ≥25 25–34 ≥35 ≥35
N=484,197 n=449 N=482,627 n=180 N=469,103 n=239
N n Risk LL UL N n Risk LL UL N n Risk LL UL
Yes  73,131  125  1.71  1.41  2.01  72,777  48  0.66  0.49  0.87  69,929  65  0.93  0.72  1.18 
No  410,997  324  0.79  0.70  0.87  409,781  132  0.32  0.27  0.38  399,105  174  0.44  0.37  0.50 
Unknown  69  -  69  -  69  - 
Table 2.28: Gestational age at birth by ethnicity among live born babies born at 20–26 weeks without congenital anomalies 2007–2016
Gestation at birth (weeks)
Māori Pacific peoples Indian Other*
N=156,250 N=68,666 N=23,790 N=367,789
n % n % n % n %
20 43 0.03 23 0.03 5 0.02 41 0.01
21 48 0.03 24 0.03 15 0.06 63 0.02
22 75 0.05 42 0.06 11 0.05 72 0.02
23 99 0.06 43 0.06 13 0.05 103 0.03
24 152 0.10 60 0.09 20 0.08 174 0.05
25 155 0.10 72 0.10 21 0.09 223 0.06
26 172 0.11 69 0.10 27 0.11 274 0.07
* Other ethnicity includes New Zealand and Other European; Other Asian; Middle Eastern, Latin American or African (MELAA); Other ethnicities and unknown; and not stated.































Table 2.29: Cause-specific (PSANZ-PDC) neonatal death rate after birth at 25–34 weeks gestation excluding congenital anomalies (per 1000 




Māori Pacific peoples Indian Other*
N=159,803 N=70,229 N=24,236 N=373,805
n Rate LL UL n Rate LL UL n Rate LL UL n Rate LL UL
Perinatal infection  4  0.03  0.01  0.06  7  0.10  0.04  0.21  1  0.04  0.00  0.23  7  0.02  0.01  0.04 
Hypertension  7  0.04  0.02  0.09  1  0.01  0.00  0.08  1  0.04  0.00  0.23  17  0.05  0.03  0.07 
Antepartum haemorrhage  12  0.08  0.04  0.13  11  0.16  0.08  0.28  3  0.12  0.03  0.36  19  0.05  0.03  0.08 
Maternal conditions  5  0.03  0.01  0.07  2  0.03  0.00  0.10  2  0.08  0.01  0.30  7  0.02  0.01  0.04 
Specific perinatal conditions  6  0.04  0.01  0.08  5  0.07  0.02  0.17  2  0.08  0.01  0.30  21  0.06  0.03  0.09 
Hypoxic peripartum death  -  -  -  -  -  -  -  -  -  -  -  -  1  0.00  0.00  0.01 
Fetal growth restriction  2  0.01  0.00  0.05  1  0.01  0.00  0.08  -  -  -  -  9  0.02  0.01  0.05 
Spontaneous preterm  50  0.31  0.23  0.41  13  0.19  0.10  0.32  2  0.08  0.01  0.30  45  0.12  0.09  0.16 
* Other ethnicity includes New Zealand and Other European; Other Asian; Middle Eastern, Latin American or African (MELAA); Other ethnicities and unknown; and not stated.
Table 2.30: Cause-specific (PSANZ-NDC) neonatal death rate after birth at 25–34 weeks gestation excluding congenital anomalies (per 1000 




Māori Pacific peoples Indian Other*
N=159,803 N=70,229 N=24,236 N=373,805
n Rate LL UL n Rate LL UL n Rate LL UL n Rate LL UL
Extreme prematurity  5  0.03  0.01  0.07  1  0.01  0.00  0.08  -  -  -  -  4  0.01  0.00  0.03 
Cardio-respiratory disorders  25  0.16  0.10  0.23  4  0.06  0.02  0.15  1  0.04  0.00  0.23  36  0.10  0.07  0.13 
Infection  18  0.11  0.07  0.18  16  0.23  0.13  0.37  4  0.17  0.04  0.42  26  0.07  0.05  0.10 
Neurological  23  0.14  0.09  0.22  10  0.14  0.07  0.26  4  0.17  0.04  0.42  37  0.10  0.07  0.14 
Gastro-intestinal  7  0.04  0.02  0.09  2  0.03  0.00  0.10  -  -  -  -  12  0.03  0.02  0.06 
Other  8  0.05  0.02  0.10  7  0.10  0.04  0.21  2  0.08  0.01  0.30  11  0.03  0.01  0.05 
* Other ethnicity includes New Zealand and Other European; Other Asian; Middle Eastern, Latin American or African (MELAA); Other ethnicities and unknown; and not stated.
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Table 2.31: Neonatal death and primary neonatal death classification (PSANZ-NDC) 2007–2016
Neonatal death classification (PSANZ-NDC)
2007–2015 2016
n=1,580 n=148
n % n %
Congenital abnormality
1.1 Central nervous system  38  2.4  1  0.7 
1.2 Cardiovascular system  61  3.9  8  5.4 
1.3 Urinary system  37  2.3  4  2.7 
1.4 Gastrointestinal system  12  0.8  -  - 
1.5 Chromosomal  86  5.4  9  6.1 
1.6 Metabolic  23  1.5  1  0.7 
1.7 Multiple/Non-chromosomal syndromes  60  3.8  6  4.1 
1.8 Other congenital abnormality
1.81 Musculoskeletal  13  0.8  2  1.4 
1.82 Respiratory  4  0.3  -  - 
1.83 Diaphragmatic hernia  29  1.8  1  0.7 
1.84 Haematological  2  0.1  -  - 
1.85 Tumours  6  0.4  -  - 
1.88 Other specified congenital abnormality  8  0.5  1  0.7 
Extreme prematurity
2.1 Not resuscitated  485  30.7  51  34.5 
2.2 Unsuccessful resuscitation  69  4.4  2  1.4 
2.9 Unspecified or not known whether resuscitation attempted  1  0.1  -  - 
Cardio-respiratory disorders
3.1 Hyaline membrane disease/Respiratory distress syndrome (RDS)  50  3.2  4  2.7 
3.2 Meconium aspiration syndrome  2  0.1  -  - 
3.3 Primary persistent pulmonary hypertension  5  0.3  -  - 
3.4 Pulmonary hypoplasia  27  1.7  4  2.7 
3.5 Chronic neonatal lung disease (typically, bronchopulmonary dysplasia)  5  0.3  -  - 
3.6 Pulmonary haemorrhage  12  0.8  1  0.7 
3.7 Pneumothorax  1  0.1  -  - 




4.111 Group B Streptococcus  23  1.5  4  2.7 
4.112 E. coli  14  0.9  1  0.7 
4.113 Listeria monocytogenes  4  0.3  -  - 
4.118 Other bacterial  14  0.9  1  0.7 
4.119 Unspecified bacterial  12  0.8  2  1.4 
4.12 Acquired bacterial
4.121 Group B Streptococcus  4  0.3  1  0.7 
4.122 E. coli  4  0.3  -  - 
4.125 Other Gram negative bacilli (other than E. coli)  6  0.4  -  - 
4.126 Staphylococcus aureus  9  0.6  -  - 
4.127 Coagulase negative Staphylococcus  4  0.3  -  - 
4.128 Other specified bacterial  8  0.5  -  - 
4.129 Unspecified bacterial  2  0.1  2  1.4 
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4.2 Viral
4.21 Congenital viral
4.211 Cytomegalovirus  3  0.2  -  - 
4.213 Herpes simplex virus  6  0.4  -  - 
4.218 Other specified viral  2  0.1  -  - 
4.22 Acquired viral
4.223 Herpes simplex virus  3  0.2  -  - 
4.228 Other specified viral  3  0.2  -  - 
4.229 Unspecified viral  1  0.1  -  - 
4.5 Fungal  1  0.1  1  0.7 
4.9 Unspecified organism  9  0.6  1  0.7 
Neurological
5.1 Hypoxic ischaemic encephalopathy/Perinatal asphyxia (typically infants of 
>24 weeks gestation or >600g birthweight)
 191  12.1  14  9.5 
5.2 Intracranial haemorrhage
5.21 Intraventrical haemorrhage  59  3.7  6  4.1 
5.22 Subgaleal haemorrhage  2  0.1  -  - 
5.23 Subarachnoid haemorrhage  1  0.1  -  - 
5.24 Subdural haemorrhage  2  0.1  1  0.7 
5.28 Other intracranial haemorrhage  2  0.1  2  1.4 
5.8 Other  3  0.2  -  - 
Gastrointestinal
6.1 Necrotising enterocolitis  23  1.5  5  3.4 
6.8 Other  3  0.2  -  - 
Other
7.1 Sudden infant death syndrome (SIDS)
7.11 SIDS Category IA: Classic features of SIDS present and completely 
documented
 1  0.1  -  - 
7.13 SIDS Category II: Infant deaths that meet category I except for one or more 
features
 3  0.2  -  - 
7.2 Multisystem failure
7.21 Multisystem failure: Secondary to intrauterine growth restriction  6  0.4  1  0.7 
7.28 Multisystem failure: Other specified  10  0.6  2  1.4 
7.29 Multisystem failure: Unspecified/undetermined primary cause or trigger event  1  0.1  -  - 
7.3 Trauma
7.31 Trauma: Accidental  10  0.6  2  1.4 
7.32 Trauma: Non accidental  1  0.1  -  - 
7.4 Treatment complications  2  0.1  -  - 
7.41 Treatment complications: Surgical  2  0.1  -  - 
7.42 Treatment complications: Medical  3  0.2  -  - 
7.8 Other specified  15  0.9  1  0.7 
7.9 Unknown/Undetermined  5  0.3  -  - 
7.91 Unclassified sudden infant death  12  0.8  -  - 
7.911 Unclassified sudden infant death: Bed sharing  38  2.4  3  2.0 
7.912 Unclassified sudden infant death: Not bed sharing  5  0.3  1  0.7 
Neonatal death classification (PSANZ-NDC)
2007–2015 2016
n=1,580 n=148
n % n %
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3 Neonatal Encephalopathy 2016
3.1 Neonatal Encephalopathy Key Findings 2016
In 2016, there were 56 cases of neonatal encephalopathy (NE) in babies born from 37 weeks 
gestation reported to the PMMRC (1.0/1000 term births). In 2010, the rate was 1.4/1000 term births, 
but the reduction from 2010 to 2016 is not statistically significant.
From 2010 to 2016, 94 (20 percent) of 479 babies diagnosed with NE at term died within the 
neonatal period, and a further 13 are known to have died subsequently for a total mortality of 22 
percent. 
This year the babies diagnosed with NE were matched to their National Maternity Collection (MAT) 
record. Use of this dataset allowed analysis of associations of NE with smoking, body mass index 
(BMI), parity, gestation at registration with a lead maternity carer (LMC), and birthweight customised for 
gestational age.
There was no statistically significant association seen between NE and smoking or gestation at 
registration with a lead maternity carer (LMC). 
There was, however, an increase in risk of NE with increasing BMI. The rate of NE was statistically 
significantly higher among mothers with a BMI of 30 and higher compared to a BMI of 18.50–24.99 
(considered normal BMI). 
There is a ‘U-shaped’ relationship between gestation and NE rates and between parity and NE rates, 
but these are somewhat linked. The risk is similar for nulliparous and multiparous women at 37 weeks, 
but the risk increases among nulliparous women with increasing gestation while the risk reduces with 
gestation among multiparous women (Figure 3.7).
Babies born small for gestational age as measured by customised birthweight centile were twice as 
likely to be diagnosed with NE compared to babies born with appropriate birthweight for gestational 
age. Babies born large for gestational age were significantly less likely to be diagnosed with NE.
A multivariable analysis is required to explore the independent predictors of NE among babies born at 
term, and this will be included in the work plan for 2018–2019.
Acute peripartum events were reported in 22 percent of NE cases from 2012 to 2016. In 2016, 
the NEWG reviewed a series of 47 babies with NE born from 2013 to 2015 following an acute 
peripartum event. In two-thirds of the cases reviewed, the mortality or severe morbidity were considered 
potentially avoidable. A summary of the review findings is provided in the text box titled "Summary of 
multidisciplinary review of neonatal encephalopathy associated with acute peripartum events 2013–
2015" on page 82.
In an analysis of the rate of NE by place of birth, the rate of NE was found to be lower among term 
babies born at primary units than among those born at secondary and tertiary units. The rate of NE 
among babies born at home was also estimated as lower than at secondary and tertiary units but the 
difference was not statistically significant. The proportion of severe Sarnat stage cases, survival, and 
use of induced cooling were not statistically significantly different by place of birth.
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In 2016, 79 percent of babies born at term with moderate or severe NE were treated with induced 
cooling, and of those cooled, 77 percent were cooled within six hours of birth as recommended for 
maximal benefit. The 12 babies not cooled in 2016 were reviewed. It was thought that two of these 
babies should have been referred/transferred for cooling, and the following points were emphasised: 
• Neonatal observation is required for neonates with risk factors for NE. 
• Regular assessment of Sarnat stage (hourly to 6 hours) is required for neonates identified with 
probable asphyxia to ensure cooling is not delayed for babies who deteriorate after their initial 
assessment (Battin 2015).
The Neonatal Encephalopathy Working Group (NEWG) audited review of 2016 NE cases at DHB 
of birth and found that while most cases (75 percent) were reviewed locally, only 64 percent had 
multidisciplinary review. Of those cases not reviewed, the most common reason given was that there 
was no resource locally for morbidity review.
3.2 Neonatal Encephalopathy Recommendations
1. The PMMRC recommends that DHBs with rates of neonatal encephalopathy significantly higher 
than the national rate review, or continue to review, the higher rate of neonatal encephalopathy 
in their area and identify areas for improvement.
Justification 
Taranaki and Capital & Coast DHBs have significantly higher rates of NE than the national rate (Figure 
3.4).
Evidence 
Previous reports have shown that review of NE using a confidential enquiry methodology revealed 
suboptimal care in more than 50 percent of cases (Draper et al 2002; Kernaghan and Penney 2006).
72
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International comparisons
There are limited international data that can be used for comparison. One estimate of median incidence 
of NE associated with intrapartum events was 1.60/1000 births (range 0.68–3.75/1000) for 1980 
to 2013 (Lee et al 2013). A more recent study from Spain (Arnaez et al 2018) reported an incidence 
equivalent to 1.09 per 1000 live births ≥35 weeks gestation. This would suggest that the currently 
reported rates for New Zealand are similar to other comparable health systems.
3.3 Methodology
The methodology for the NE report is included with the ‘Methodology and Definitions for PMMRC 
Reporting’ document on the PMMRC website (www.hqsc.govt.nz/our-programmes/mrc/pmmrc/
publications-and-resources/publication/3367/). 
NE cases reported at 35 and 36 weeks are not included in the majority of analyses in this chapter.
3.4 Findings
In 2016 there were 59 moderate and severe NE cases (56 from 37 weeks and 3 at 35 to 36 weeks) 
reported to the PMMRC. There have been 482 cases reported from 2010 to 2016 (479 from 37 
weeks gestation at birth), making the NE rate for 2010–2016 1.11/1000 births (95% CI 1.01–1.21) 
(479/432,505 births from 20 weeks gestation or 400g if gestation unknown) or 1.21/1000 term 
births (95% CI 1.10–1.32) (479/394,712 term births). Although there is a downward trend apparent 
in the NE rate (Figure 3.1), from 1.4/1000 term births in 2010 to 1.0/1000 births in 2016, this is not 
a statistically significant trend (chi-square test for trend p=0.12).
Three-year rolling NE rate represented at final year of triennium.
PERINATAL AND MATERNAL MORTALITY REVIEW COMMITTEE: 12th ANNUAL REPORT 73
There were statistically significant differences in NE rate by maternal ethnicity. Mothers of Other 
European (ie, European from countries other than New Zealand) ethnicity had the lowest rate of NE, 
which was significantly lower than the rate of Māori, Pacific, Indian, MELAA (Middle Eastern, Latin 
American or African), and New Zealand European mothers. The rate among mothers of non-Indian 
(Other) Asian ethnicity was lower than the rate among Māori, Pacific and New Zealand European 
mothers.
Although the rate of NE among mothers under 20 years of age (1.64/1000 term births) was higher 
than among mothers 20 to 34 years of age (1.20/1000) or 35 years and older (1.06/1000), this 
difference was not statistically significant.
Figure 3.2: Neonatal encephalopathy rates (per 1000 term births) by maternal prioritised ethnicity 























Demography and neonatal encephalopathy
MELAA = Middle Eastern, Latin American or African.
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DHB of maternal residence
Figure 3.4: Neonatal encephalopathy rates (per 1000 term births) by DHB of maternal residence* 























DHB of maternal residence 
NE rate/1000 term births NE rate NZ
* Excludes any DHB with fewer than three cases.
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Taranaki and Capital & Coast DHBs have statistically significantly higher rates of NE than the national 
rate. All DHBs should be routinely identifying and undertaking multidisciplinary review of cases of 
moderate and severe NE.
Multidisciplinary review should include obstetricians, midwives (LMC midwives involved in primary 
care and hospital midwives), paediatricians, neonatal nurses, anaesthetists (where relevant), and any 
other relevant stakeholders who might be represented among those caring for pregnant women, women 
in labour and during birth, and babies in the neonatal period. The perspective and concerns of the 
parents, families and whānau should be considered at the review. Multidisciplinary review enables all 
perspectives to be presented and considered. Clinicians can learn and adjust clinical practice from the 
review of an adverse outcome. Sharing the conclusions from the multidisciplinary review with family/
whānau may help them to better understand the event.
Previous PMMRC recommendation (eighth report – PMMRC 2014) 
That all DHBs review local incident cases of neonatal encephalopathy (Sarnat stages 2 and 3). The 
findings of these reviews should be shared at multidisciplinary local forums and form the basis of 
quality improvements as appropriate.
Local review of neonatal encephalopathy at place of birth 2016
In 2017 PMMRC local coordinators were asked about review of babies born in their DHB who were 
diagnosed with NE. 
Forty-four babies (75 percent) diagnosed with NE were reviewed within their DHB of birth. The 
review was multidisciplinary for 37 babies (64 percent) and 23 (38 percent) were reviewed as a 
serious adverse event. Twenty-two reviews (37 percent) were presented at local perinatal meetings. 
A complaint was submitted to the Health and Disability Commissioner (HDC) regarding eight babies 
(14 percent). 














 N n % n % n % n % n % n % n %
Morbidity 46 32 70 14 30 12 26 29 63 17 37 4 9
Mortality 13 12 92 1 8 10 77 8 62 6 46 4 31 6 46
Total 59 44 75 15 25 22 37 37 64 23 38 8 14
* Some babies are represented in multiple categories
HDC = Health and Disability Commissioner
Explanation of why NE cases were not reviewed included: no resources to review morbidity (5), baby 
born at home (2), reviewed by senior clinician who determined no further review required (2), NE 
presented after discharge (1), classified locally as NE stage 1 (1), and not aware of this NE case (1).
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Gestation, sex, birthweight and plurality
Table 3.1: Neonatal encephalopathy rate (per 1000 term births) by gestation, sex, birthweight, and 
plurality 2012–2016
MAT births 2012–2016 
≥37 weeks
NE babies Rate 
(/1000 term births)
N=277,193 n=330
n % n % /1000 95% CI
Gestation at birth (weeks)
37  19,499  7.0  30  9.1  1.54  1.04–2.20 
38  49,002  17.7  54  16.4  1.10  0.83–1.44 
39  80,377  29.0  73  22.1  0.91  0.71–1.14 
40  81,595  29.4  89  27.0  1.09  0.88–1.34 
41  41,078  14.8  78  23.6  1.90  1.50–2.37 
≥42  5,642  2.0  6  1.8  1.06  0.39–2.31 
Sex
Male  141,832  51.2  178  53.9  1.26  1.07–1.44 
Female  135,346  48.8  152  46.1  1.12  0.94–1.30 
Undetermined/unknown  15  0.0  -  -  -  - 
Birthweight (g)
<2,500  5,148  1.9  13  3.9  2.53  1.34–4.32 
2,500–3,999  218,889  79.0  282  85.5  1.29  1.14–1.44 
4,000–4,499  34,173  12.3  25  7.6  0.73  0.47–1.08 
≥4,500  6,833  2.5  10  3.0  1.46  0.70–2.69 
Unknown  12,150  4.4  -  -  -  - 
Plurality
Singleton  272,902  98.5  323  97.9  1.18  1.05–1.31 
Multiple  3,241  1.2  7  2.1  2.16  0.87–4.45 
Unknown  1,050  0.4  -  -  -  - 






















Gestation at birth (weeks)
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There was a significant association between gestation at birth and NE risk. The rate at 37 weeks 
gestation was significantly higher than the rate among babies born at 39 weeks. The rate at 41 weeks 
gestation was significantly higher than the rate among babies born at 38 to 40 weeks. The rate at 
42 weeks and above was difficult to estimate as numbers are small and the confidence interval is 
necessarily wide.
The rate of NE reported among male babies (1.26/1000 term males) was higher compared to female 
babies (1.12/1000 term females) but the difference did not reach statistical significance. 
Numbers of babies born in multiple pregnancies at term with NE are small, so it is difficult to be certain 
whether a difference exists. 























* MAT data numerator and denominator; limited to mothers who were registered for care with an LMC (either a midwife, obstetrician or GP) claiming from the 
Section 88 Primary Maternity Services Notice.
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Gestation at birth (weeks)
Parity 0 Parity ≥1
* MAT data numerator and denominator; limited to mothers who were registered for care with an LMC (either a midwife, obstetrician or GP) claiming from the 
Section 88 Primary Maternity Services Notice.
The association between parity and NE is not as simple as it appears in Figure 3.6. The risk at 37 
weeks was the same for mothers having the first or subsequent babies, but from 39 weeks, the rate of 
NE was higher among mothers having their first baby than mothers having later babies (Figure 3.7). 
For multiparous women the rate of NE reduced significantly after 37 weeks, while among nulliparous 
women, the risk remained similar from 37 to 40 weeks and then was significantly higher at 41 weeks.
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Maternal smoking, BMI, gestation at first antenatal visit, customised birthweight 
centiles, and parity
Table 3.2: Maternal smoking, body mass index (BMI), gestation at first antenatal visit, customised 
birthweight centiles, and parity among neonatal encephalopathy babies* 2012–2016
MAT births 
≥37 weeks
NE cases Rate 
(/1000 term births)
N=252,440 n=291
n % n % /1000 95% CI
Currently smoking
Yes  35,836  14.2  47  16.2  1.31  0.96–1.74 
No  216,593  85.8  244  83.8  1.13  0.99–1.27 
Unknown  11  0.0  -  -  -  - 
Maternal BMI (kg/m2) 
<18.50  7,094  2.8  3  1.0  0.42  0.09–1.24 
18.50–24.99  122,564  48.6  121  41.6  0.99  0.81–1.16 
25.00–29.99  65,471  25.9  78  26.8  1.19  0.94–1.49 
30.00–34.99  33,225  13.2  50  17.2  1.50  1.12–1.98 
35.00–39.99  15,105  6.0  24  8.2  1.59  1.02–2.36 
≥40  8,606  3.4  15  5.2  1.74  0.98–2.87 
Missing data for height and or weight  375  0.1  -  -  -  - 
Gestation first antenatal visit (weeks)
≤14  171,483  67.9  185  63.6  1.08  0.92–1.23 
15–27  69,604  27.6  86  29.6  1.24  0.99–1.53 
≥28  10,323  4.1  18  6.2  1.74  1.03–2.76 
Postnatal registration  1,023  0.4  2  0.7  1.96  0.24–7.06 
Unknown  7  0.0  -  -  -  - 
Customised birthweight centiles
Small for gestational age  22,971  9.1  57  19.6  2.48  1.88–3.21 
Appropriate for gestational age  187,430  74.2  213  73.2  1.14  0.98–1.29 
Large for gestational age  29,860  11.8  21  7.2  0.70  0.44–1.08 
Unknown  12,179  4.8  -  -  -  - 
Parity
0  102,865  40.7  180  61.9  1.75  1.49–2.01 
1  86,002  34.1  58  19.9  0.67  0.51–0.87 
2  37,594  14.9  26  8.9  0.69  0.45–1.01 
3  14,465  5.7  17  5.8  1.18  0.68–1.88 
≥4  11,501  4.6  10  3.4  0.87  0.42–1.60 
Unknown  13  0.0  -  -  -  - 
* MAT data numerator and denominator; limited to mothers who were registered for care with an LMC (either a midwife, obstetrician or GP) claiming from the 
Section 88 Primary Maternity Services Notice.
Table 3.2 shows unadjusted associations between smoking, BMI, parity, gestation at first antenatal 
visit, and customised birthweight centile and NE for 2012–2016. As these variables are not reliably 
available for women receiving primary maternity care from DHBs, these analyses are limited to mothers 
who were registered for care with an LMC (either a midwife, obstetrician or GP) claiming from the 
Section 88 Primary Maternity Services Notice.
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There was no statistically significant association seen between smoking and NE, although the NE rate 
for smokers was higher than that for non-smokers. There was, however, an increase in risk of NE with 
increasing BMI. The rate of NE was statistically significantly higher among mothers with a BMI of 30 
and higher compared to mothers with a BMI of 18.50–24.99 (considered normal BMI), and this was 
not a threshold effect, with rate increasing as BMI increased. 
Although the rate of NE appears to increase among mothers who engage later with antenatal care 
during pregnancy, this was not statistically significant. 
Babies born small for gestational age as measured by customised birthweight centile were twice as 
likely to be diagnosed with NE compared to babies born with appropriate birthweight for gestational 
age. Babies born large for gestational age were significantly less likely to be diagnosed with NE.
These are unadjusted findings. A multivariable analysis is required to explore the independent 
predictors of NE. This will be included in the work plan for 2018–2019.
Antenatal complications, interventions, and maternal outcome
Table 3.3: Antenatal complications, obstetric interventions, and maternal outcome among neonatal 
encephalopathy cases by parity and Sarnat stage 2012–2016
NE cases Primiparous Multiparous
Sarnat stage
Moderate Severe
n=330 n=202 n=128 n=235 n=95
n % n % n % n % n %
Antenatal complications
APH (≥20 weeks vaginal bleeding) 32 9.7 18 8.9 14 10.9  21 8.9  11 11.6
Hypertension 45 13.6 35 17.3 10 7.8  34 14.5  11 11.6
Pre-eclampsia 9 2.7 8 4.0 1 0.8  8 3.4  1 1.1
Gestational hypertension 14 4.2 10 5.0 4 3.1  12 5.1  2 2.1
Unspecified hypertension 22 6.7 17 8.4 5 3.9  14 6.0  8 8.4
Maternal trauma (antenatal)* 6 1.8 2 1.0 4 3.1  2 0.9  4 4.2
Induction/augmentation of labour
Induction of labour 84 25.5 56 27.7 28 21.9  65 27.7  19 20.0
Induced or augmented labour (any 
method)
163 49.4 114 56.4 49 38.3  126 53.6  37 38.9
Oxytocin for induction or augmentation 80 24.2 58 28.7 22 17.2  64 27.2  16 16.8
Epidural anaesthesia 81 24.5 62 30.7 19 14.8  68 28.9  13 13.7
Maternal outcome
Deceased 3 0.9 1 0.5 2 1.6  2 0.9  1 1.1
Alive but with serious morbidity 7 2.1 0 0.0 7 5.5  5 2.1  2 2.1
Alive and well 320 97.0 201 99.5 119 93.0  228 97.0  92 96.8
* Vehicular, violent personal injury, other.
Primiparous: parity = 0 defined prior to current birth.
Multiparous: parity ≥1 defined prior to current birth.
APH = antepartum haemorrhage.
Antepartum haemorrhage and hypertension in pregnancy complicated 10 percent and 14 percent of 
pregnancies where babies were diagnosed with NE respectively. 
The national rate of induction of labour (all births) was 23.8 percent in 2015 (27.8 percent among 
women having their first baby and 19.9 percent among women having subsequent babies), which is 
similar to that among mothers of babies diagnosed with NE from 2012 to 2016 (25.5 percent, 27.7 
percent and 21.9 percent respectively) (Ministry of Health 2017b).
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Among mothers of babies diagnosed with NE, 24.5 percent had an epidural in labour (2012–2016) 
compared to a national rate in 2014 of 26.4 percent (41.3 percent of women having their first baby, 
and 14.8 percent of women having subsequent babies).
Over the five years of NE data collection from 2012 to 2016, there have been three babies diagnosed 
with NE associated with maternal death and seven with severe maternal morbidity. Of these 10 babies, 
three had severe NE.
Peripartum complications and mode of birth





Acute peripartum events  73  22.1 
Cord prolapse  10  3.0 
Placental abruption  18  5.5 
Uterine rupture  7  2.1 
Shoulder dystocia  22  6.7 
Breech complication  7  2.1 
Other complication  12  3.6 
Liquor
Blood stained  24  7.3 
Thick meconium  74  22.4 
Thin meconium  41  12.4 
Mode of birth
Normal vaginal birth  128  38.8 
Operative vaginal birth  50  15.2 
Forceps  21  6.4 
Ventouse  28  8.5 
Unknown  1  0.3 
Vaginal breech birth   6  1.8 
Caesarean section birth  146  44.2 
Elective  8  2.4 
Prelabour emergency  30  9.1 
Antepartum haemorrhage/Placental abruption  2  0.6 
Suspected fetal distress  23  7.0 
Failed induction  1  0.3 
Other  4  1.2 
In labour emergency  108  32.7 
Antepartum haemorrhage/Placental abruption  7  2.1 
Suspected fetal distress  82  24.8 
Failure to progress/Cephalopelvic disproportion  8  2.4 
Other  1  0.3 
Unknown  10  3.0 
Attempt at operative vaginal birth before caesarean  9  2.7 
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Acute peripartum events were reported in 73 cases (22 percent) in the five years from 2012 to 2016. 
Of these, abruption (18 babies) and shoulder dystocia (22 babies) were the most common. Other 
complications included amniotic fluid embolism, maternal collapse, complications at birth of the second 
twin, vasa praevia and drug error. 
Among babies diagnosed with NE from 2012 to 2016, 44 percent were born by caesarean section. 
Thirty-three percent were born by in-labour emergency caesarean section, which was most often 
performed for suspected fetal distress (25 percent). This compares with a national caesarean section 
rate of 25.5 percent among all births in 2015 (Ministry of Health 2017b). 
Six babies in the five-year period 2012–2016 (1.8 percent) were breech vaginal births at term, 
compared to 0.4 percent vaginal breech births in New Zealand in 2015 (Ministry of Health 2017b).
In 2016–2017 the NEWG reviewed the maternity and early neonatal care of 47 cases of NE from 
2013–2015 associated with an acute peripartum event. The Accident Compensation Commission 
(ACC) funded this work. The following text box presents a summary of the findings of this review.
Summary of multidisciplinary review of neonatal encephalopathy associated with acute 
peripartum events 2013–2015
Forty-seven babies with NE were reviewed by a team including midwives, obstetricians, 
neonatologists, neonatal nurse practitioners and a human factors psychologist. 
NE was associated with placental abruption (12), shoulder dystocia (11), cord prolapse (6), maternal 
collapse (5), uterine rupture (4), breech complications (4), and five other events.
Contributory factors were identified in 42 (89 percent) of the 47 cases reviewed. In 66 percent of 
cases, mortality or the severity of morbidity was determined to be potentially avoidable.
Specific areas for improvement highlighted 
1. Support for recommended best practice around maternal weight measurement, fundal height measurement, 
serial scanning, screening for diabetes in pregnancy 
2. Simulation training/skill enhancement around rare but known obstetric emergencies, including how to 
maintain skill in remote or small units where exposure is limited, linking midwifery, obstetric and emergency 
staff, considering the use of short emergency training events, and simulation training or credentialing for 
neonatal resuscitation 
3. Checklists to assist with learning/action and documentation (eg, shoulder dystocia) 
4. Reinforcing learning around difficult discussions and subsequent documentation of discussions, as they apply 
to assessment and management of risk related to antenatal and intrapartum care 
5. Documentation of acute peripartum events, facilitated by debrief and collegial support 
6. Reinforcement of regular assessment of the newborn with risk factors for NE 
7. Maternal and fetal surveillance in labour: cardiotocography training, role of lactate estimation in labour 
8. Transfer, especially of neonates from Level 1 or 2 facilities; availability of transports and support/
coordination for neonatal retrieval 
9. Process for NE review including where and how this is best done, local and/or independent or a mixture of 
both, consider inclusion of an anaesthetist in reviews 
10. Incorporation of human factors items into the PMMRC review tool 
11. Conceptualisation of human factors and how to capture and learn from an understanding of these.
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The findings from the first review of NE babies, without peripartum events (Sadler et al 2016), informed 
the ACC-led NE Taskforce’s current work programme. This work and further review of evidence by the 
NE Taskforce led to four national initiatives:
• Fetal Growth Assessment Protocol (GAP)
• Fetal heart monitoring education
• Newborn observation chart and Newborn Early Warning Score (NEWS)
• Fetal cord blood lactate testing.
Working Groups have been established, comprising relevant experts and representatives, to deliver 
these projects with the NE Taskforce providing governance.
Place of birth




























From 2012 to 2016, 3.4 percent of babies were confirmed as born at home in New Zealand (defined 
by LMC claim for home-birthing fee), 9.9 percent in a primary unit (including birthing unit and Level 1 
hospital), 41 percent in a Level 2 hospital and 45 percent in a tertiary hospital. One percent of births 
had unknown place of birth (Table 3.13).
The rate of NE was significantly lower among term babies born at primary units than among those born 
at secondary and tertiary units from 2012 to 2016. The rate of NE among term babies born at home 
was also estimated as lower than at secondary and tertiary units, but the difference was not statistically 
significant. There was no significant difference in the rate of NE between babies born at home and in 
primary units. 
The proportions of severe Sarnat stage cases, survival, and use of induced cooling were not statistically 
significantly different by place of birth. 
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Immediate newborn wellbeing
Table 3.5: Immediate newborn wellbeing among neonatal encephalopathy babies 2010–2016
2010 2011 2012 2013 2014 2015 2016 Total
n=82 n=67 n=79 n=70 n=55 n=70 n=56 n=479
n % n % n % n % n % n % n % n %
Apgar scores
Apgar score <3 at 1 
minute  48  58.5  41  61.2  47  59.5  40  57.1  37  67.3  39  55.7  37  66.1  289  60.3 
Apgar score <5 at 1 
minute  65  79.3  54  80.6  62  78.5  58  82.9  49  89.1  51  72.9  48  85.7  387  80.8 
Apgar score <7 at 1 
minute  73  89.0  61  91.0  70  88.6  65  92.9  53  96.4  59  84.3  51  91.1  432  90.2 
Apgar score <7 at 5 
minutes  61  74.4  54  80.6  62  78.5  57  81.4  43  78.2  50  71.4  46  82.1  373  77.9 
Apgar score <7 at 10 
minutes  39  47.6  38  56.7  49  62.0  32  45.7  29  52.7  35  50.0  33  58.9  255  53.2 
Apgar score <9 at 10 
minutes  52  63.4  52  77.6  62  78.5  52  74.3  45  81.8  48  68.6  44  78.6  355  74.1 
Cord blood gases: summary data
Normal (none of pH ≤7, 
BE ≤−12, lactate ≥6)  12  14.6  14  20.9  11  13.9  13  18.6  7  12.7  8  11.4  6  10.7  71  14.8 
Abnormal (any of pH 
≤7, BE ≤−12, lactate ≥6)  47  57.3  41  61.2  55  69.6  48  68.6  40  72.7  47  67.1  42  75.0  320  66.8 
No gases reported  23  28.0  12  17.9  13  16.5  9  12.9  8  14.5  15  21.4  8  14.3  88  18.4 
No gases and Apgar <7 
at 1 minute  14  17.1  8  11.9  8  10.1  6  8.6  8  14.5  6  8.6  6  10.7  56  11.7 
No gases and Apgar ≥7 
at 1 minute  8  9.8  4  6.0  5  6.3  3  4.3  -  -  9  12.9  2  3.6  31  6.5 
No gases and unknown 
Apgar  1  1.2  -  -  -  -  -  -  -  -  -  -  -  -  1  0.2 
BE = base excess.
Sixty percent of the babies diagnosed with moderate or severe NE from 2010 to 2016 had an Apgar 
score under 3 at one minute, 81 percent under 5 at one minute, 78 percent under 7 at five minutes, 
and 53 percent still had a score under 7 at 10 minutes. Sixty-seven percent had abnormal arterial or 
venous cord blood gases (defined as pH of ≤7.0 and/or base excess of ≤−12mmol/L and/or lactate of 
≥6mmol/L), and a further 12 percent who had no gas result had an Apgar score of <7 at one minute. 
These data indicate the majority of babies diagnosed with moderate and severe NE have evidence of 
asphyxia at birth.
The reduction in the proportion of babies without cord gases reported from 2010 (28 percent) to 2016 
(14 percent) was not statistically significant (score test for trend p=0.19).
The practice of collection and review of umbilical cord bloods may vary by DHB. Every birthing facility 
needs to ensure that umbilical cord gas results are reviewed and managed in a timely manner. For 
reference, the Auckland DHB guideline on management of umbilical cord blood results is given below. 
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Management of Umbilical Cord Blood Results 
Management of umbilical cord lactate results 
Cord lactates should be taken and processed within 10 minutes of cord clamping.
Management of umbilical cord gas results 
Umbilical cord gases can be analysed within one hour of birth if clamped immediately after delivery. 
Both umbilical cord arterial and venous gases should be analysed.
(Auckland District Health Board 2017)
Umbilical cord lactate result Action
Less than 6.0 mmol/L Document results
6.0 mmol/L or above Send paired umbilical cord gases
Umbilical cord gas result Action
pH less than 7.0 or base excess less than or equal to −12 mmol/L Call paediatrician for review. 
pH 7.0–7.15 or base excess −11 to −7 mmol/L
Or umbilical cord gas result not available and cord lactate greater 
than or equal to 6.0 mmol/L
Monitor baby for signs of neonatal encephalopathy 
(hypotonia, poor feeding, lethargy, weak or absent suck/
gag or Moro reflex, seizures).  
Call paediatrician if any concerns. 
pH above 7.15 and base excess above −7 mmol/L Document results.
Induced cooling
Table 3.6: Induced cooling therapy among neonatal encephalopathy babies 2010–2016
Cooling
2010 2011 2012 2013 2014 2015 2016 Total
n=82 n=67 n=79 n=70 n=55 n=70 n=56 n=479
n % n % n % n % n % n % n %
Yes  56  68.3  51  76.1  62  78.5  58  82.9  45  81.8  56  80.0  44  78.6  372  77.7 
No  26  31.7  16  23.9  17  21.5  12  17.1  10  18.2  14  20.0  12  21.4  107  22.3 
Age at cooling  n=56  n=51  n=62  n=58  n=45  n=56  n=44  n=372 
≤6 hours  46  82.1  39  76.5  53  85.5  47  81.0  39  86.7  44  78.6  34  77.3  302  81.2 
>6 hours  10  17.9  8  15.7  9  14.5  11  19.0  6  13.3  11  19.6  10  22.7  65  17.5 
Unknown time  -  -  4  7.8  -  -  -  -  -  -  1  1.8  -  -  5  1.3 
Induced cooling has been shown to reduce mortality by 25 percent and neurodevelopmental disability 
in survivors of NE by 23 percent (Jacobs et al 2013).
In 2016, 79 percent of babies born in New Zealand with moderate or severe NE were treated 
with induced cooling. The proportion of those cooled who were cooled within six hours of birth as 
recommended for maximal benefit was 77 percent. There has been little change in this rate over the 
years of data collection.
Review of the 54 neonates from 2011 to 20143 who were not cooled found that 20 of 22 Sarnat stage 
severe babies were appropriately not cooled, reasons including early neonatal death, withdrawal of 
care, disseminated infection, and one late presentation with seizures on day 2. In only two severe cases 
could cooling possibly have been initiated; one infant was transferred to Level 3 at 12 hours, the other 
developed seizures at 4 hours of age with normal cord gases (PMMRC 2017).
3 An extra late notification (to total 55 cases 2011–2014) included in Table 3.6 was not included in the review.
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Of the 32 Sarnat stage moderate babies who were not cooled, it was found that 23 were appropriately 
not cooled. Reasons for not cooling included late presentation, NE unrelated to hypoxic ischemic 
encephalopathy, and one case was considered but did not proceed to cooling. Of the remaining nine 
infants, cooling may have been indicated as low pH on cord gases and earlier consultation could have 
prompted transfer to a tertiary unit. 
The 12 babies (four severe, eight moderate) not cooled in 2016 were reviewed. In some of these 
cases, documentation was insufficient to be certain whether an opportunity for cooling existed and did 
not describe the rationale for a decision not to cool. An update to the data collection tool requesting 
additional information on decision-making (in response to the previous review) should help with review 
of these cases in the future. There were, however, two babies with NE who on review should have been 
referred/transferred for cooling. 
The following points arose from the review:
• Neonatal observation is required for neonates with risk factors for NE. 
• Regular assessment of Sarnat stage (hourly to 6 hours) is required for neonates identified with 
probable asphyxia to ensure cooling is not delayed for babies who deteriorate after their initial 
assessment (Battin 2015).
Neonatal resuscitation






n  % n % n %
Resuscitation at birth
Yes  305  92.4  216  91.9  89  93.7 
No  25  7.6  19  8.1  6  6.3 
Type of resuscitation at birth
Oxygen only  4  1.2  4  1.7  -  - 
IPPV with mask  226  68.5  167  71.1  59  62.1 
IPPV with ETT  171  51.8  105  44.7  66  69.5 
Cardiac massage  118  35.8  60  25.5  58  61.1 
Adrenaline  44  13.3  15  6.4  29  30.5 
Respiratory and ventilation management
Mechanical ventilation  271  82.1  181  77.0  90  94.7 
Nitric oxide  82  24.8  52  22.1  30  31.6 
Infection
Positive blood culture  13  3.9  10  4.3  3  3.2 
Antibiotics  308  93.3  221  94.0  87  91.6 
Anticonvulsant therapy  241  73.0  165  70.2  76  80.0 
Phenobarbitone  212  64.2  140  59.6  72  75.8 
Phenytoin  74  22.4  38  16.2  36  37.9 
Benzodiazepines  91  27.6  56  23.8  35  36.8 
Other  51  15.5  38  16.2  13  13.7 
IPPV = intermittent positive pressure ventilation.
ETT = endotracheal tube.
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Among the cohort of 330 NE babies from 2012 to 2016, 92 percent were resuscitated at birth, 36 
percent required cardiac massage, 13 percent adrenalin, and 52 percent intubation and intermittent 
positive pressure ventilation. 
Outcomes of babies with neonatal encephalopathy
Table 3.8: Use of cooling and outcomes of encephalopathy by Sarnat stage among neonatal 
encephalopathy babies 2012–2016
Sarnat stage
NE babies Moderate Severe
n=330 n=235 n=95
n % n % n %
Induced cooling
Yes  265  80.3  195  83.0  70  73.7 
No  65  19.7  40  17.0  25  26.3 
Deceased
Yes  58  17.6  5  2.1  53  55.8 
No  272  82.4  230  97.9  42  44.2 
Babies with severe Sarnat stage NE are less likely to be cooled, and this has been shown at review to 
be related to their severe ill-health. Of babies with moderate Sarnat stage NE from 2012 to 2016, 83 
percent were treated with induced cooling. 
Among the 58 deaths of babies with NE from 2012 to 2016, 53 (91 percent) were severe Sarnat 
stage. Of the babies with severe Sarnat stage NE who did not die, 35 (83 percent) were cooled. 
From 2010 to 2016, 94 (20 percent) of 479 babies diagnosed with NE at term died within the first six 
weeks of life, and a further 13 are known to have died subsequently (22 percent). 
The proportion of babies dying, in the first 28 days of age, per year has not changed significantly since 
2010.
Ninety-two babies with NE died within the neonatal period (up to 28 days), 21 (23 percent) within the 
first day, 55 (60 percent) within the first three days, and 83 (90 percent) within the first week of birth. A 
further nine babies (10 percent) died after one week but within 28 days of birth, and two babies died 
in the post-neonatal period (at five and six weeks). As of the year ended December 2016, a further 13 
babies died after discharge from three months to five years of age.
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Investigations and neonatal outcome by Sarnat stage (survivors)
Table 3.9: Investigations and neonatal outcome by Sarnat stage of neonatal encephalopathy survivors 2010–2016




n=59 n=54 n=67 n=59 n=44 n=58 n=44 n=385 n=325 n=60
n % n % n % n % n % n % n % n % n % n %
Examination on discharge/transfer
Normal  32  54.2  25  46.3  30  44.8  24  40.7  17  38.6  29  50.0  15  34.1  172  44.7  163  50.2  9  15.0 
Mild or moderate abnormality  14  23.7  20  37.0  19  28.4  23  39.0  17  38.6  14  24.1  23  52.3  130  33.8  108  33.2  22  36.7 
Severe abnormality  3  5.1  1  1.9  5  7.5  5  8.5  3  6.8  4  6.9  3  6.8  24  6.2  3  0.9  21  35.0 
Not examined  1  1.7  4  7.4  7  10.4  5  8.5  2  4.5  3  5.2  -  -  22  5.7  19  5.8  3  5.0 
Examined but finding unknown  3  5.1  1  1.9  5  7.5  2  3.4  2  4.5  2  3.4  -  -  15  3.9  11  3.4  4  6.7 
Missing data  6  10.2  3  5.6  1  1.5  -  -  3  6.8  6  10.3  3  6.8  22  5.7  21  6.5  1  1.7 
MRI (investigation done)  41  69.5  35  64.8  43  64.2  50  84.7  38  86.4  48  82.8  40  90.9  295  76.6  237  72.9  58  96.7 
No MRI or Unknown  18  30.5  19  35.2  24  35.8  9  15.3  6  13.6  10  17.2  4  9.1  90  23.4  88  27.1  2  3.3 
Results of MRI
Moderately/Severely abnormal  16  27.1  11  20.4  17  25.4  22  37.3  13  29.5  15  25.9  18  40.9  112  29.1  73  22.5  39  65.0 
Normal or only mildly abnormal  24  40.7  23  42.6  24  35.8  27  45.8  25  56.8  33  56.9  21  47.7  177  46.0  159  48.9  18  30.0 
Unknown result  1  1.7  1  1.9  2  3.0  1  1.7  -  -  -  -  1  2.3  6  1.6  5  1.5  1  1.7 
MRI = magnetic resonance imaging (of the brain).
There has been a statistically significant increase in the proportion of surviving babies who had an MRI investigation since collection of NE data 
began, from 70 percent in 2010 to 91 percent in 2016 (score test for trend p=0.0001). 
Of survivors during 2010–2016, 29 percent had a moderately or severely abnormal MRI (23 percent of moderate and 65 percent of severe 
cases) and 46 percent had a normal or only mildly abnormal scan (49 percent of moderate and 30 percent of severe cases). Twenty-three 
percent of survivors during 2010–2016 did not have an MRI (27 percent of moderate and 3 percent of severe cases). In 2016 four surviving 
babies (9 percent) did not have an MRI.
From 2018, the NEWG will not collect or report electroencephalogram (EEG) investigation as this has been replaced by cot-side amplitude-
integrated electroencephalography (aEEG). Data on cot-side aEEG will be collected going forward. 
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3.5 Neonatal Encephalopathy 2016: Appended Tables
Table 3.10: Neonatal encephalopathy rates (per 1000 term births) by prioritised maternal ethnicity, 
maternal age and deprivation quintile 2012–2016
MAT births 
≥37 weeks
NE cases Rate 
(/1000 term births)
N=277,193 n=330
n % n % /1000 95% CI
Maternal ethnicity
Māori  68,096  24.6  91 27.6  1.34 1.08–1.64
Pacific peoples  29,182  10.5  44 13.3  1.51 1.10–2.02
Indian  12,987  4.7  14 4.2  1.08 0.59–1.81
Other Asian  29,600  10.7  23 7.0  0.78 0.49–1.17
MELAA  6,107  2.2  8 2.4  1.31 0.57–2.58
Other European  26,937  9.7  14 4.2  0.52 0.28–0.87
NZ European  104,252  37.6  136 41.2  1.30 1.09–1.52
Unknown/Other  32  0.0  - 0.0  - -
Maternal age (years)
<20  14,064  5.1  23  7.0  1.64 1.04–2.45
20–34  205,362  74.1  246  74.5  1.20 1.05–1.35
35–39  46,399  16.7  49  14.8  1.06 0.78–1.40
≥40  11,352  4.1  12  3.6  1.06 0.55–1.85
Unknown  16  0.0  -  -  - -
Deprivation quintile
1 (least deprived)  39,616  14.3  33  10.0  0.83 0.57–1.17
2  43,699  15.8  52  15.8  1.19 0.89–1.56
3  50,412  18.2  60  18.2  1.19 0.91–1.53
4  62,925  22.7  83  25.2  1.32 1.05–1.64
5 (most deprived)  78,795  28.4  102  30.9  1.29 1.04–1.55
Unknown  1,746  0.6  -  -  - -
Table 3.11: Actual and intended place of birth among neonatal encephalopathy cases 2012–2016
Intended place of 
birth
NE cases Actual place of birth





n % n % n % n % n % n % n %
Home  13  3.9  8  61.5  -  -  -  -  4  30.8  1  7.7  -  - 
Birthing unit  48  14.5  1  2.1  17  35.4  -  -  7  14.6  23  47.9  -  - 
Hospital level 1  16  4.8  -  -  -  -  3  18.8  3  18.8  10  62.5  -  - 
Hospital level 2  131  39.7  1  0.8  -  -  2  1.5  124  94.7  3  2.3  1  0.8 
Hospital level 3  118  35.8  -  -  -  -  -  -  1  0.8  117  99.2  -  - 
Unknown  4  1.2  -  -  -  -  -  -  2  50.0  2  50.0  -  - 
Total  330  10  3.0  17  5.2  5  1.5  141  42.7  156  47.3  1  0.3 
MELAA = Middle Eastern, Latin American or African.
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≥37 weeks 2012 2013 2014 2015 2016
Total 
NE cases Rate 
(/1000 term births)
N=277,193 n=79 n=70 n=55 n=70 n=56 n=330
n n n n n n n /1000 95% CI
Northland  10,196  2  1  1  1  4  9  0.88 0.40–1.68
Waitemata  36,471  4  5  9  4  5  27  0.74 0.49–1.08
Auckland  28,982  4  8  5  6  5  28  0.97 0.64–1.40
Counties Manukau  38,365  14  6  5  4  6  35  0.91 0.64–1.27
Waikato  24,660  9  5  6  12  7  39  1.58 1.12–2.16
Bay of Plenty  13,182  2  3  1  6  4  16  1.21 0.69–1.97
Lakes  6,901  2  1  1  2  1  7  1.01 0.41–2.09
Tairawhiti  3,363  2  1  1  -  -  4  1.19 0.32–3.05
Taranaki  7,015  6  5  4  4  -  19  2.71 1.63–4.23
Hawke’s Bay  9,622  3  2  3  3  3  14  1.45 0.80–2.44
Whanganui  3,810  2  1  -  1  2  6  1.57 0.58–3.43
MidCentral  9,656  2  3  2  4  1  12  1.24 0.64–2.17
Wairarapa  2,247  -  -  1  -  -  1  0.45 0.01–2.48
Capital & Coast  16,704  9  10  3  7  6  35  2.10 1.46–2.91
Hutt Valley  8,921  2  5  2  -  2  11  1.23 0.62–2.21
Nelson and Marlborough  6,971  2  5  1  2  1  11  1.58 0.79–2.82
West Coast  1,657  2  -  2  -  1  5  3.02 0.98–7.04
Canterbury  28,081  7  2  6  6  5  26  0.93 0.60–1.36
South Canterbury  3,038  2  1  -  3  -  6  1.97 0.72–4.30
Southern  15,787  3  6  2  5  3  19  1.20 0.72–1.88
Other*  1,564  -  -  -  -  -  -  - -
* Other includes Overseas, Unknown and Other.
Table 3.13: Neonatal encephalopathy rates (per 1000 term births) by place of birth* 2012–2016
Facility of birth
MAT births ≥37 weeks NE cases
N=277,193 n=324
n % n % Rate 95% CI
Home  9,505  3.4  9  2.8  0.95  0.43–1.80 
Primary  27,551  9.9  20  6.2  0.73  0.44–1.12 
Secondary  113,314  40.9  136  42.0  1.20  1.00–1.40 
Tertiary  124,114  44.8  157  48.5  1.26  1.07–1.46 
Unknown  2,709  1.0  2  0.6  -  - 
* MAT data numerator and denominator
PERINATAL AND MATERNAL MORTALITY REVIEW COMMITTEE: 12th ANNUAL REPORT 91
4 Perinatal Mortality 2016
4.1 Perinatal Mortality Key Findings 2016
The perinatal related mortality rate, which includes all deaths from 20 weeks gestation to 27 days 
of life (including late terminations of pregnancy, stillbirths, and early and late neonatal deaths), was 
10.1 per 1000 total births in New Zealand in 2016. While there has been no statistically significant 
reduction in perinatal related mortality since 2007 using the New Zealand definition (chi-square test 
for trend p=0.06), there has been a significant reduction in perinatal related mortality from 1000g or 
28 weeks (international definition (WHO 2006)) (p=0.0009) and a significant reduction in stillbirths 
(p=0.006 (New Zealand definition), p=0.0003 (international definition)). 
There has been a highly significant reduction in perinatal related mortality, using the New Zealand 
definition, from hypoxic peripartum death (p=0.00005); and a highly significant reduction in perinatal 
mortality using the international definition (from 1000g or 28 weeks) from hypoxic peripartum death 
(p=0.00005), antepartum haemorrhage (p=0.009) and fetal growth restriction (p=0.001). 
There was a statistically significant reduction in the proportion of small for gestational age babies born 
from 2008 to 2016 and a statistically significant reduction in perinatal related mortality among small 
for gestational age babies (score test for trend p=0.046) (Figure 4.17).
There has been no significant change in overall neonatal death rates or rates of death from termination 
of pregnancy. Neonatal deaths are the topic of a special report this year (chapter “2 Special Topic: 
Neonatal Mortality 2007–2016”).
The number of mothers under 20 years of age halved from 2007 to 2016, while the perinatal related 
mortality among these mothers increased from 11.9/1000 births in 2007 to 21.9/1000 births 
in 2016 (p<0.005). Mothers under 20 years of age are at higher risk of perinatal related death 
(excluding congenital anomalies) from spontaneous preterm birth, fetal growth restriction, antepartum 
haemorrhage, and perinatal infection than any other age group.
There are also inequities in perinatal related death rates by ethnicity and socioeconomic deprivation. 
Pacific and Indian mothers have the highest rates of perinatal related mortality. 
There has been a statistically significant reduction in stillbirths at 28 to 31 weeks (p=0.009) and at term 
(37 to 40 weeks) (p=0.003). There has been no change in stillbirth rate or perinatal related death rate 
at 41 weeks and beyond, although there has been a reduction in numbers of deaths (20 stillbirths and 
34 perinatal related deaths in 2007 and 14 and 20 in 2016). This is because there were 29 percent 
fewer births at 41 weeks and beyond in 2016 (8766) compared to 2007 (12,325), presumably due to 
changing patterns of induction of labour and elective caesarean section. (There were 7 percent fewer 
births overall in 2016 compared to 2007).
Māori and Pacific babies who die in the perinatal period remain less likely to have any investigation 
of their death than babies born to mothers of all other ethnic groupings (Table 4.35). A discussion on 
equity of access to perinatal investigations for Māori is included in a text box later in this chapter (see 
“Perinatal death investigations, counsel and considerations”). 
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4.2 Perinatal Mortality Recommendations
1. Maternity and primary care providers need to be aware of the increasing risk of perinatal 
mortality for mothers under 20 years of age in New Zealand. Inequity in perinatal mortality for 
babies born to mothers under 20 years of age needs to be actively addressed. 
The PMMRC recommends the Ministry of Health and DHBs:
a. develop, in consultation with young mothers, acceptable and safe methods for mothers 
under 20 years of age to access and engage with care in order to achieve equitable health 
outcomes
b. identify and adequately resource evidence-based solutions to address risks for mothers 
under 20 years of age, paying attention to smoking cessation, screening and treatment for 
infections, screening for fetal growth restriction, and providing adequate information about 
the causes and symptoms of preterm labour
c. consider how they can support LMCs caring for mothers aged under 20 years.
Justification
The number of mothers under 20 years of age has halved from 2007 to 2016, and in this time there 
has been a significant increase in perinatal related mortality in this group (p=0.0045).
Mothers under 20 years of age were less likely to birth their 23 to 26 week babies in a tertiary unit 
compared to mothers who were 20 years and older (Table 2.9). 
Evidence
Support services do exist in New Zealand for teenage mothers; however, these have not impacted on 
perinatal death for these mothers.
Nationally, women under 20 years of age are less likely to register for LMC care in the first trimester 
than women from any other age group (Ministry of Health 2017b).
2. The PMMRC recommends that DHBs with rates of perinatal related mortality significantly higher 
than the national rate review, or continue to review, the higher rate of mortality in their area 
and identify areas for improvement. 
Justification 
There is a statistically significantly higher perinatal related mortality rate than the national rate among 
residents of Counties Manukau DHB (Figure 4.12). This is significantly higher for both stillbirth (Figure 
4.13) and neonatal death (Figure 4.14).
There is a statistically significantly higher perinatal related mortality and stillbirth rate than the national 
rate among residents of Northland DHB (Figure 4.12 and Figure 4.13).
There is a statistically significantly higher stillbirth rate than the national rate among residents of 
Wairarapa DHB (Figure 4.13).
There is a statistically significantly higher neonatal death rate than the national rate among residents of 
Bay of Plenty DHB (Figure 4.14).
Evidence
Audits of perinatal deaths are required to understand causes and focus prevention efforts (The Lancet 
2016).
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4.3 Methodology
In this 12th report of the PMMRC, the perinatal chapter includes a reduced selection of tables and 
figures compared to recent past reports. The limited commentary addresses new data presented in the 
chapter.
The methodology for the perinatal mortality report is included with the ‘Methodology and Definitions 
for PMMRC Reporting’ document on the PMMRC website (www.hqsc.govt.nz/our-programmes/mrc/
pmmrc/publications-and-resources/publication/3367/).
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Figure 4.2: Perinatal related mortality rates (per 1000 births) using the international definition 
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Table 4.1: Summary of New Zealand perinatal mortality rates using New Zealand definition (≥20 weeks or ≥400g if gestation unknown) 
2007–2016
* Fetal death rate per 1000 babies born (includes terminations and stillbirths).
# Neonatal death rate per 1000 live born babies.
+ Fetal deaths and early neonatal deaths per 1000 babies born.
^ Fetal deaths and early and late neonatal deaths per 1000 babies born.
• Lethal and terminated fetal abnormalities are all perinatal related deaths with PSANZ-PDC of congenital abnormality and neonatal deaths with PSANZ-NDC of congenital abnormality.





2007 2008 2009 2010 2011 2012 2013 2014 2015 2016
Total births 65,202 65,624 65,198 65,445 63,236 63,274 60,133 60,073 59,768 60,576  
Fetal deaths (terminations of pregnancy and stillbirths)* 513 524 547 498 503 492 447 477 412 458~ 0.037
Terminations of pregnancy 144 145 138 151 171 172 141 150 107 148 0.68
Stillbirths 369 379 409 347 332 320 306 327 305 310~ 0.0053
Early neonatal deaths <7 days 133 134 137 165 139 142 122 150 131 121 0.71
Late neonatal deaths 7–27 days 34 43 46 45 25 36 31 32 35 30 0.26
Neonatal deaths <28 days# 167 177 183 210 164 178 153 182 166 151 0.86
Perinatal mortalities+ 646 658 684 663 642 634 569 627 543 579~ 0.097
Perinatal related mortalities^ 680 701 730 708 667 670 600 659 578 609~ 0.06
Perinatal mortalities excluding lethal and terminated fetal 
abnormalities• 462 488 515 466 446 445 417 449 402 414 0.10
Perinatal related mortalities excluding lethal and 
terminated fetal abnormalities• 482 516 546 497 462 467 436 468 420 435 0.064
Rate
2007 2008 2009 2010 2011 2012 2013 2014 2015 2016
Fetal deaths (terminations of pregnancy and stillbirths)* 7.9 8.0 8.4 7.6 8.0 7.8 7.4 7.9 6.9 7.6
Terminations of pregnancy 2.2 2.2 2.1 2.3 2.7 2.7 2.3 2.5 1.8 2.4
Stillbirths 5.7 5.8 6.3 5.3 5.3 5.1 5.1 5.4 5.1 5.1
Early neonatal deaths <7 days
Late neonatal deaths 7–27 days
Neonatal deaths <28 days# 2.6 2.7 2.8 3.2 2.6 2.8 2.6 3.1 2.8 2.5
Perinatal mortalities+ 9.9 10.0 10.5 10.1 10.2 10.0 9.5 10.4 9.1 9.6
Perinatal related mortalities^ 10.4 10.7 11.2 10.8 10.5 10.6 10.0 11.0 9.7 10.1
Perinatal mortalities excluding lethal and terminated fetal 
abnormalities• 7.1 7.4 7.9 7.1 7.1 7.0 6.9 7.5 6.7 6.8
Perinatal related mortalities excluding lethal and 
terminated fetal abnormalities• 7.4 7.9 8.4 7.6 7.3 7.4 7.3 7.8 7.0 7.2
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2007 2008 2009 2010 2011 2012 2013 2014 2015 2016
Total births 64,651 65,077 64,625 64,881 62,688 62,712 59,601 59,510 59,305 60,072  
Fetal deaths (terminations of pregnancy and stillbirths)* 212 207 231 199 191 166 155 162 164 170 0.00097
Terminations of pregnancy 6 14 9 17 24 13 12 13 7 15 0.43
Stillbirths 206 193 222 182 167 153 143 149 157 155 0.00028
Early neonatal deaths <7 days 57 67 59 68 65 54 45 59 57 53 0.61
Late neonatal deaths 7–27 days 28 35 30 31 18 24 24 23 28 22 0.28
Neonatal deaths <28 days# 85 102 89 99 83 78 69 82 85 75 0.30
Perinatal mortalities+ 269 274 290 267 256 220 200 221 221 223 0.0018
Perinatal related mortalities^ 297 309 320 298 274 244 224 244 249 245 0.00093
Perinatal mortalities excluding lethal and terminated fetal 
abnormalities• 224 220 238 204 180 169 158 168 177 169 0.00024
Perinatal related mortalities excluding lethal and 
terminated fetal abnormalities• 238 240 254 221 189 179 170 178 188 182 0.000097
Rate
2007 2008 2009 2010 2011 2012 2013 2014 2015 2016
Fetal deaths (terminations of pregnancy and stillbirths)* 3.3 3.2 3.6 3.1 3.0 2.6 2.6 2.7 2.8 2.8
Terminations of pregnancy 0.1 0.2 0.1 0.3 0.4 0.2 0.2 0.2 0.1 0.2
Stillbirths 3.2 3.0 3.4 2.8 2.7 2.4 2.4 2.5 2.6 2.6
Early neonatal deaths <7 days
Late neonatal deaths 7–27 days
Neonatal deaths <28 days# 1.3 1.6 1.4 1.5 1.3 1.2 1.2 1.4 1.4 1.3
Perinatal mortalities+ 4.2 4.2 4.5 4.1 4.1 3.5 3.4 3.7 3.7 3.7
Perinatal related mortalities^ 4.6 4.7 5.0 4.6 4.4 3.9 3.8 4.1 4.2 4.1
Perinatal mortalities excluding lethal and terminated fetal 
abnormalities• 3.5 3.4 3.7 3.1 2.9 2.7 2.7 2.8 3.0 2.8
Perinatal related mortalities excluding lethal and 
terminated fetal abnormalities• 3.7 3.7 3.9 3.4 3.0 2.9 2.9 3.0 3.2 3.0
* Fetal death rate per 1000 babies born (includes terminations and stillbirths).
# Neonatal death rate per 1000 live born babies.
+ Fetal deaths and early neonatal deaths per 1000 babies born.
^ Fetal deaths and early and late neonatal deaths per 1000 babies born.
• Lethal and terminated fetal abnormalities are all perinatal related deaths with PSANZ-PDC of congenital abnormality and neonatal deaths with PSANZ-NDC of congenital abnormality.
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Causes of perinatal related death
Table 4.3: Perinatal related deaths by perinatal death classification (PSANZ-PDC) 2016
Perinatal death classification 
(PSANZ-PDC)
Fetal deaths
Neonatal deaths Perinatal related deathsTermination of 
pregnancy Stillbirths
n=148 n=309 n=151 n=608
n % n % n % n %
Congenital abnormality  109  73.6  31  10.0  33  21.9  173  28.5 
Perinatal infection  2  1.4  10  3.2  14  9.3  26  4.3 
Hypertension  -  -  8  2.6  1  0.7  9  1.5 
Antepartum haemorrhage  10  6.8  38  12.3  24  15.9  72  11.8 
Maternal conditions  11  7.4  17  5.5  9  6.0  37  6.1 
Specific perinatal conditions  4  2.7  53  17.2  12  7.9  69  11.3 
Hypoxic peripartum death  -  -  4  1.3  9  6.0  13  2.1 
Fetal growth restriction  4  2.7  33  10.7  4  2.6  41  6.7 
Spontaneous preterm  8  5.4  25  8.1  39  25.8  72  11.8 
Unexplained antepartum death  -  -  90  29.1  -  -  90  14.8 
No obstetric antecedent  -  -  -  -  6  4.0  6  1.0 
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2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 Chi-square 
test for 
trend (p)
N=65,202 N=65,624 N=65,198 N=65,445 N=63,236 N=63,274 N=60,133 N=60,073 N=59,768 N=60,576
n Rate n Rate n Rate n Rate n Rate n Rate n Rate n Rate n Rate n Rate
Congenital abnormality  197  3.02  185  2.82  182  2.79  211  3.22  203  3.21  201  3.18  160  2.66  189  3.15  158  2.64  173  2.86 0.52
Perinatal infection  29  0.44  28  0.43  25  0.38  28  0.43  21  0.33  19  0.30  20  0.33  24  0.40  22  0.37  26  0.43 0.56
Hypertension  19  0.29  22  0.34  29  0.44  27  0.41  21  0.33  19  0.30  13  0.22  13  0.22  21  0.35  9  0.15 0.022
Antepartum haemorrhage  64  0.98  66  1.01  79  1.21  78  1.19  78  1.23  60  0.95  75  1.25  69  1.15  79  1.32  72  1.19 0.14
Maternal conditions  27  0.41  23  0.35  38  0.58  32  0.49  26  0.41  36  0.57  34  0.57  39  0.65  29  0.49  37  0.61 0.035
Specific perinatal 
conditions  57  0.87  71  1.08  76  1.17  69  1.05  73  1.15  70  1.11  63  1.05  69  1.15  60  1.00  69  1.14 0.47
Hypoxic peripartum death  33  0.51  34  0.52  28  0.43  20  0.31  20  0.32  20  0.32  11  0.18  17  0.28  17  0.28  13  0.21 0.000052
Fetal growth restriction  48  0.74  62  0.94  53  0.81  48  0.73  44  0.70  49  0.77  48  0.80  36  0.60  33  0.55  41  0.68 0.039
Spontaneous preterm  99  1.52  94  1.43  110  1.69  113  1.73  85  1.34  102  1.61  80  1.33  106  1.76  65  1.09  72  1.19 0.036
Unexplained antepartum 
death  96  1.47  102  1.55  103  1.58  72  1.10  92  1.45  85  1.34  90  1.50  90  1.50  87  1.46  90  1.49 0.99
No obstetric antecedent  11  0.17  14  0.21  7  0.11  10  0.15  4  0.06  9  0.14  6  0.10  7  0.12  7  0.12  6  0.10 0.10
Table 4.5: Perinatal death classification (PSANZ-PDC) specific perinatal related mortality rate (per 1000 births) using international definition (≥1000g or 




2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 Chi-square 
test for 
trend (p) N=64,651  N=65,077  N=64,625  N=64,881  N=62,688  N=62,712  N=59,601  N=59,510  N=59,306  N=60,072 
n Rate n Rate n Rate n Rate n Rate n Rate n Rate n Rate n Rate n Rate
Congenital abnormality  58  0.90  69  1.06  64  0.99  77  1.19  85  1.36  64  1.02  51  0.86  64  1.08  61  1.03  62  1.03 0.94
Perinatal infection  16  0.25  16  0.25  15  0.23  13  0.20  12  0.19  9  0.14  9  0.15  12  0.20  12  0.20  17  0.28 0.72
Hypertension  7  0.11  7  0.11  14  0.22  11  0.17  9  0.14  3  0.05  5  0.08  6  0.10  10  0.17  6  0.10 0.47
Antepartum haemorrhage  23  0.36  25  0.38  24  0.37  23  0.35  17  0.27  13  0.21  18  0.30  11  0.18  17  0.29  12  0.20 0.009
Maternal conditions  14  0.22  9  0.14  19  0.29  19  0.29  7  0.11  17  0.27  22  0.37  14  0.24  15  0.25  16  0.27 0.24
Specific perinatal conditions  29  0.45  23  0.35  32  0.50  30  0.46  32  0.51  21  0.33  24  0.40  25  0.42  32  0.54  27  0.45 0.71
Hypoxic peripartum death  33  0.51  34  0.52  28  0.43  20  0.31  20  0.32  20  0.32  11  0.18  17  0.29  17  0.29  13  0.22 0.000052
Fetal growth restriction  31  0.48  32  0.49  31  0.48  31  0.48  18  0.29  32  0.51  21  0.35  20  0.34  14  0.24  15  0.25 0.0011
Spontaneous preterm  9  0.14  7  0.11  10  0.15  19  0.29  9  0.14  10  0.16  5  0.08  9  0.15  14  0.24  8  0.13 0.81
Unexplained antepartum 
death  66  1.02  73  1.12  75  1.16  45  0.69  61  0.97  46  0.73  52  0.87  59  0.99  50  0.84  63  1.05 0.30



































2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 Chi-square 
test for 
trend (p)
N=65,202 N=65,624 N=65,198 N=65,445 N=63,236 N=63,274 N=60,133 N=60,073 N=59,768 N=60,576
n Rate n Rate n Rate n Rate n Rate n Rate n Rate n Rate n Rate n Rate
Congenital abnormality  35  0.54  28  0.43  30  0.46  37  0.57  27  0.43  35  0.55  22  0.37  34  0.57  25  0.42  31  0.51 0.89
Perinatal infection  21  0.32  15  0.23  16  0.25  17  0.26  10  0.16  9  0.14  10  0.17  12  0.20  12  0.20  10  0.17 0.039
Hypertension  13  0.20  12  0.18  24  0.37  18  0.28  12  0.19  9  0.14  8  0.13  9  0.15  16  0.27  8  0.13 0.13
Antepartum haemorrhage  46  0.71  49  0.75  53  0.81  46  0.70  48  0.76  31  0.49  44  0.73  33  0.55  46  0.77  38  0.63 0.28
Maternal conditions  20  0.31  13  0.20  26  0.40  23  0.35  13  0.21  19  0.30  22  0.37  21  0.35  22  0.37  17  0.28 0.51
Specific perinatal condition  38  0.58  53  0.81  60  0.92  45  0.69  51  0.81  42  0.66  39  0.65  43  0.72  42  0.70  53  0.87 0.76
Hypoxic peripartum death  18  0.28  15  0.23  11  0.17  7  0.11  9  0.14  11  0.17  3  0.05  7  0.12  9  0.15  4  0.07 0.0013
Fetal growth restriction  43  0.66  53  0.81  44  0.67  39  0.60  37  0.59  42  0.66  44  0.73  33  0.55  27  0.45  33  0.54 0.045
Spontaneous preterm  39  0.60  39  0.59  42  0.64  43  0.66  33  0.52  37  0.58  24  0.40  45  0.75  19  0.32  25  0.41 0.027
Unexplained antepartum death  96  1.47  102  1.55  103  1.58  72  1.10  92  1.45  85  1.34  90  1.50  90  1.50  87  1.46  90  1.49 0.99




2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 Chi-square 
test for 
trend (p)
N=64,689 N=65,100 N=64,651 N=64,947 N=62,733 N=62,782 N=59,686 N=59,596 N=59,356 N=60,119
n Rate n Rate n Rate n Rate n Rate n Rate n Rate n Rate n Rate n Rate
Congenital abnormality  38  0.59  43  0.66  43  0.67  46  0.71  50  0.80  38  0.61  32  0.54  44  0.74  45  0.76  34  0.57 0.93
Extreme prematurity  57  0.88  52  0.80  58  0.90  84  1.29  54  0.86  67  1.07  63  1.06  69  1.16  51  0.86  53  0.88 0.57
Cardio-respiratory disorders  11  0.17  11  0.17  11  0.17  18  0.28  11  0.18  14  0.22  6  0.10  16  0.27  16  0.27  11  0.18 0.42
Infection  14  0.22  21  0.32  12  0.19  19  0.29  15  0.24  17  0.27  12  0.20  15  0.25  7  0.12  14  0.23 0.29
Neurological  31  0.48  33  0.51  40  0.62  28  0.43  23  0.37  25  0.40  25  0.42  24  0.40  31  0.52  24  0.40 0.26
Gastrointestinal  2  0.03  -  -  8  0.12  5  0.08  2  0.03  3  0.05  1  0.02  3  0.05  2  0.03  5  0.08 0.73
Other  14  0.22  17  0.26  11  0.17  10  0.15  9  0.14  14  0.22  14  0.23  11  0.18  14  0.24  10  0.17 0.81
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Maternal age


























<20 20–24 25–29 30–34 35–39 ≥40 years






Neonatal deaths Total perinatal related deathsTermination of 
pregnancy Stillbirths
N=303,824 n=718 n=1,567 n=830 n=3,115
n % n % Rate n % Rate n % Rate n % Rate
<20  15,713  5.2  47  6.5  2.99  133  8.5  8.46  98  11.8  6.31  278  8.9  17.69 
20–24  53,090  17.5  102  14.2  1.92  290  18.5  5.46  175  21.1  3.32  567  18.2  10.68 
25–29  80,748  26.6  174  24.2  2.15  376  24.0  4.66  195  23.5  2.43  745  23.9  9.23 
30–34  89,996  29.6  208  29.0  2.31  413  26.4  4.59  191  23.0  2.14  812  26.1  9.02 
35–39  51,095  16.8  137  19.1  2.68  255  16.3  4.99  123  14.8  2.43  515  16.5  10.08 
≥40  13,087  4.3  50  7.0  3.82  99  6.3  7.56  48  5.8  3.71  197  6.3  15.05 































Table 4.9: Perinatal related mortality rate (per 1000 births) by maternal age and year 2007–2016
Maternal 
age (years)
2007 2008 2009 2010 2011 2012 2013 2014 2015 2016
n N n N n N n N n N n N n N n N n N n N
<20  61  5,118  85  5,336  80  4,911  57  4,625  65  4,127  63  3,968  65  3,381  51  3,046  45  2,828  54  2,490 
20–24  140  11,371  133  11,871  142  12,085  164  12,258  116  11,938  126  11,695  115  11,005  116  10,478  86  10,137  124  9,775 
25–29  161  15,819  153  15,901  169  16,004  162  16,308  147  15,865  149  16,264  139  15,599  165  16,012  150  15,990  142  16,883 
30–34  163  18,626  169  18,015  169  17,838  149  18,100  160  17,607  163  17,852  147  17,134  175  17,981  158  18,292  169  18,737 
35–39  124  11,777  125  11,974  138  11,764  136  11,396  145  11,024  119  10,671  89  10,314  111  9,937  107  9,977  89  10,196 
≥40  31  2,463  35  2,504  32  2,567  40  2,730  34  2,650  50  2,805  45  2,679  40  2,598  32  2,524  30  2,481 
Unknown  -  28  1  23  -  29  -  28  -  25  -  19  -  21  1  21  -  20  -  14 
Maternal 
age (years)
2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 Chi-square 
test for 
trend (p)Rate Rate Rate Rate Rate Rate
Rate Rate Rate Rate
<20  11.9  15.9  16.3  12.3  15.7  15.9  19.2  16.7  15.9  21.7 0.0046
20–24  12.3  11.2  11.8  13.4  9.7  10.8  10.4  11.1  8.5  12.7 0.12
25–29  10.2  9.6  10.6  9.9  9.3  9.2  8.9  10.3  9.4  8.4 0.11
30–34  8.8  9.4  9.5  8.2  9.1  9.1  8.6  9.7  8.6  9.0 0.98
35–39  10.5  10.4  11.7  11.9  13.2  11.2  8.6  11.2  10.7  8.7 0.13
≥40  12.6  14.0  12.5  14.7  12.8  17.8  16.8  15.4  12.7  12.1 0.75
102






<20 20–24 25–34 35–39 ≥40
N=15,652 N=52,963 N=170,324 N=50,917 N=13,008
N % Rate N % Rate N % Rate N % Rate N % Rate
Perinatal infection  16  7.4  1.02  19  4.4  0.36  62  5.5  0.36  13  3.9  0.26  1  0.9  0.08 
Hypertension  1  0.5  0.06  17  3.9  0.32  40  3.6  0.23  11  3.3  0.22  6  5.2  0.46 
Antepartum haemorrhage  31  14.4  1.98  67  15.4  1.27  192  17.1  1.13  47  14.2  0.92  18  15.5  1.38 
Maternal conditions  20  9.3  1.28  38  8.7  0.72  72  6.4  0.42  24  7.2  0.47  12  10.3  0.92 
Specific perinatal 
condition  16  7.4  1.02  48  11.0  0.91  165  14.7  0.97  73  22.0  1.43  29  25.0  2.23 
Hypoxic peripartum death  4  1.9  0.26  15  3.4  0.28  45  4.0  0.26  13  3.9  0.26  1  0.9  0.08 
Fetal growth restriction  22  10.2  1.41  35  8.0  0.66  110  9.8  0.65  32  9.6  0.63  8  6.9  0.62 
Spontaneous preterm*  64  29.8  4.09  97  22.2  1.83  192  17.1  1.13  54  16.3  1.06  17  14.7  1.31 
Unexplained antepartum 
death  35  16.3  2.24  88  20.2  1.66  233  20.7  1.37  63  19.0  1.24  23  19.8  1.77 
No obstetric antecedent  6  2.8  0.38  12  2.8  0.23  14  1.2  0.08  2  0.6  0.04  1  0.9  0.08 
* Excludes one maternal age missing.
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Figure 4.4: Perinatal death classification (PSANZ-PDC) specific perinatal related mortality rates 
(excluding congenital anomaly) by maternal age (with 95% CIs) 2012–2016











PSANZ-PDC specific perinatal related mortality rate/1000 births
<20 20–24 25–34 35–39 ≥40 years
The number of mothers under 20 years of age has halved from 2007 to 2016, but in this time there 
has been a significant increase in perinatal related mortality in this group (chi-square test for trend 
p=0.005). 
Mothers under 20 years of age are at higher risk of perinatal related death (excluding congenital 
anomalies) from spontaneous preterm birth, fetal growth restriction, antepartum haemorrhage, and 
perinatal infection than any other age group (Figure 4.4).
When women under 20 years of age who gave birth in 2015–2016 were compared to women under 
20 who gave birth in 2008–2009, women under 20 who gave birth in 2015–2016 were more often 
19 years old than under 19 than in the earlier period (44.2 percent cf 38.9 percent); more often in 
deprivation quintile 5 (most deprived) (51.4 percent cf 46 percent); more often Māori (61.3 percent 
cf 56.6 percent), Pacific (13.7 percent cf 12.9 percent), or MELAA (0.9 percent cf 0.6 percent), and 
less often European (22.8 percent cf 28.4 percent) or Other Asian (0.9 percent cf 1.1 percent) ethnic 
groupings; more often had a BMI of 30 or higher (21.7 percent cf 14.3 percent), but were less often 
smokers (34.3 percent cf 36.1 percent); and more likely to have registered with an LMC in the first 
trimester (53.5 percent cf 35.4 percent) (Table 4.11).
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Table 4.11: Demographic characteristics by time period (2008–2009 and 2015–2016) among 
mothers <20 years of age




n % n %
Termination of pregnancy (/1000 births)  20  2.0  14  2.6 0.39
Stillbirth (/1000 births)  89  8.7  41  7.7 0.53
Neonatal death (/1000 live births)  48  4.7  35  6.6 0.13
Age (years)
<16  383  3.7  185  3.5 
16  885  8.6  406  7.6 
17  1,944  19.0  864  16.2 
18  3,048  29.7  1,511  28.4 
19  3,987  38.9  2,352  44.2 <0.001
Deprivation quintile
1 (least deprived)  488  4.8  224  4.2 
2  852  8.3  407  7.7 
3  1,438  14.0  650  12.2 
4  2,631  25.7  1,263  23.7 
5 (most deprived)  4,718  46.0  2,732  51.4 <0.001
Missing  120  1.2  42  0.8 
Ethnicity (maternal)
Māori  5,800  56.6  3,258  61.3 
Pacific peoples  1,326  12.9  729  13.7 
Indian  41  0.4  25  0.5 
Other Asian  109  1.1  47  0.9 
MELAA  61  0.6  47  0.9 
Other European  252  2.5  110  2.1 
NZ European  2,652  25.9  1,102  20.7 <0.001
Other/Unknown  6  0.1  -  - 
Limited to mothers who were registered for care with an LMC* N=7,677 N=4,773 
Smoking at registration with LMC
Yes  2,823  36.8  1,654  34.7 
No  4,849  63.2  3,119  65.3 0.015
Missing  5  0.1  -  - 
BMI at registration (kg/m2)
<18.50  337  4.4  159  3.3 
18.50-24.99  4,175  54.4  2,207  46.2 
25.00-29.99  2,041  26.6  1,365  28.6 
30.00-34.99  751  9.8  701  14.7 
35.00-39.99  250  3.3  238  5.0 
≥40.00  93  1.2  96  2.0 <0.001
Unknown  30  0.4  7  0.1 
First registration with LMC
First trimester  2,719  35.4  2,552  53.5 
Second trimester  4,279  55.7  1,877  39.3 
Third trimester  626  8.2  310  6.5 
Postpartum  52  0.7  34  0.7 <0.001
Missing  1  0.0  -  - 
* LMC (either a midwife, Obstetrician or GP) claiming from the Section 88 Primary Maternity Services Notice
MELAA = Middle Eastern, Latin American or African
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Maternal ethnicity

























Māori Pacific peoples Indian Other Asian MELAA Other European NZ European
MELAA = Middle Eastern, Latin American or African
Congenital abnormality  33  21.0  22  24.4 
Perinatal infection  10  6.4  5  5.6 
Hypertension  1  0.6  1  1.1 
Antepartum haemorrhage  19  12.1  10  11.1 
Maternal conditions  5  3.2  9  10.0 
Specific perinatal conditions  10  6.4  2  2.2 
Hypoxic peripartum death  9  5.7  3  3.3 
Fetal growth restriction  17  10.8  5  5.6 
Spontaneous preterm birth  30  19.1  21  23.3 
Unexplained antepartum death  21  13.4  12  13.3 
No obstetric antecedent  2  1.3  -  -  0.33





n % n %
Table 4.12: Perinatal death classification (PSANZ-PDC) by time period (2008–2009 and 2015–2016) 
among babies of mothers <20 years of age
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Figure 4.6: Perinatal death classification (PSANZ-PDC) specific perinatal related mortality rates (per 
1000 births) (excluding congenital anomaly) by maternal prioritised ethnicity 2012–2016











PSANZ-PDC specific perinatal related mortality rate/1000 births
Māori Pacific peoples Indian All other*
* ‘All other’ includes Other Asian; Middle Eastern, Latin American or African (MELAA); Other European; New Zealand European; Unknown/Other.




Neonatal deaths Perinatal related deathsTermination of 
pregnancy Stillbirths
N=303,824 n=718 n=1,567 n=830 n=3,115
n % n % Rate n % Rate n % Rate n % Rate
Ethnicity (mother)
Māori  75,703  24.9  133  18.5  1.76  403  25.7  5.32  273  32.9  3.63  809  26.0  10.69 
Pacific peoples  31,967  10.5  45  6.3  1.41  220  14.0  6.88  141  17.0  4.45  406  13.0  12.70 
Indian  14,282  4.7  49  6.8  3.43  109  7.0  7.63  57  6.9  4.04  215  6.9  15.05 
Other Asian  31,932  10.5  101  14.1  3.16  111  7.1  3.48  52  6.3  1.64  264  8.5  8.27 
MELAA  6,611  2.2  16  2.2  2.42  29  1.9  4.39  19  2.3  2.89  64  2.1  9.68 
Other European  29,308  9.6  65  9.1  2.22  90  5.7  3.07  27  3.3  0.93  182  5.8  6.21 
NZ European  113,843  37.5  309  43.0  2.71  604  38.5  5.31  261  31.4  2.31  1,174  37.7  10.31 
Unknown/Other  178  0.1  -  -  -  1  0.1  5.62  -  -  -  1  0.0  5.62 































Table 4.14: Perinatal related mortality rate (per 1000 births) by maternal prioritised ethnicity and year 2007–2016
MELAA = Middle Eastern, Latin American or African
Maternal 
ethnicity
2007 2008 2009 2010 2011 2012 2013 2014 2015 2016
n N n N n N n N n N n N n N n N n N n N
Māori  179  16,895  170  17,109  209  16,972  193  16,841  176  16,283  163  16,105  156  14,974  166  14,634  143  14,888  181  15,102 
Pacific peoples  87  7,994  98  7,832  106  7,555  109  7,645  79  7,236  94  7,060  84  6,507  83  6,278  71  6,175  74  5,947 
Indian  25  1,841  30  1,916  33  1,940  34  2,083  35  2,174  38  2,384  37  2,464  45  2,782  43  3,138  52  3,514 
Other Asian  36  4,105  39  4,193  42  4,478  54  4,947  51  5,083  62  6,215  46  5,792  50  6,569  53  6,194  53  7,162 
MELAA  17  1,019  12  1,121  12  1,205  5  1,319  13  1,309  16  1,266  10  1,309  15  1,295  15  1,353  8  1,388 
NZ European  300  27,251  312  27,144  292  26,765  271  26,337  263  25,073  250  24,324  230  23,170  262  22,568  224  22,147  208  21,634 
Other European  36  6,046  40  6,238  36  6,228  41  6,231  50  6,019  47  5,878  37  5,874  37  5,902  29  5,848  32  5,806 
Unknown/Other  -  51  -  71  -  55  1  42  -  59  -  42  -  43  1  45  -  25  -  23 
Maternal 
ethnicity
2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 Chi-square 
test for 
trend (p)Rate Rate Rate Rate Rate Rate Rate Rate Rate Rate
Māori  10.6  9.9  12.3  11.5  10.8  10.1  10.4  11.3  9.6  12.0 0.92
Pacific peoples  10.9  12.5  14.0  14.3  10.9  13.3  12.9  13.2  11.5  12.4 0.89
Indian  13.6  15.7  17.0  16.3  16.1  15.9  15.0  16.2  13.7  14.8 0.71
Other Asian  8.8  9.3  9.4  10.9  10.0  10.0  7.9  7.6  8.6  7.4 0.08
MELAA  16.7  10.7  10.0  3.8  9.9  12.6  7.6  11.6  11.1  5.8 0.21
NZ European  11.0  11.5  10.9  10.3  10.5  10.3  9.9  11.6  10.1  9.6 0.09
Other European  6.0  6.4  5.8  6.6  8.3  8.0  6.3  6.3  5.0  5.5 0.51
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Māori Pacific peoples Indian Other Asian MELAA Other European NZ European
N=75,514 N=31,885 N=14,227 N=31,828 N=6,593 N=29,215 N=113,519
n % Rate n % Rate n % Rate n % Rate n % Rate n % Rate n % Rate
Perinatal infection  31  5.0  0.41  21  6.4  0.66  9  5.6  0.63  8  5.3  0.25  1  2.1  0.15  5  4.6  0.17  36  4.4  0.32 
Hypertension  25  4.0  0.33  12  3.7  0.38  5  3.1  0.35  4  2.7  0.13  2  4.3  0.30  2  1.8  0.07  25  3.1  0.22 
Antepartum haemorrhage  95  15.3  1.26  57  17.4  1.79  33  20.6  2.32  25  16.7  0.79  7  14.9  1.06  13  11.9  0.44  125  15.4  1.10 
Maternal conditions  52  8.4  0.69  39  11.9  1.22  11  6.9  0.77  8  5.3  0.25  4  8.5  0.61  4  3.7  0.14  48  5.9  0.42 
Specific perinatal 
conditions  66  10.6  0.87  43  13.1  1.35  29  18.1  2.04  25  16.7  0.79  8  17.0  1.21  25  22.9  0.86  135  16.6  1.19 
Hypoxic peripartum death  21  3.4  0.28  6  1.8  0.19  3  1.9  0.21  2  1.3  0.06  2  4.3  0.30  3  2.8  0.10  41  5.1  0.36 
Fetal growth restriction  42  6.8  0.56  19  5.8  0.60  18  11.3  1.27  16  10.7  0.50  1  2.1  0.15  14  12.8  0.48  97  12.0  0.85 
Spontaneous preterm*  160  25.8  2.12  64  19.6  2.01  24  15.0  1.69  21  14.0  0.66  10  21.3  1.52  16  14.7  0.55  129  15.9  1.14 
Unexplained antepartum 
death  113  18.2  1.50  58  17.7  1.82  27  16.9  1.90  40  26.7  1.26  12  25.5  1.82  27  24.8  0.92  165  20.3  1.45 
No obstetric antecedent  15  2.4  0.20  8  2.4  0.25  1  0.6  0.07  1  0.7  0.03  -  -  -  -  -  -  10  1.2  0.09 
* 1 spontaneous preterm = unknown/other ethnicity
MELAA = Middle Eastern, Latin American or African
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Socioeconomic deprivation

































Quintile 1 (least deprived) Quintile 2 Quintile 3 Quintile 4 Quintile 5 (most deprived)





Neonatal deaths Perinatal related deathsTermination of 
pregnancy Stillbirths
N=303,824 n=718 n=1,567 n=830 n=3,115
n % n % Rate n % Rate n % Rate n % Rate
1 (least deprived)  43,073  14.2  115  16.0  2.67  179  11.4  4.16  85  10.2  1.99  379  12.2  8.80 
2  47,523  15.6  123  17.1  2.59  211  13.5  4.44  83  10.0  1.76  417  13.4  8.77 
3  54,870  18.1  149  20.8  2.72  248  15.8  4.52  139  16.7  2.55  536  17.2  9.77 
4  68,668  22.6  145  20.2  2.11  339  21.6  4.94  169  20.4  2.48  653  21.0  9.51 
5 (most deprived)  87,177  28.7  183  25.5  2.10  583  37.2  6.69  350  42.2  4.05  1,116  35.8  12.80 
Unknown  2,513  0.8  3  0.4  -  7  0.4  -  4  0.5  -  14  0.4  - 
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Figure 4.8: Perinatal death classification (PSANZ-PDC) specific perinatal related mortality rates (per 
1000 births) (excluding congenital anomaly) by deprivation quintile (with 95% CIs) 2012–2016
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Table 4.17: Perinatal related mortality rate (per 1000 births) by deprivation quintile and year 2007–2016
Table 4.18: Perinatal death classification (PSANZ-PDC) specific perinatal related mortality rates (per 1000 births) (excluding congenital anomaly) by 
deprivation quintile* 2012–2016 
Perinatal death classification 
(PSANZ-PDC)
Quintile 1 (least deprived) Quintile 2 Quintile 3 Quintile 4 Quintile 5 (most deprived)
N=42,961 N=47,396 N=54,710 N=68,483 N=86,906
n % Rate n % Rate n % Rate n % Rate n % Rate
Perinatal infection  11  4.3  0.26  13  4.1  0.27  26  6.5  0.48  18  3.9  0.26  43  5.5  0.49 
Hypertension  7  2.8  0.16  12  3.8  0.25  14  3.5  0.26  22  4.8  0.32  20  2.6  0.23 
Antepartum haemorrhage  38  15.0  0.88  40  12.7  0.84  63  15.6  1.15  75  16.3  1.10  134  17.1  1.54 
Maternal conditions  13  5.1  0.30  15  4.8  0.32  26  6.5  0.48  31  6.7  0.45  81  10.4  0.93 
Specific perinatal condition  53  20.9  1.23  58  18.4  1.22  56  13.9  1.02  70  15.2  1.02  90  11.5  1.04 
Hypoxic peripartum death  5  2.0  0.12  14  4.4  0.30  16  4.0  0.29  21  4.6  0.31  22  2.8  0.25 
Fetal growth restriction  28  11.0  0.65  29  9.2  0.61  48  11.9  0.88  40  8.7  0.58  62  7.9  0.71 
Spontaneous preterm  33  13.0  0.77  64  20.3  1.35  61  15.1  1.11  90  19.6  1.31  175  22.4  2.01 
Unexplained antepartum death  61  24.0  1.42  65  20.6  1.37  88  21.8  1.61  84  18.3  1.23  144  18.4  1.66 
No obstetric antecedent  5  2.0  0.12  5  1.6  0.11  5  1.2  0.09  9  2.0  0.13  11  1.4  0.13 
Deprivation 
quintile
2007 2008 2009 2010 2011 2012 2013 2014 2015 2016
n N n N n N n N n N n N n N n N n N n N
1 (least deprived)  72  9,124  97  8,782  75  9,098  79  9,034  103  8,827  80  8,976  61  8,312  93  8,599  75  8,366  70  8,820 
2  93  9,566  87  9,545  107  9,536  105  9,778  99  9,558  89  9,537  77  9,386  77  9,330  83  9,477  91  9,793 
3  131  11,419  134  12,057  119  12,097  118  12,169  116  11,694  106  11,775  124  10,796  118  10,705  89  10,738  99  10,856 
4  172  15,628  142  15,395  179  15,182  154  15,198  153  14,801  140  14,721  113  13,567  138  13,473  137  13,435  125  13,472 
5 (most deprived)  210  18,805  236  19,120  249  18,607  251  18,652  195  17,781  253  17,754  222  17,558  229  17,429  190  17,247  222  17,189 
Unknown  2  660  5  725  1  678  1  614  1  575  2  511  3  514  4  537  4  505  1  446 
Deprivation 
quintile




Rate Rate Rate Rate Rate Rate Rate Rate Rate Rate
1 (least deprived)  7.9  11.0  8.2  8.7  11.7  8.9  7.3  10.8  9.0  7.9 0.68
2  9.7  9.1  11.2  10.7  10.4  9.3  8.2  8.3  8.8  9.3 0.10
3  11.5  11.1  9.8  9.7  9.9  9.0  11.5  11.0  8.3  9.1 0.074
4  11.0  9.2  11.8  10.1  10.3  9.5  8.3  10.2  10.2  9.3 0.13
5 (most deprived)  11.2  12.3  13.4  13.5  11.0  14.3  12.6  13.1  11.0  12.9 0.66
* Excludes 11 unknown deprivation quintile.
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Body mass index
Table 4.19: Perinatal related mortality rates (per 1000 births) by maternal body mass index (BMI) at 





Neonatal deaths Perinatal related deathsTermination of 
pregnancy Stillbirths
N=274,141 n=566 n=1,260 n=649 n=2,475
n % n % Rate n % Rate n % Rate n % Rate
<18.50  7,714  2.8  18  3.2  2.33  23  1.8  2.98  14  2.2  1.82  55  2.2  7.13 
18.50–24.99  132,842  48.5  306  54.1  2.30  501  39.8  3.77  250  38.5  1.89 1,057  42.7  7.96 
25.00–29.99  71,054  25.9  143  25.3  2.01  369  29.3  5.19  172  26.5  2.44  684  27.6  9.63 
30.00–34.99  36,145  13.2  61  10.8  1.69  183  14.5  5.06  114  17.6  3.18  358  14.5  9.90 
35.00–39.99  16,455  6.0  28  4.9  1.70  108  8.6  6.56  61  9.4  3.74  197  8.0  11.97 
≥40  9,435  3.4  10  1.8  1.06  72  5.7  7.63  37  5.7  3.96  119  4.8  12.61 
Unknown  496  0.2  -  -  -  4  0.3  -  1  0.2  -  5  0.2  - 
* MAT data numerator and denominator; limited to mothers who were registered for care with an LMC (either a midwife, obstetrician or GP) claiming from the 
Section 88 Primary Maternity Services Notice.
Figure 4.9: Perinatal related mortality rates (per 1000 births) by maternal body mass index (BMI)* 























<18.50 18.50–24.99 25.00–29.99 30.00–34.99 35.00–39.99 ≥40.00 BMI (kg/m2)
* MAT data numerator and denominator; limited to mothers who were registered for care with an LMC (either a midwife, obstetrician or GP) claiming from the 
Section 88 Primary Maternity Services Notice.
PERINATAL AND MATERNAL MORTALITY REVIEW COMMITTEE: 12th ANNUAL REPORT 113
Parity
























Parity 0 1 2 3 4 ≥5
* MAT data numerator and denominator; limited to mothers who were registered for care with an LMC (either a midwife, obstetrician or GP) claiming from the 
Section 88 Primary Maternity Services Notice.




Neonatal deaths Perinatal related  deathsTermination of 
pregnancy Stillbirths
N=274,141 n=566 n=1,260 n=649 n=2,475
n % n % Rate n % Rate n % Rate n % Rate
0  112,359  41.0  240  42.4  2.14  560  44.4  4.98  295  45.5  2.64  1,095  44.2  9.75 
1  92,366  33.7  202  35.7  2.19  338  26.8  3.66  184  28.4  2.00  724  29.3  7.84 
2  40,593  14.8  86  15.2  2.12  180  14.3  4.43  97  14.9  2.41  363  14.7  8.94 
3  15,869  5.8  25  4.4  1.58  90  7.1  5.67  41  6.3  2.60  156  6.3  9.83 
4  6,703  2.4  9  1.6  1.34  43  3.4  6.42  15  2.3  2.26  67  2.7  10.00 
≥5  6,157  2.2  4  0.7  0.65  49  3.9  7.96  17  2.6  2.79  70  2.8  11.37 
Unknown  94  0.0  -  -  -  -  -  -  -  -  -  -  -  - 
* MAT data numerator and denominator; limited to mothers who were registered for care with an LMC (either a midwife, obstetrician or GP) claiming from the 
Section 88 Primary Maternity Services Notice.
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Maternal smoking
Figure 4.11: Perinatal related mortality rates (per 1000 births) by smoking at registration with 























* MAT data numerator and denominator; limited to mothers who were registered for care with an LMC (either a midwife, obstetrician or GP) claiming from the 
Section 88 Primary Maternity Services Notice.







Neonatal deaths Perinatal related deathsTermination of 
pregnancy Stillbirths
N=274,141 n=566 n=1,260 n=649 n=2,475
n % n % Rate n % Rate n % Rate n % Rate
Smoker  40,143 14.6  57 10.1  1.42  252 20.0  6.28  156 24.0  3.92  465 18.8  11.58 
Non-smoker  233,917 85.3  509 89.9  2.18  1,008 80.0  4.31  493 76.0  2.12  2,010 81.2  8.59 
Unknown  81 0.0  - -  -  - -  -  - -  -  - -  - 
* MAT data numerator and denominator; limited to mothers who were registered for care with an LMC (either a midwife, obstetrician or GP) claiming from the 
Section 88 Primary Maternity Services Notice.
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DHB of residence
Figure 4.12: Unadjusted perinatal related mortality rates (per 1000 births) by DHB of residence 
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Unadjusted perinatal related mortality rate NZ perinatal related mortality rate 2012–2016
Figure 4.13: Unadjusted stillbirth rates (per 1000 births) by DHB of residence (mother) compared to 
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Figure 4.14: Unadjusted neonatal mortality rates (per 1000 live births) by DHB of residence (mother) 



























DHB of maternal residence
Unadjusted neonatal death rate NZ neonatal death rate 2012–2016
Table 4.22: Perinatal related mortality rates (per 1000 births) by DHB of maternal residence 2016




Neonatal deaths Perinatal related deathsTermination of 
pregnancy Stillbirths
N=60,576 n=148 n=309 n=151 n=608
n % n % Rate n % Rate n % Rate n % Rate
Northland  2,294  3.8  7  4.7  3.05  17  5.5  7.41  8  5.3  3.52  32  5.3  13.95 
Waitemata  8,055  13.3  17  11.5  2.11  35  11.3  4.35  16  10.6  2.00  68  11.2  8.44 
Auckland  5,975  9.9  19  12.8  3.18  31  10.0  5.19  11  7.3  1.86  61  10.0  10.21 
Counties Manukau  8,355  13.8  27  18.2  3.23  51  16.5  6.10  40  26.5  4.83  118  19.4  14.12 
Waikato  5,426  9.0  18  12.2  3.32  39  12.6  7.19  16  10.6  2.98  73  12.0  13.45 
Bay of Plenty  2,934  4.8  5  3.4  1.70  13  4.2  4.43  15  9.9  5.14  33  5.4  11.25 
Lakes  1,570  2.6  4  2.7  2.55  11  3.6  7.01  -  -  -  15  2.5  9.55 
Tairawhiti  794  1.3  -  -  -  4  1.3  5.04  -  -  -  4  0.7  5.04 
Taranaki  1,456  2.4  5  3.4  3.43  9  2.9  6.18  2  1.3  1.39  16  2.6  10.99 
Hawke’s Bay  2,091  3.5  1  0.7  0.48  9  2.9  4.30  2  1.3  0.96  12  2.0  5.74 
Whanganui  816  1.3  2  1.4  2.45  5  1.6  6.13  3  2.0  3.71  10  1.6  12.25 
MidCentral  2,113  3.5  3  2.0  1.42  11  3.6  5.21  6  4.0  2.86  20  3.3  9.47 
Wairarapa  465  0.8  -  -  -  5  1.6  10.75  -  -  -  5  0.8  10.75 
Capital & Coast  3,505  5.8  2  1.4  0.57  15  4.9  4.28  7  4.6  2.01  24  3.9  6.85 
Hutt Valley  1,996  3.3  2  1.4  1.00  3  1.0  1.50  7  4.6  3.52  12  2.0  6.01 
Nelson Marlborough  1,559  2.6  1  0.7  0.64  3  1.0  1.92  -  -  -  4  0.7  2.57 
West Coast  320  0.5  2  1.4  6.25  4  1.3  12.50  -  -  -  6  1.0  18.75 
Canterbury  6,388  10.5  13  8.8  2.04  30  9.7  4.70  11  7.3  1.73  54  8.9  8.45 
South Canterbury  661  1.1  2  1.4  3.03  2  0.6  3.03  2  1.3  3.04  6  1.0  9.08 
Southern  3,370  5.6  18  12.2  5.34  11  3.6  3.26  5  3.3  1.50  34  5.6  10.09 
Other*  433  0.7  -  -  -  1  0.3  -  -  -  -  1  0.2  - 
* Other includes Overseas, Unknown and Other. 
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Table 4.23: Perinatal related mortality rates (per 1000 births) by DHB of maternal residence 2012–
2016




Neonatal deaths Perinatal related deathsTermination of 
pregnancy Stillbirths
N=303,824 n=718 n=1,567 n=830 n=3,115
n % n % Rate n % Rate n % Rate n % Rate
Northland  11,076  3.6  27  3.8  2.44  79  5.0  7.13  38  4.6  3.46  144  4.6  13.00 
Waitemata  39,569  13.0  113  15.7  2.86  156  10.0  3.94  80  9.6  2.04  349  11.2  8.82 
Auckland  31,476  10.4  104  14.5  3.30  146  9.3  4.64  82  9.9  2.63  332  10.7  10.55 
Counties Manukau  42,201  13.9  107  14.9  2.54  269  17.2  6.37  172  20.7  4.11  548  17.6  12.99 
Waikato  26,961  8.9  54  7.5  2.00  163  10.4  6.05  90  10.8  3.37  307  9.9  11.39 
Bay of Plenty  14,392  4.7  25  3.5  1.74  77  4.9  5.35  60  7.2  4.20  162  5.2  11.26 
Lakes  7,535  2.5  26  3.6  3.45  41  2.6  5.44  17  2.0  2.28  84  2.7  11.15 
Tairawhiti  3,698  1.2  4  0.6  1.08  18  1.1  4.87  9  1.1  2.45  31  1.0  8.38 
Taranaki  7,675  2.5  13  1.8  1.69  40  2.6  5.21  24  2.9  3.15  77  2.5  10.03 
Hawke’s Bay  10,690  3.5  22  3.1  2.06  54  3.4  5.05  18  2.2  1.70  94  3.0  8.79 
Whanganui  4,188  1.4  6  0.8  1.43  27  1.7  6.45  13  1.6  3.13  46  1.5  10.98 
MidCentral  10,699  3.5  26  3.6  2.43  45  2.9  4.21  25  3.0  2.35  96  3.1  8.97 
Wairarapa  2,433  0.8  2  0.3  0.82  22  1.4  9.04  4  0.5  1.66  28  0.9  11.51 
Capital & Coast  18,286  6.0  28  3.9  1.53  77  4.9  4.21  38  4.6  2.09  143  4.6  7.82 
Hutt Valley  9,845  3.2  14  1.9  1.42  45  2.9  4.57  26  3.1  2.66  85  2.7  8.63 
Nelson Marlborough  7,569  2.5  11  1.5  1.45  32  2.0  4.23  17  2.0  2.26  60  1.9  7.93 
West Coast  1,827  0.6  6  0.8  3.28  12  0.8  6.57  5  0.6  2.76  23  0.7  12.59 
Canterbury  30,810  10.1  78  10.9  2.53  162  10.3  5.26  58  7.0  1.90  298  9.6  9.67 
South Canterbury  3,297  1.1  6  0.8  1.82  12  0.8  3.64  13  1.6  3.96  31  1.0  9.40 
Southern  17,291  5.7  44  6.1  2.54  84  5.4  4.86  37  4.5  2.16  165  5.3  9.54 
Other*  2,306  0.8  2  0.3  -  6  0.4  -  4  0.5  -  12  0.4  - 
* Other includes Overseas, Unknown and Other.
Gestation and birthweight and perinatal related mortality
Perinatal related mortality risk (Figure 4.15), as a proportion of ongoing pregnancies (women who are 
still pregnant) at a specified gestation, is highest at the extremes of the perinatal period. Figure 4.15 
shows that 27 to 32 weeks gestation is the time of lowest risk for perinatal related mortality for women 
who are still pregnant at that time, while the risk of perinatal related mortality is higher among women 
pregnant at 20 to 22 weeks and then rises to the highest risk among women still pregnant at 41 weeks. 
The number of women who are pregnant at each gestation (the denominator) obviously changes 
throughout and is the lowest at 41 weeks.
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Figure 4.15: Perinatal related mortality risk (per 1000 ongoing pregnancies) by gestational age at 





































Gestation at birth (weeks)
2008–2010 2011–2013 2014–2016
Table 4.24: Perinatal related mortality rates (per 1000 births) by gestation and birthweight 2016
Total births
Fetal deaths
Neonatal deaths Perinatal related deathsTermination of 
pregnancy Stillbirths
N=60,576 n=148 n=309 n=151 n=608
n % n % Rate n % Rate n % Rate n % Rate
Gestation at birth (weeks)
20–22  205 0.3  87  58.8  *  83  26.9  *  44  29.1  *  214  35.2  * 
23–24  125 0.2  32  21.6  256.00  29  9.4  232.00  23  15.2  359.38  84  13.8  672.00 
25–27  185 0.3  13  8.8  70.27  26  8.4  140.54  11  7.3  75.34  50  8.2  270.27 
28–31  477 0.8  14  9.5  29.35  22  7.1  46.12  12  7.9  27.21  48  7.9  100.63 
32–36  3,793 6.3  2  1.4  0.53  60  19.4  15.82  16  10.6  4.29  78  12.8  20.56 
37–40  46,429 76.6  -  -  -  75  24.3  1.62  39  25.8  0.84  114  18.8  2.46 
≥41  8,766 14.5  -  -  -  14  4.5  1.60  6  4.0  0.69  20  3.3  2.28 
Unknown  596 1.0  -  -  -  -  -  -  -  -  -  -  -  - 
Birthweight (g)
<500  198  0.3  65  43.9  *  111  35.9  *  29  19.2  *  205  33.7  * 
500–999  303  0.5  62  41.9  204.62  43  13.9  141.91  46  30.5  232.32  151  24.8  498.35 
1000–1499  359  0.6  9  6.1  25.07  20  6.5  55.71  7  4.6  21.21  36  5.9  100.28 
1500–1999  710  1.2  4  2.7  5.63  17  5.5  23.94  13  8.6  18.87  34  5.6  47.89 
2000–2499  2,209  3.6  2  1.4  0.91  25  8.1  11.32  13  8.6  5.96  40  6.6  18.11 
2500–2999  8,218  13.6  -  -  -  33  10.7  4.02  12  7.9  1.47  45  7.4  5.48 
3000–3499  19,487  32.2  -  -  -  40  12.9  2.05  10  6.6  0.51  50  8.2  2.57 
3500–3999  17,978  29.7  -  -  -  11  3.6  0.61  16  10.6  0.89  27  4.4  1.50 
4000–4499  6,628  10.9  -  -  -  4  1.3  0.60  3  2.0  0.45  7  1.2  1.06 
≥4500  1,326  2.2  -  -  -  3  1.0  2.26  -  -  -  3  0.5  2.26 
Unknown  3,160  5.2  6  4.1  -  2  0.6  -  2  1.3  -  10  1.6  - 































Table 4.25: Perinatal related mortality risk (per 1000 ongoing pregnancies) 2007–2016





















Gestation at birth (weeks)
20–22  204  217  207  218  210  216  231  248  230  235  231  247  215  217  245  253  169  175  205  214 
23–24  117  81  131  98  137  105  122  81  128  95  119  94  123  85  137  98  117  92  125  84 
25–27  232  64  241  62  237  70  228  73  186  52  218  70  191  55  183  49  206  52  185  50 
28–31  530  57  558  65  539  66  559  52  511  58  502  50  470  49  460  46  457  41  477  48 
32–36  3,843  88  3,959  80  3,974  90  4,003  101  3,908  87  3,924  73  3,723  91  3,724  85  3,643  78  3,793  78 
37–38  12,853  65  13,011  59  13,139  78  13,609  62  13,174  64  13,430  65  13,384  38  13,665  56  13,587  42  14,435  59 
39–40  34,362  73  34,707  82  34,619  72  34,590  65  33,876  59  33,551  51  32,184  51  32,142  60  32,101  69  31,994  55 
≥41  12,325  34  11,663  37  11,739  32  11,543  26  10,727  17  10,321  20  9,478  14  9,090  12  9,065  29  8,766  20 
Unknown  736  1  1,147  -  604  1  560  -  496  -  978  -  365  -  427  -  423  -  596  - 
2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 Chi-square 
test for 
trend (p)Risk Risk Risk Risk Risk Risk Risk Risk Risk Risk
Gestation at birth (weeks)
20–22  3.37  3.38  3.34  3.82  3.75  3.96  3.63  4.24  2.95  3.57 0.47
23–24  1.26  1.52  1.63  1.25  1.52  1.51  1.43  1.65  1.55  1.41 0.44
25–27  1.00  0.97  1.09  1.13  0.83  1.13  0.93  0.83  0.88  0.84 0.11
28–31  0.89  1.02  1.03  0.81  0.93  0.81  0.83  0.78  0.70  0.81 0.044
32–36  1.39  1.26  1.42  1.58  1.41  1.19  1.55  1.45  1.34  1.32 0.93
37–38  1.09  0.99  1.31  1.04  1.11  1.13  0.69  1.02  0.77  1.07 0.082
39–40  1.56  1.77  1.55  1.41  1.32  1.16  1.22  1.46  1.68  1.35 0.23
≥41  2.76  3.17  2.73  2.25  1.58  1.94  1.48  1.32  3.20  2.28 0.082
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20–22  204  103  207  94  210  88  231  92  230  107  231  118  215  83  245  91  169  66  205  87 
23–24  117  22  131  25  137  31  122  20  128  29  119  32  123  32  137  31  117  27  125  32 
25–27  232  10  241  14  237  9  228  20  186  15  218  14  191  16  183  10  206  8  185  13 
28–31  530  6  558  7  539  4  559  6  511  11  502  5  470  5  460  7  457  3  477  14 
≥32  63,383  3  63,340  5  63,471  6  63,745  13  61,685  9  61,226  3  58,769  5  58,621  11  58,396  3  58,988  2 




2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 Chi-square 
test for 
trend (p)Rate Rate Rate Rate Rate Rate Rate Rate Rate Rate
Termination of pregnancies
20–22  1.60  1.46  1.36  1.42  1.71  1.89  1.39  1.53  1.11  1.45 0.34
23–24  0.34  0.39  0.48  0.31  0.46  0.52  0.54  0.52  0.46  0.54 0.042
25–27  0.16  0.22  0.14  0.31  0.24  0.23  0.27  0.17  0.14  0.22 0.98
28–31  0.09  0.11  0.06  0.09  0.18  0.08  0.08  0.12  0.05  0.24 0.18

























































20–22  204  79  207  95  210  88  231  94  230  90  231  85  215  88  245  110  169  73  205  83 
23–24  117  25  131  40  137  43  122  31  128  37  119  28  123  29  137  28  117  32  125  29 
25–27  232  39  241  34  237  39  228  32  186  24  218  36  191  25  183  25  206  31  185  26 
28–31  530  43  558  38  539  48  559  32  511  34  502  30  470  32  460  31  457  29  477  22 
32–36  3,843  64  3,959  54  3,974  60  4,003  66  3,908  55  3,924  54  3,723  63  3,724  58  3,643  48  3,793  60 
37–40  47,215  98  47,718  99  47,758  111  48,199  78  47,050  83  46,981  78  45,568  60  45,807  72  45,688  72  46,429  75 
≥41  12,325  20  11,663  19  11,739  19  11,543  14  10,727  9  10,321  9  9,478  9  9,090  3  9,065  20  8,766  14 




2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 Chi-square 
test for 
trend (p)Risk Risk Risk Risk Risk Risk Risk Risk Risk Risk
Stillbirths
20–22  1.23  1.47  1.36  1.45  1.43  1.36  1.47  1.84  1.23  1.38 0.43
23–24  0.39  0.62  0.67  0.48  0.59  0.45  0.49  0.47  0.54  0.49 0.63
25–27  0.61  0.53  0.61  0.50  0.38  0.58  0.42  0.42  0.52  0.44 0.12
28–31  0.67  0.59  0.75  0.50  0.55  0.49  0.54  0.52  0.49  0.37 0.0086
32–36  1.01  0.85  0.95  1.04  0.89  0.88  1.07  0.99  0.82  1.02 0.94
37–40  1.65  1.67  1.87  1.31  1.44  1.36  1.09  1.31  1.31  1.36 0.0028
≥41  1.62  1.63  1.62  1.21  0.84  0.87  0.95  0.33  2.21  1.60 0.44
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20–22  22  35  18  29  34  40  45  62  33  38  28  44  44  46  44  52  30  36  35  44 
23–24  70  34  66  33  63  31  71  30  62  29  59  34  62  24  78  39  58  33  64  23 
25–27  183  15  193  14  189  22  176  21  147  13  168  20  150  14  148  14  167  13  146  11 
28–31  481  8  513  20  487  14  521  14  466  13  467  15  433  12  422  8  425  9  441  12 
32–36  3,776  21  3,900  21  3,909  25  3,928  26  3,845  24  3,867  16  3,656  24  3,661  22  3,592  27  3,731  16 
37–40  47,117  40  47,619  42  47,646  38  48,117  45  46,966  39  46,903  38  45,507  28  45,729  38  45,616  39  46,354  39 
≥41  12,305  14  11,644  18  11,720  13  11,529  12  10,718  8  10,312  11  9,469  5  9,087  9  9,045  9  8,752  6 




2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 Chi-square 
test for 
trend (p)Risk Risk Risk Risk Risk Risk Risk Risk Risk Risk
Neonatal deaths
20–22  0.55  0.45  0.62  0.96  0.61  0.71  0.78  0.88  0.61  0.74 0.055
23–24  0.53  0.52  0.48  0.47  0.47  0.55  0.40  0.66  0.56  0.39 0.89
25–27  0.23  0.22  0.34  0.33  0.21  0.32  0.24  0.24  0.22  0.19 0.35
28–31  0.13  0.31  0.22  0.22  0.21  0.24  0.20  0.14  0.15  0.20 0.42
32–36  0.33  0.33  0.40  0.41  0.39  0.26  0.41  0.38  0.46  0.27 0.9
37–40  0.67  0.71  0.64  0.75  0.68  0.66  0.51  0.69  0.71  0.71 0.9





































20–22 23–24 25–27 28–31 32–36 37–40 ≥41
n % n % n % n % n % n % n %
Congenital abnormality  694  371  53.5  131  18.9  58  8.4  43  6.2  58  8.4  27  3.9  6  0.9 
Perinatal infection  63  19  30.2  11  17.5  6  9.5  9  14.3  6  9.5  9  14.3  3  4.8 
Hypertension  59  7  11.9  7  11.9  16  27.1  8  13.6  13  22.0  7  11.9  1  1.7 
Antepartum haemorrhage  225  131  58.2  24  10.7  10  4.4  14  6.2  26  11.6  18  8.0  2  0.9 
Maternal conditions  141  45  31.9  17  12.1  10  7.1  16  11.3  25  17.7  25  17.7  3  2.1 
Specific perinatal conditions  252  74  29.4  32  12.7  25  9.9  23  9.1  47  18.7  47  18.7  4  1.6 
Hypoxic peripartum death  34  -  -  -  -  -  -  -  -  1  2.9  23  67.6  10  29.4 
Fetal growth restriction  193  15  7.8  20  10.4  35  18.1  30  15.5  38  19.7  46  23.8  9  4.7 
Spontaneous preterm  182  137  75.3  28  15.4  6  3.3  6  3.3  5  2.7  -  -  -  - 
Unexplained antepartum death  442  85  19.2  30  6.8  38  8.6  29  6.6  81  18.3  162  36.7  17  3.8 
Total  2,285  884  38.7  300  13.1  204  8.9  178  7.8  300  13.1  364  15.9  55  2.4 
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Total 20–22 23–24 25–27 28–31 32–36 37–40 ≥41
n % n % n % n % n % n % n %
Perinatal death classification (PSANZ-PDC)
Congenital abnormality  187  4  2.1  1  0.5  5.0  2.7  15  8.0  59  31.6  90  48.1  13  7.0 
Perinatal infection  48  10  20.8  3  6.3  5.0  10.4  4  8.3  4  8.3  15  31.3  7  14.6 
Hypertension  16  2  12.5  5  31.3  5.0  31.3  2  12.5  2  12.5  -  -  -  - 
Antepartum haemorrhage  130  64  49.2  38  29.2  17.0  13.1  4  3.1  5  3.8  2  1.5  -  - 
Maternal conditions  34  11  32.4  2  5.9  2.0  5.9  4  11.8  10  29.4  5  14.7  -  - 
Specific perinatal conditions  79  36  45.6  14  17.7  5.0  6.3  11  13.9  5  6.3  7  8.9  1  1.3 
Hypoxic peripartum death  44  -  -  -  -  -  -  1  2.3  2  4.5  31  70.5  10  22.7 
Fetal growth restriction  14  -  -  -  -  2.0  14.3  3  21.4  2  14.3  6  42.9  1  7.1 
Spontaneous preterm  243  95  39.1  90  37.0  31.0  12.8  12  4.9  15  6.2  -  -  -  - 
No obstetric antecedent  35  -  -  -  -  -  -  -  -  1  2.9  26  74.3  8  22.9 
Neonatal death classification (PSANZ-NDC)
Congenital abnormality  193  4  2.1  1  0.5  4.0  2.1  15  7.8  63  32.6  93  48.2  13  6.7 
Extreme prematurity  303  218  71.9  81  26.7  4.0  1.3  -  -  -  -  -  -  -  - 
Cardio-respiratory disorders  63  -  -  23  36.5  20.0  31.7  11  17.5  4  6.3  5  7.9  -  - 
Infection  65  -  -  10  15.4  18.0  27.7  4  6.2  9  13.8  16  24.6  8  12.3 
Neurological  129  -  -  27  20.9  18.0  14.0  11  8.5  22  17.1  40  31.0  11  8.5 
Gastrointestinal  14  -  -  4  28.6  5.0  35.7  5  35.7  -  -  -  -  -  - 
Other  63  -  -  7  11.1  3.0  4.8  10  15.9  7  11.1  28  44.4  8  12.7 



































2007 2008 2009 2010 2011 2012 2013 2014 2015 2016
n N n N n N n N n N n N n N n N n N n N
23–27  8  64,167  13  64,173  18  64,282  13  64,534  16  62,391  10  61,958  10  59,458  8  59,292  8  59,081  6  59,668 
28–36  6  63,850  5  63,831  5  63,942  2  64,227  4  62,112  3  61,664  2  59,182  3  59,011  2  58,791  2  59,400 




2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 Chi-square 
test for 
trend (p)Rate Rate Rate Rate Rate Rate Rate Rate Rate Rate
23–27 0.12 0.20 0.28 0.20 0.26 0.16 0.17 0.13 0.14 0.10 0.11
28–36 0.09 0.08 0.08 0.03 0.06 0.05 0.03 0.05 0.03 0.03 0.065
≥37 0.42 0.35 0.37 0.27 0.16 0.21 0.05 0.18 0.31 0.22 0.0022
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Figure 4.16: Intrapartum stillbirth risk (per 1000 ongoing pregnancies) by gestation at birth (weeks) 

































23–27 28–36 ≥37 weeks
Small for gestational age infants
Figure 4.17: Perinatal related mortality rate by customised birthweight centile group among singleton 































Small for geatational age Appropriate for gestational age Large for gestational age
* MAT data numerator and denominator; limited to mothers who were registered for care with an LMC (either a midwife, obstetrician or GP) claiming from the 































Table 4.32: Perinatal related mortality rates by customised birthweight centile group among singleton births*from 26 weeks gestation without 
congenital anomalies 2008–2016 
* MAT data numerator and denominator; limited to mothers who were registered for care with an LMC (either a midwife, obstetrician or GP) claiming from the Section 88 Primary Maternity Services Notice.
This year denominator data are available for analysis of perinatal related mortality by customised birthweight centile at a population level. This 
analysis was limited to mothers who were registered for care with an LMC (a midwife, obstetrician or GP) claiming from the Section 88 Primary 
Maternity Services Notice, for whom maternal height, weight, and parity data are almost complete. The analysis was also limited to the years 
from 2008 as the variable denoting LMC was not reliable prior to 2008.
There has been a significant reduction in the proportion of babies born small for gestational age from 10.8 percent in 2008 to 10.4 percent in 
2016 (chi square test for trend p<0.0001) using the same customised birthweight centile calculator for all years (www.gestation.net). Over the 
same period, there has been an increase in the proportion of babies born appropriate for gestational age (p=0.001), and no change in babies 
born large for gestational age (p=1.0).
Figure 4.17 shows perinatal related mortality rates for small, appropriate, and large for gestational age babies under LMC care over time. It 
illustrates that the rate of death is significantly higher (approximately three times higher) for small for gestational age babies as measured by 
customised birthweight centiles compared to appropriately grown and large for gestational age babies. It also shows a reduction in perinatal 
related mortality among small for gestational age babies from 2008 to 2016, which is statistically significant (score test for trend p=0.046). 
There may be a small reduction in perinatal related mortality rate for appropriate and large for gestational age babies but this is not statistically 
significant. 
Figure 4.18 shows that the lowest perinatal related mortality rate by customised birthweight centile for babies born in New Zealand lies 




Small for gestational age Appropriate for gestational age Large for gestational age Unknown/missing data Total
N=44,709 n=409 N=344,359 n=858 N=56,848 n=175 N=22,478 n=97 N=468,394 n=1,539
N n Rate N n Rate N n Rate N n Rate N n Rate
2008  4,815  50  10.38  36,487  99  2.71  6,153  22  3.58  2,706  17  6.28  50,161  188  3.75 
2009  5,024  54  10.75  37,100  109  2.94  6,143  21  3.42  2,560  19  7.42  50,827  203  3.99 
2010  5,081  52  10.23  38,178  96  2.51  6,293  22  3.50  2,694  7  2.60  52,246  177  3.39 
2011  5,092  44  8.64  37,979  80  2.11  6,128  22  3.59  2,756  13  4.72  51,955  159  3.06 
2012  5,039  44  8.73  39,203  96  2.45  6,535  12  1.84  2,240  6  2.68  53,017  158  2.98 
2013  4,893  42  8.58  37,994  87  2.29  6,193  23  3.71  2,361  7  2.96  51,441  159  3.09 
2014  4,954  44  8.88  38,667  93  2.41  6,377  15  2.35  2,259  5  2.21  52,257  157  3.00 
2015  4,867  43  8.84  39,195  102  2.60  6,376  19  2.98  2,482  7  2.82  52,920  171  3.23 

































Customised birthweight centile group
Figure 4.18: Perinatal related mortality rates (with 95% CIs) by customised birthweight centile group 
among singleton births from 26 weeks gestation without congenital anomalies 2008–2016*
* MAT data numerator and denominator; limited to mothers who were registered for care with an LMC (either a midwife, obstetrician or GP) claiming from the 
Section 88 Primary Maternity Services Notice.
Multiple birth 
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Neonatal deaths Perinatal related deathsTermination of 
pregnancy Stillbirths
n=72 n=319 n=244 n=635
n Rate n Rate n Rate n Rate
2007  2,011  3  1.49  34  16.91  25  12.66  62  30.83 
2008  1,924  3  1.56  33  17.15  18  9.53  54  28.07 
2009  1,849  5  2.70  32  17.31  31  17.11  68  36.78 
2010  1,906  9  4.72  35  18.36  35  18.80  79  41.45 
2011  1,827  18  9.85  48  26.27  27  15.33  93  50.90 
2012  1,804  14  7.76  34  18.85  32  18.22  80  44.35 
2013  1,743  8  4.59  40  22.95  16  9.44  64  36.72 
2014  1,727  10  5.79  34  19.69  40  23.77  84  48.64 
2015  1,667  2  1.20  29  17.40  20  12.22  51  30.59 
2016  1,633  3  1.84  33  20.21  11  6.89  47  28.78 
Chi-square test for trend 
(p) 0.45 0.36 0.76 0.48
The perinatal related mortality rate among multiple pregnancies in 2016 was not significantly different 
from the rate in 2007 (Figure 4.19; Table 4.33). However, multiple births as a proportion of all births 
reduced significantly from 3.1 percent in 2007 to 2.7 percent in 2016 (Chi square test for trend 
p=0.0002), which is likely to have had an impact on absolute numbers of multiple pregnancy perinatal 
related deaths.
Investigation of perinatal related deaths 
Table 4.34: Perinatal related deaths and completeness of perinatal death investigations 2016
* Optimum investigation is defined as post-mortem or karyotype confirming congenital anomaly or clinical examination/investigation confirming diagnosis. Note: 
More than one option can be selected.
# No post-mortem; investigations may have included placental pathology, MRI, ultrasound scan or x-ray.
+ Includes both placental histology with post-mortem and as part of partial investigation.
^ No post-mortem, placental pathology, MRI, ultrasound scan or x-ray.
Perinatal death investigation
Fetal deaths
Neonatal deaths Perinatal related deathsTermination of 
pregnancy Stillbirths
n=148 n=309 n=151 n=608
n % n % n % n %
Optimum investigation*  71  48.0  132  42.7  59  39.1  262  43.1 
Post-mortem  35  23.6  122  39.5  48  31.8  205  33.7 
Karyotype  35  23.6  17  5.5  9  6.0  61  10.0 
Clinical examination/investigations 
confirm diagnosis
4  2.7 7  2.3 2  1.3  13  2.1 
Partial investigations only #  65  43.9  132  42.7  68  45.0  265  43.6 
Placental pathology performed+  76  51.4  236  76.4  97  64.2  409  67.3 
No investigation +  11  7.4  42  13.6  23  15.2  76  12.5 
Unknown  1  0.7  3  1.0  1  0.7  5  0.8 
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Table 4.35: Perinatal related deaths and perinatal death investigations by ethnicity 2012–2016
* Optimum investigation is defined as post-mortem or karyotype confirming congenital anomaly or clinical examination/investigation confirming diagnosis. Note: More than one option can be selected.
# No post-mortem; investigations may have included placental pathology, MRI, ultrasound scan or x-ray.
+ No post-mortem, placental pathology, MRI, ultrasound scan or x-ray.
^ One unknown ethnicity
MELAA = Middle Eastern, Latin American or African.
Post-mortem examination offered





n=809 n=406 n=215 n=264 n=64 n=1,174 n=182 n=3,115
n % n % n % n % n % n % n % n %
Post-mortem offered and parental consent given  192  23.7  123  30.3  94  43.7  116  43.9  25  39.1  552  47.0  87  47.8  1,190  38.2 
Post-mortem offered and parents declined  550  68.0  250  61.6  111  51.6  127  48.1  31  48.4  540  46.0  77  42.3  1,686  54.1 
Post-mortem not offered  53  6.6  28  6.9  6  2.8  20  7.6  8  12.5  71  6.0  15  8.2  201  6.5 
Unknown  14  1.7  5  1.2  4  1.9  1  0.4  -  -  11  0.9  3  1.6  38  1.2 
Optimum investigation*  264  32.6  157  38.7  106  49.3  164  62.1  30  46.9  668  56.9  112  61.5  1,502  48.2 
Post-mortem  192  23.7  123  30.3  94  43.7  116  43.9  25  39.1  552  47.0  87  47.8  1,190  38.2 
Karyotype  52  6.4  26  6.4  13  6.0  45  17.0  5  7.8  125  10.6  22  12.1  288  9.2 
Clinical examination/investigations confirm 
diagnosis  37  4.6  16  3.9  4  1.9  14  5.3  1  1.6  56  4.8  8  4.4  136  4.4 
Partial investigations only#  360  44.5  194  47.8  94  43.7  90  34.1  29  45.3  433  36.9  56  30.8  1,256  40.3 
No investigation+  182  22.5  52  12.8  14  6.5  9  3.4  5  7.8  62  5.3  13  7.1  337  10.8 
Unknown  3  0.4  3  0.7  1  0.5  1  0.4  -  -  11  0.9  1  0.5  20  0.6 
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Perinatal death investigations, counsel and considerations
Authors Associate Professor Sue Crengle and Lisa Pakaru
The 12th PMMRC report found that, compared to other ethnic groupings, a smaller proportion of 
Māori and Pacific perinatal related deaths were investigated by post-mortem or investigated optimally 
(Table 4.35).
s The New Zealand Multicentre Stillbirth Study found the decision to decline a post-mortem 
(70/169, 41.4 percent) was more common among women of Māori and Pacific ethnicity 
compared to European. The main reason for declining was that women ‘did not want baby  
 to be cut’. Ten percent (7/70) who declined said they would not make this decision again.  
 No woman who consented regretted her decision (Cronin et al 2018).
s
With regard to Māori the Māori Affairs Select Committee report following their 
inquiry into whānau access to and management of tūpāpaku made a number of 
recommendations that are relevant to our work (Māori Affairs Select Committee  
 2017). These include the following applicable recommendations:
• that national standards are implemented across agencies (in this instance DHBs) to ensure that 
cultural needs are met 
• that a formal communication procedure be developed and implemented having regard for 
tikanga Māori and the expectations of non-Māori
• that cultural competency training is made mandatory so that effective counsel can be 
provided to whānau
• that mortuary infrastructure, staffing and other resources enable Māori to meet their cultural 
obligations and also ensure post-mortem can be completed without delay
• that cultural considerations can differ between whānau, iwi and hapū.
s From discussions with whānau involved in Sands and a number of   
 Māori hui, the key considerations of whānau are: 
• the need for Māori immediate whānau members to stay with the 
tūpāpaku from death to burial
• concerns about post-mortem and resulting report timeframes, which 
are dependent on multiple factors
• the transportation of babies, including being placed in the hold of a plane and passing over 
other tūpāpaku within the rohe 
• the need for karakia including a safe space for whānau to perform it 
• the return of all parts of the tūpāpaku so that the appropriate cultural process can be applied 
• what the tūpāpaku will look like when returned
• the need for staff engaging with whānau to have appropriate cultural competency training 
so that the option of post-mortem is understood, that equitable options and outcomes are 
provided and that the lens applied to any discussion is free of bias
• that there is a framework in place that is flexible enough to work within whānau, iwi and hapū 
cultural needs.
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Contributory factors and potentially avoidable perinatal related death
Table 4.36: Contributory factors and potentially avoidable perinatal related deaths 2016
Fetal deaths
Neonatal deaths Perinatal related deathsTermination of 
pregnancy Stillbirths
n=148 n=309 n=151 n=608
n % n % n % n %
Contributory factors
Present  14  9.5  89  28.8  67  44.4  170  28.0 
Absent  133  89.9  217  70.2  82  54.3  432  71.1 
Missing data  1  0.7  3  1.0  2  1.3  6  1.0 
Potentially avoidable
Yes  6  4.1  50  16.2  36  23.8  92  15.1 
Contributory factors present but 
not potentially avoidable  8  5.4  37  12.0  31  20.5  76  12.5 
Contributory factors present but 
avoidability unknown  -  -  1  0.3  -  -  1  0.2 
s A survey conducted with the PMMRC DHB local coordinators regarding transporting babies 
 for post-mortem confirmed that services remain inconsistent across DHBs in Aotearoa New  
 Zealand.
 To improve Māori participation in post-mortem, there is an immediate need for national   
 standards to be implemented across DHBs that ensure that cultural needs are met and that  
 whānau experience is consistent and appropriate.
 Requesting post-mortems from recently bereaved family may be challenging for some health  
 professionals, and this may be more so if the professional is aware that, for some Māori   
 whānau, post-mortems are not an acceptable practice. It is possible that this knowledge   
 affects the way health professionals discuss post-mortem with whānau and this, in turn, may  
 impact on consent rates for optimum and partial post-mortem investigation. 
s
Talking with health professionals about their experience of discussing post-mortem  
investigations with families/whānau would provide valuable information about this  
process, and whether there are differences in approaches across ethnic groupings.  
 Similarly, talking with Māori whānau who have experienced a death and listening   
 to their stories of being offered post-mortem might help to inform practice changes.
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Table 4.37: Detail of contributory factors among perinatal related deaths 2016
Contributory factors 2016
n %
Any contributory factor  170  28.0 
Organisational and/or management factors  30  4.1 
Poor organisational arrangements of staff  4 
Inadequate education and training  7 
Lack of policies, protocols or guidelines  3 
Inadequate numbers of staff  3 
Poor access to senior clinical staff  4 
Failure or delay in emergency response  3 
Delay in procedure (eg, caesarean section)  4 
Inadequate systems for sharing of clinical information  11 
Delayed access to test results or inaccurate results  2 
Equipment (eg, faulty equipment, inadequate maintenance, inadequate quality or lack of equipment)  2 
Building and design functionality (eg, space, privacy, ease of access, lighting, noise, power failure, operating 
theatre in distant location)
 2 
Other  8 
Not stated  3 
Personnel factors  51  7.0 
Knowledge and skills of staff were lacking  9 
Delayed emergency response by staff  5 
Failure to maintain competence  1 
Failure of communication between staff  10 
Failure to seek help/supervision  4 
Failure to offer or follow recommended best practice  29 
Lack of recognition of complexity or seriousness of condition by care giver  25 
Other  4 
Barriers to access and/or engagement with care  125  17.1 
No antenatal care  24 
Infrequent care or late booking  46 
Declined treatment or advice  30 
Obesity impacted on delivery of optimal care (eg, USS)  7 
Substance use  25 
Family violence  17 
Lack of recognition of complexity or seriousness of condition by the woman and/or family  35 
Maternal mental illness  8 
Cultural barriers  4 
Language barriers  6 
Not eligible to access free care  7 
Environment (eg, isolated, long transfer, weather prevented transport)  5 
Other  14 
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Figure 4.20: Main contributory factor(s) in potentially avoidable perinatal related deaths (as a 

























Perinatal death classification (PSANZ-PDC)
Organisation/management Personnel Barriers
Table 4.38: Main contributory factor(s) in potentially avoidable perinatal related death by perinatal 
death classification (PSANZ-PDC) 2012–2016









n n % 95% CI n % 95% CI n % 95% CI
Congenital abnormality  881  2  0.2 0.03–0.82  5  0.6 0.18–1.32  9  1.0 0.47–1.93
Perinatal infection  111  2  1.8 0.22–6.36  14  12.6 7.07–20.26  21  18.9 12.11–27.45
Hypertension  75  3  4.0 0.83–11.25  12  16.0 8.55–26.28  9  12.0 5.64–21.56
Antepartum haemorrhage  355  7  2.0 0.80–4.02  15  4.2 2.38–6.87  26  7.3 4.84–10.55
Maternal conditions*  175  9  5.1 2.38–9.54  19  10.9 6.66–16.43  61  34.9 27.82–42.41
Specific perinatal 
conditions
 331  10  3.0 1.46–5.49  18  5.4 3.25–8.46  17  5.1 3.02–8.10
Hypoxic peripartum 
death
 78  16  20.5 12.20–31.16  25  32.1 21.93–43.58  12  15.4 8.21–25.33
Fetal growth restriction  207  13  6.3 3.39–10.50  31  15.0 10.41–20.58  29  14.0 9.59–19.50
Spontaneous preterm  425  14  3.3 1.81–5.47  20  4.7 2.90–7.17  52  12.2 9.27–15.73
Unexplained antepartum 
death
 442  9  2.0 0.94–3.83  18  4.1 2.43–6.36  39  8.8 6.35–11.86
No obstetric antecedent  35  2  5.7 0.70–19.16  4  11.4 3.20–26.74  22  62.9 44.92–78.53
* Excludes two Specific contributory factor not identified.
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Figure 4.21: Main contributory factor(s) in potentially avoidable perinatal related deaths (as a 



























* Excludes two Specific contributory factor not identified.
MELAA = Middle Eastern, Latin American or African.
Table 4.39: Main contributory factor(s) in potentially avoidable perinatal related deaths by maternal 







n n % 95% CI n % 95% CI n % 95% CI
Māori*  809  19  2.3 1.42–3.64  45  5.6 4.09–7.37  141  17.4 14.88–20.22
Pacific peoples*  406  10  2.5 1.19–4.48  24  5.9 3.82–8.67  69  17.0 13.47–21.01
Indian  215  5  2.3 0.76–5.34  16  7.4 4.31–11.80  10  4.7 2.25–8.39
Other Asian  264  4  1.5 0.41–3.83  8  3.0 1.32–5.88  6  2.3 0.84–4.88
MELAA  64  3  4.7 0.98–13.09  8  12.5 5.55–23.15  1  1.6 0.04–8.40
NZ European  1,174  42  3.6 2.59–4.81  75  6.4 5.06–7.94  66  5.6 4.37–7.10
Other European  182  4  2.2 0.60–5.53  5  2.7 0.90–6.29  4  2.2 0.60–5.53
Unknown/Other  1  -  - -  -  - -  -  - -
MELAA = Middle Eastern, Latin American or African.
* Excludes two Specific contributory factor not identified.
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Figure 4.22: Main contributory factor(s) in potentially avoidable perinatal related deaths (as a 




























Table 4.40: Main contributory factor(s) in potentially avoidable perinatal related deaths by deprivation 








n n % 95% CI n % 95% CI n % 95% CI
1 (least deprived)  379  11  2.9 1.46–5.13  19  5.0 3.04–7.72  21  5.5 3.46–8.35
2*  417  12  2.9 1.50–4.97  14  3.4 1.85–5.57  19  4.6 2.77–7.02
3  536  20  3.7 2.29–5.70  37  6.9 4.91–9.39  33  6.2 4.28–8.54
4*  653  17  2.6 1.52–4.14  33  5.1 3.50–7.02  54  8.3 6.27–10.65
5 (most deprived)  1,116  25  2.2 1.45–3.29  78  7.0 5.56–8.65  166  14.9 12.84–17.10
Unknown  14  2  14.3 -  -  - -  4  28.6 -
* Excludes two Specific contributory factor not identified.
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Table 4.41: Perinatal related death and perinatal death classification (PSANZ-PDC) 2007–2016
Perinatal death classification (PSANZ-PDC)
2007–2015 2016
n=5,415 n=608
n % n %
Congenital abnormality
1.1 Central nervous system  313  5.8  26  4.3 
1.2 Cardiovascular system  200  3.7  28  4.6 
1.3 Urinary system  102  1.9  12  2.0 
1.4 Gastrointestinal system  33  0.6  2  0.3 
1.5 Chromosomal  470  8.7  60  9.9 
1.6 Metabolic  20  0.4  1  0.2 
1.7 Multiple/Non-chromosomal syndromes  188  3.5  22  3.6 
1.8 Other congenital abnormality
1.81 Musculoskeletal  73  1.3  12  2.0 
1.82 Respiratory  6  0.1  1  0.2 
1.83 Diaphragmatic hernia  40  0.7  3  0.5 
1.84 Haematological  8  0.1  -  - 
1.85 Tumours  18  0.3  1  0.2 
1.88 Other specified congenital abnormality  31  0.6  2  0.3 
1.9 Unspecified congenital abnormality  26  0.5  3  0.5 
Perinatal infection
2.1 Bacterial
2.11 Group B Streptococcus  41  0.8  8  1.3 
2.12 E. coli  19  0.4  2  0.3 
2.13 Listeria monocytogenes  14  0.3  2  0.3 
2.14 Spirochaetal (eg, syphilis)  1  0.0  1  0.2 
2.18 Other bacterial  22  0.4  5  0.8 
2.19 Unspecified bacterial  16  0.3  6  1.0 
2.2 Viral
2.21 Cytomegalovirus  30  0.6  1  0.2 
2.22 Parvovirus  12  0.2  -  - 
2.23 Herpes simplex virus  8  0.1  -  - 
2.28 Other viral  1  0.0  -  - 
2.29 Unspecified viral  3  0.1  -  - 
2.3 Protozoal (eg, Toxoplasma)  11  0.2  -  - 
2.5 Fungal  1  0.0  -  - 
2.8 Other specified organism  1  0.0  -  - 
2.9 Other unspecified organism  14  0.3  1  0.2 
Hypertension
3.1 Chronic hypertension: essential  15  0.3  1  0.2 
3.2 Chronic hypertension: secondary, (eg, renal disease)  6  0.1  -  - 
3.3 Chronic hypertension: unspecified  6  0.1  -  - 
3.4 Gestational hypertension  14  0.3  1  0.2 
3.5 Pre-eclampsia  88  1.6  5  0.8 
3.51 Pre-eclampsia: With laboratory evidence of thrombophilia  4  0.1  2  0.3 
3.6 Pre-eclampsia superimposed on chronic hypertension  23  0.4  -  - 
3.61 Pre-eclampsia superimposed on chronic hypertension: With laboratory 
evidence of thrombophilia
 3  0.1  -  - 
3.9 Unspecified hypertension  4  0.1  -  - 
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Antepartum haemorrhage (APH)
4.1 Placental abruption  286  5.3  25  4.1 
4.11 Placental abruption: With laboratory evidence of thrombophilia  20  0.4  1  0.2 
4.2 Placenta praevia  15  0.3  2  0.3 
4.3 Vasa praevia  4  0.1  -  - 
4.8 Other APH  88  1.6  13  2.1 
4.9 APH of undetermined origin  156  2.9  31  5.1 
Maternal conditions
5.1 Termination of pregnancy for maternal psychosocial indications  28  0.5  8  1.3 
5.2 Diabetes/Gestational diabetes  101  1.9  12  2.0 
5.3 Maternal injury  1  0.0  -  - 
5.31 Maternal injury: Accidental  13  0.2  7  1.2 
5.32 Maternal injury: Non-accidental  8  0.1  -  - 
5.4 Maternal sepsis  14  0.3  6  1.0 
5.5 Antiphospholipid syndrome  25  0.5  -  - 
5.51 Other maternal thrombophilia (if considered cause of death)  3  0.1  -  - 
5.6 Obstetric cholestasis  1  0.0  1  0.2 
5.8 Other specified maternal conditions  61  1.1  3  0.5 
Specific perinatal conditions
6.1 Twin–twin transfusion  163  3.0  18  3.0 
6.2 Fetomaternal haemorrhage  58  1.1  6  1.0 
6.3 Antepartum cord complications (eg, cord haemorrhage; true knot with 
evidence of occlusion)
 27  0.5  -  - 
6.31 Cord haemorrhage  9  0.2  1  0.2 
6.32 True knot with evidence of occlusion  17  0.3  5  0.8 
6.38 Other  53  1.0  8  1.3 
6.4 Uterine abnormalities, eg, bicornuate uterus, cervical incompetence  97  1.8  14  2.3 
6.5 Birth trauma (typically infants of >24 weeks gestation or >600g birthweight)  1  0.0  -  - 
6.6 Alloimmune disease
6.61 Alloimmune disease: Rhesus  2  0.0  -  - 
6.64 Alloimmune disease: Alloimmune thrombocytopenia  6  0.1  1  0.2 
6.68 Alloimmune disease: Other  -  -  1  0.2 
6.7 Idiopathic hydrops  26  0.5  3  0.5 
6.8 Other specific perinatal conditions (includes iatrogenic conditions such as 
rupture of membranes after amniocentesis, termination of pregnancy for 
suspected but unconfirmed congenital abnormality)
6.81 Rupture of membranes after amniocentesis  11  0.2  1  0.2 
6.82 Termination of pregnancy for suspected but unconfirmed congenital 
abnormality
 3  0.1  -  - 
6.83 Fetal subdural haematoma  5  0.1  2  0.3 
6.88 Other  69  1.3  9  1.5 
6.89 Unspecified  1  0.0  -  - 
Perinatal death classification (PSANZ-PDC)
2007–2015 2016
n=5,415 n=608
n % n %
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Hypoxic peripartum death
7.1 With intrapartum complications
7.11 With intrapartum complications: Uterine rupture  7  0.1  1  0.2 
7.12 With intrapartum complications: Cord prolapse  16  0.3  2  0.3 
7.13 With intrapartum complications: Shoulder dystocia  4  0.1  -  - 
7.18 With intrapartum complications: Other  24  0.4  1  0.2 
7.2 Evidence of non-reassuring fetal status in a normally grown infant (eg, 
abnormal fetal heart rate, fetal scalp ph/lactate, fetal pulse oximetry without 
intrapartum complications)
 84  1.6  8  1.3 
7.3 No intrapartum complications and no evidence of non-reassuring fetal status  12  0.2  1  0.2 
7.9 Unspecified hypoxic peripartum death  36  0.7  -  - 
Fetal growth restriction (FGR)
8.1 With evidence of reduced vascular perfusion on Doppler studies and/or 
placental histopathology (eg, significant infarction, acute atherosis, maternal 
and/or fetal vascular thrombosis or maternal floor infarction)
 248  4.6  25  4.1 
8.2 With chronic villitis  6  0.1  3  0.5 
8.3 No placental pathology  33  0.6  -  - 
8.4 No examination of placenta  23  0.4  3  0.5 
8.8 Other specified placental pathology  75  1.4  10  1.6 
8.9 Unspecified or not known whether placenta examined  3  0.1  -  - 
Spontaneous preterm
9.1 Spontaneous preterm with intact membranes, or membrane rupture <24 hours 
before delivery
9.11 Spontaneous preterm with intact membranes, or membrane rupture <24 hours 
before delivery: With chorioamnionitis
 187  3.5  20  3.3 
9.12 Spontaneous preterm with intact membranes, or membrane rupture <24 hours 
before delivery: Without chorioamnionitis
 96  1.8  1  0.2 
9.13 Spontaneous preterm with intact membranes, or membrane rupture <24 hours 
before delivery: No examination of placenta
 16  0.3  1  0.2 
9.17 No clinical signs of chorioamnionitis, no examination of placenta  85  1.6  15  2.5 
9.19 Spontaneous preterm with intact membranes, or membrane rupture <24 hours 
before delivery: Unspecified or not known whether placenta examined
 42  0.8  1  0.2 
9.2 Spontaneous preterm with membrane rupture ≥24 hours before delivery
9.21 Spontaneous preterm with membrane rupture ≥24 hours before delivery: With 
chorioamnionitis
 204  3.8  15  2.5 
9.22 Spontaneous preterm with membrane rupture ≥24 hours before delivery: 
Without chorioamnionitis
 25  0.5  2  0.3 
9.23 Spontaneous preterm with membrane rupture ≥24 hours before delivery: With 
clinical evidence of chorioamnionitis, no examination of placenta
 28  0.5  3  0.5 
9.27 No clinical signs of chorioamnionitis, no examination of placenta  37  0.7  7  1.2 
9.29 Spontaneous preterm with membrane rupture ≥24 hours before delivery: 
Unspecified or not known whether placenta examined
 14  0.3  1  0.2 
9.3 Spontaneous preterm with membrane rupture of unknown duration before 
delivery
9.31 Spontaneous preterm with membrane rupture of unknown duration before 
delivery: With chorioamnionitis
 17  0.3  4  0.7 
9.32 Spontaneous preterm with membrane rupture of unknown duration before 
delivery: Without chorioamnionitis
 9  0.2  -  - 
Perinatal death classification (PSANZ-PDC)
2007–2015 2016
n=5,415 n=608
n % n %
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9.33 Spontaneous preterm with membrane rupture of unknown duration before 
delivery: With clinical evidence of chorioamnionitis, no examination of 
placenta
 4  0.1  -  - 
9.37 No clinical signs of chorioamnionitis, no examination of placenta  6  0.1  1  0.2 
9.39 Spontaneous preterm with membrane rupture of unknown duration before 
delivery: Unspecified or not known whether placenta examined
 19  0.4  1  0.2 
Unexplained antepartum death
10.1 With evidence of reduced vascular perfusion on Doppler studies and/or 
placental histopathology (eg, significant infarction, acute atherosis, maternal 
and/or fetal vascular thrombosis or maternal floor infarction)
 93  1.7  6  1.0 
10.2 With chronic villitis  11  0.2  2  0.3 
10.3 No placental pathology  190  3.5  27  4.4 
10.4 No examination of placenta  138  2.5  13  2.1 
10.8 Other specified placental pathology  276  5.1  41  6.7 
10.9 Unspecified or not known whether placenta examined  22  0.4  1  0.2 
No obstetric antecedent
11.1 Sudden infant death syndrome (SIDS)
11.11 SIDS Category IA: Classic features of SIDS present, completely documented  1  0.0  -  - 
11.13 SIDS Category II: Infant deaths that meet Category I except for one or more 
features
 3  0.1  -  - 
11.2 Postnatally acquired infection  13  0.2  -  - 
11.3 Accidental asphyxiation  5  0.1  2  0.3 
11.4 Other accident, poisoning or violence (postnatal)  3  0.1  -  - 
11.8 Other specified  5  0.1  1  0.2 
11.9 Unknown/Undetermined  5  0.1  -  - 
11.91 Unclassified sudden infant death  32  0.6  3  0.5 
11.92 Other Unknown/Undetermined  1 0.0  -  - 
Perinatal death classification (PSANZ-PDC)
2007–2015 2016
n=5,415 n=608
n % n %
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5 New Zealand Maternal Mortality 2016
5.1 Maternal Mortality Key Findings
There has been a statistically significant reduction in maternal mortality in New Zealand from 2006 to 
2016 (chi-square test for trend p=0.026).
In this 12th report, the PMMRC has identified maternal suicide and care for women in early pregnancy 
with a pregnancy of unknown location as areas of focus.
In 2016 there were two maternal deaths in New Zealand meeting the definition for direct or indirect 
death during pregnancy or within 42 days of termination of pregnancy, and five coincidental deaths. 
The maternal mortality ratio (maternal deaths/100,000 births at 20 weeks or beyond) for the triennium 
2014–2016 was 9.42/100,000 (see Figure 5.1 and Figure 5.2). This is the lowest triennial ratio since 
the PMMRC started reporting in 2006.
In this report, New Zealand has adopted the World Health Organization (WHO) International 
Classification of Diseases – Maternal Mortality (ICD-MM) tenth revision (ICD-10) classification system. 
The most important change has been to include maternal suicide among direct maternal deaths. There 
have been only minor changes to the presentation of the remainder of the data to align with ICD-
MM (Table 5.1). The adoption of this classification highlights the importance of maternal suicide by 
acknowledging suicide as a direct cause of maternal death, and facilitates international comparison of 
data.
There were more deaths reported among Māori mothers in New Zealand from 2006 to 2016 than 
among any other ethnicity (Table 5.2). However, the data suggest that there has been a reduction in 
the inequity seen from 2006 to 2016. The Māori maternal mortality ratio in 2014–2016 is statistically 
significantly lower than in 2006–2008 (Table 5.3). 
Maternal suicide is the leading cause of maternal mortality in New Zealand. The rate of maternal 
suicide in New Zealand is seven times the rate in the United Kingdom. Māori women are over-
represented among maternal suicides. Between 2006 and 2016, 16 of the 28 women who died by 
suicide in pregnancy or within six weeks of pregnancy (57 percent) were Māori. Further review of 
Māori maternal suicide found that most of the women who died from suicide experienced multiple risk 
factors. Early recognition of these risk factors, particularly where there are multiple factors, will assist 
health services and professionals to provide better services for these women (PMMRC 2017).
Following review of maternal mortality, an emerging theme and practice point were identified to 
support consistency of approach amongst practitioners. The emerging theme relates to ectopic 
pregnancy (see “Ectopic pregnancy: Emerging themes in care of women with pregnancy of unknown 
location”), and the practice point integrates previously published practice points related to maternal 
suicide and psychosocial health (see “Practice point: Psychosocial health and maternal suicide”). An 
example of a maternal mental health birth plan is also provided. 
5.2 Maternal Mortality Recommendations
Maternal and Infant Mental Health Network 
The 10th PMMRC report recommended that a Maternal and Infant Mental Health Network be 
established to provide an interdisciplinary and national forum to discuss perinatal mental health issues 
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(PMMRC 2016). This work has progressed to development of service specifications for the network. We 
strongly reiterate the previous recommendation:
1. The PMMRC recommends that a Maternal and Infant Mental Health Network is funded by the 
Ministry of Health; and that the network then determine an achievable work stream by the end 
of 2018, detailing work to be completed by the end of 2020, to include as potential areas of 
priority: 
a. a stocktake of current mental health services available across New Zealand for pregnant and 
recently pregnant women to identify both the strengths of services and gaps or inequity in 
current services and skills in the workforce 
b. a national pathway for accessing maternal mental health services, including: 
 i.  cultural appropriateness to ensure equity of service access and provision
 ii. appropriate screening
 iii. care for women with a history of mental illness
 iv. communication and coordination.
Justification
This recommendation highlights and supports a Healthy Beginnings 2012 recommendation (Ministry of 
Health 2012b). 
When women have maternal mental health concerns there may be multiple services involved – primary 
care, maternity, termination of pregnancy, general mental health, perinatal mental health, alcohol 
and other drugs, and social services. Communication, support and sharing information to ensure 
a consistent approach to care is important. Maternal mental health services need to be equitable, 
available and accessible across the country with consistent pathways for engagement.
Evidence
As a number of different agencies are involved in the provision of mental health care during the 
perinatal period, there is a need for a strategic approach to the planning of services, including the 
development of integrated care pathways within a stepped-care framework. This is in keeping with 
recommendations within the UK, including the National Institute for Health and Care Excellence (NICE) 
guidelines on antenatal and postnatal mental health (NICE 2014), which recommend the establishment 
of perinatal mental health clinical networks of perinatal clinicians and resources and other stakeholders, 
including service users, and the Scottish Intercollegiate Guidelines Network (SIGN) guidelines on the 
management of perinatal mood disorders (SIGN 2012). 
The 2008 Ministry of Health guideline about management of depression in primary care describes the 
evidence around screening for depression (New Zealand Guidelines Group 2008). 
Information on the establishment of a perinatal mental health network in the UK is described in a 
summary entitled Joining Up Care in Maternal Mental Health: Setting Up a Perinatal Mental Health 
Network (Royal College of Obstetricians and Gynaecologists 2016).
The cost to the public sector of perinatal mental health problems is five times the cost of improving 
services; 72 percent of these costs relate to the care of the child. Even a relatively modest improvement 
in outcomes as a result of better services would be sufficient to justify the additional spending to 
establish a Maternal and Infant Mental Health Network (Bauer et al 2014).
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5.3 Methodology
The methodology for the maternal mortality report is included with the ‘Methodology and Definitions 
for PMMRC Reporting’ document on the PMMRC website (www.hqsc.govt.nz/our-programmes/mrc/
pmmrc/publications-and-resources/publication/3367/).
This report classifies suicide as a direct cause of death in keeping with the ICD-10 Maternal Mortality 
classification, which is used internationally. This is a change to previous reports where suicide was 
classified as an indirect cause. The change has been applied retrospectively to all deaths from 2006 to 
2016.
It is difficult to classify suicide as either direct or indirect as it represents a very mixed group of clinical 
histories. Some suicides can be considered direct (eg, as in the case of a postpartum psychosis in 
a previously well woman), but others can be indirect (eg, in the case of a woman with a previous 
history of mental illness/substance abuse and with multiple stressors). Separating suicides into direct or 
indirect, however, is often complicated; the required information is often missing, which is likely to lead 
to inaccurate classification. This resulted in a pragmatic approach in the past, grouping all suicides 
under indirect (pregnancy/childbirth is considered to have aggravated an underlying condition) by 
many national perinatal and maternal mortality review groups, including the New Zealand PMMRC.
The change in classification of suicides to direct (ie, a consequence of pregnancy/childbirth) follows 
the introduction of ICD-10 categories of maternal death in 2012 (WHO 2012). This is an international 
classification system, which most reporting countries will use. The Mothers and Babies: Reducing Risk 
through Audits and Confidential Enquiries across the UK (MBRRACE-UK) 2016 report presented suicides 
as both direct and indirect for comparability (Knight et al 2016).
It is important to point out that reporting suicide as direct will increase the apparent direct maternal 
mortality ratio in New Zealand, but without any change to the underlying number of deaths. However, 
by reclassifying suicide as direct, we will be consistent with other countries, and thus be able to directly 
compare data. Most importantly, the reclassification of suicide will raise awareness of suicide within 
New Zealand and internationally.
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5.4 Findings
MMR = maternal mortality ratio.
Three-year rolling MMR represented at final year of triennium.



































MMR: MDAC* MMR: routine sources^ MMR: PMMRC⁺
MMR = maternal mortality ratio.
MDAC = Maternal Deaths Assessment Committee.
* Data from the MDAC, including maternal deaths to three months postpartum.
^ Data from routine New Zealand datasets (ie, the Births, Deaths and Marriages (BDM) Mortality Collection and the National Minimum Dataset), including 
maternal deaths to six weeks postpartum.































Table 5.1: Maternal mortality ratios (per 100,000 maternities) and cause of maternal death 2006–2016
2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2006–2016 2006–2016
n=107 Cause specific ratio
n n n n n n n n n n n n % /100,000 maternities
Maternities  61,484  65,202  65,624  65,198  65,445  63,236  63,274  60,133  60,073  59,768  60,576  -  - 
Direct maternal death  10  5  7  8  5  4  5  8  2  8  1  63  58.9  9.13 
Pregnancies with abortive outcome  -  1  -  -  -  -  -  1  -  -  -  2  1.9  0.29 
Hypertensive disorders  -  2  1  1  -  -  -  -  -  -  -  4  3.7  0.58 
  Obstetric haemorrhage  1  -  1  -  -  -  -  -  1  -  -  3  2.8  0.43 
  Pregnancy-related infection  2  -  -  -  -  1  1  2  -  -  -  6  5.6  0.87 
  Other obstetric complications
  Amniotic fluid embolism  3  -  1  4  1  -  1  2  -  1  -  13  12.1  1.88 
  Venous thrombo-embolism  -  1  1*  -  -  1  -  -  1  2  -  6  5.6  0.87 
  Suicide  4  -  3  3  4  2  3  3  -  5  1  28  26.2  4.06 
  Other#  -  1  -  -  -  -  -  -  -  -  -  1  0.9  0.14 
Indirect maternal death  4  5  2  6  4  4  5  4  1  3  1  39  36.4  5.65 
Cardiac  2  1  1  -  1  1  4  -  -  -  -  10  9.3  1.45 
Neurological  1  1  -  1  1  2  1  2  -  1  1  11  10.3  1.59 
Infections not a direct result of 
pregnancy
 -  1  -  5  1  -  -  1  -  -  -  8  7.5  1.16 
  Other non-obstetric complications+  1  2  1  -  1  1  -  1  1  2  -  10  9.3  1.45 
Unknown/undetermined^  1  1  -  -  -  1  -  1  1  -  -  5  4.7  0.72 
Total maternal deaths  15  11  9  14  9  9  10  13  4  11  2  107  100.0  15.51 
Single-year MMR  24.40  16.87  13.71  21.47  13.75  14.23  15.80  21.62  6.66  18.40  3.30  -  -  - 
Three-year rolling MMR
 -  -  06-08  07-09  08-10  09-11  10-12  11-13  12-14  13-15  14-16  -  -  - 
 18.20  17.34  16.30  16.51  14.59  17.15  14.72  15.56  9.42  -  -  - 
Coincidental deaths  1  3  1  -  3  3  5  -  -  1  5  22  -  - 
* Pulmonary embolism and sepsis .
# Other direct includes cardiomyopathy.
+ Other non-obstetric complications include endocrine, respiratory, neoplasm, other pre-existing medical. 
^ Unknown/undetermined – 3 fully investigated, 2 no investigation.
MMR = maternal mortality ratio.
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Table 5.2: Demographic characteristics among maternal deaths 2006–2016
Maternities
Maternal deaths
2006 2007 2008 2009 2010 2011 2012 2013 2014 2015 2016 2006–2016
N=690,013 n=15 n=11 n=9 n=14 n=9 n=9 n=10 n=13 n=4 n=11 n=2 n=107 Maternal mortality ratio
95% CI
N % n n n n n n n n n n n n % /100,000 maternities
Maternal age (years)
  <20  44,351  6.4  -  -  1  1  1  1  2  -  -  -  -  6  5.6  13.53  4.96–29.45 
  20–24  123,400  17.9  3  2  -  -  -  1  3  3  -  1  1  14  13.1  11.35  6.20–19.04 
  25–29  175,341  25.4  3  1  3  4  3  3  1  5  2  2  -  27  25.2  15.40  10.15–22.40 
  30–34  198,585  28.8  2  5  3  4  1  1  2  3  -  4  1  26  24.3  13.09  8.55–19.18 
  35–39  119,822  17.4  4  2  2  3  2  2  2  -  1  3  -  21  19.6  17.53  10.85–26.79 
  ≥40  28,259  4.1  3  1  -  2  2  1  -  2  1  1  -  13  12.1  46.00  24.49–78.67 
  Unknown  255  0.0  -  -  -  -  -  -  -  -  -  -  -  -  -  -  - 
Ethnicity (prioritised)
Māori  175,729  25.5  9  2  4  4  3  5  8  4  -  3  1  43  40.2  24.47  17.71–32.96 
Pacific peoples  77,528  11.2  1  2  -  6  3  3  -  1  1  -  -  17  15.9  21.93  12.77–35.11 
Indian  26,006  3.8  1  1  -  1  -  -  -  -  -  -  -  3  2.8  11.54  2.38–33.71 
  Other Asian  58,144  8.4  -  -  2  1  -  -  -  2  -  1  -  6  5.6  10.32  3.79–22.46 
  MELAA  13,532  2.0  -  -  -  -  -  -  -  -  -  -  -  -  -  -  - 
  Other European  66,014  9.6  1  1  -  -  -  -  -  -  -  1  -  3  2.8  4.54  0.94–13.28 
  NZ European  272,556  39.5  3  5  3  2  3  1  2  6  3  6  1  35  32.7  12.84  8.94–17.86 
  Unknown/Other  504  0.1  -  -  -  -  -  -  -  -  -  -  -  -  -  -  - 
Deprivation quintile
  1 (least deprived)  96,667  14.0  1  2  1  2  3  -  -  1  -  1  -  11  10.3  11.38  5.68–20.36 
  2  104,606  15.2  1  1  1  1  -  1  2  2  2  -  -  11  10.3  10.52  5.25–18.82 
  3  125,187  18.1  4  1  2  2  -  4  1  3  2  3  1  23  21.5  18.37  11.65–27.57 
  4  159,133  23.1  3  3  2  4  3  -  3  4  -  4  -  26  24.3  16.34  10.67–23.94 
  5 (most deprived)  198,084  28.7  6  4  3  5  3  4  4  3  -  3  1  36  33.6  18.17  12.73–25.16 
  Unknown  6,336  0.9  -  -  -  -  -  -  -  -  -  -  -  -  -  -  - 
Parity
  0  *  *  2  4  5  1  3  1  4  3  2  3  1  29  27.1  *  * 
  1–3  *  *  7  4  3  8  4  5  5  7  2  7  1  53  49.5  *  * 
  4+  *  *  5  3  1  5  2  3  1  2  -  1  -  23  21.5  *  * 
Unknown  *  *  1  -  -  -  -  -  -  1  -  -  -  2  1.9  *  * 
* Parity denominator data unreliable.































Figure 5.3: Cause-specific maternal mortality ratios (per 100,000 maternities) in New Zealand 2010–2016 and the UK 2010–2015 (with 
95% CIs)
MMR = maternal mortality ratio.
AFE = amniotic fluid embolism.
VTE = venous thromboembolism.
‘Other direct’ includes cardiomyopathy.
‘Other indirect’ includes endocrine, respiratory, neoplasm, other pre-existing medical.
Coincidental includes motor vehicle accident, external causes of accidental injury, assault, malignancy not related to pregnancy.




































Cause of maternal death
NZ MMR 2010–2016 UK MMR 2010–2015
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Table 5.3: Maternal mortality ratios (per 100,000 maternities) by ethnicity (Māori and New Zealand 




2006–2008 49,930  15  30.04
2009–2011  50,096 12 23.95
2012–2014  45,713 12 26.25
2014–2016  44,624 4 8.96
New Zealand European
2006–2008  80,538 11  13.66
2009–2011  78,175 6 7.68
2012–2014  70,062 11  15.70
2014–2016  66,349 10  15.07
Emerging themes and practice points 
Ectopic pregnancy
Emerging themes in care of women with pregnancy of unknown location
Some women with ectopic pregnancy will not have typical symptoms or signs. 
A high index of suspicion should be maintained in early pregnancy if the location of the pregnancy has not been 
confirmed on scan, as rupture of an ectopic pregnancy can be associated with catastrophic internal bleeding and 
death.
Early pregnancy scans need to be interpreted with human chorionic gonadotropin (hCG) levels. These should be 
interpreted with the advice of the gynaecology service or based on gynaecology protocols. 
Timing of follow up and responsibility for follow up should be clearly planned and communicated. 
Collapse in a woman of reproductive age should include a differential diagnosis of ectopic pregnancy. 
Collapse due to ectopic pregnancy requires rapid assessment and surgical management, as delay increases the risk 































Practice point: Psychosocial health and maternal suicide
Pregnancy and the postpartum period are not protective against mental 
illness, and can be a trigger for onset and for deterioration of mental illness.
Suicide is a leading cause of maternal mortality, with Māori women and 
young women (<20 years old) over-represented among maternal suicides.
Psychosocial health screening
Early during a woman’s contact with health services, including request for 
termination of pregnancy, a comprehensive assessment of her psychosocial 
health and risk factors should be undertaken. This will involve identifying:
• her current social situation, including relationship with partner/
ex-partner, whānau supports, and social stressors such as financial 
issues, housing, whether their other children are in care of other 
people, and phone and transport availability
• any previous and current experience of family violence, sexual 
abuse and assault
• a history of termination of pregnancy or miscarriage in the previous 
12 months
• any past or present mental illness, including self-harm and previous 
suicide attempts, use of alcohol and other drugs
• any past or present treatment by a specialist mental health service, 
including in-patient care
• a family history of severe mental illness, including perinatal mental 
illness or suicide in a first degree relative.
Pregnant and postpartum women who use substances often have complex 
social and mental health needs, and face additional barriers in accessing 
services. 
Communication
All clinicians involved in a woman’s care need relevant mental health history 
and current knowledge of a woman’s pregnancy to support them to provide 
the best care. Routine sharing of relevant information across general practice, 
LMC and mental health service interfaces will enable better-informed care, 
and any concerns regarding risk need to be clearly communicated to all 
clinicians involved.
Care provision
Women who have a history of severe mental illness (eg, severe depression/
bipolar disorder/psychosis) should be referred to a secondary mental 
health service even if currently well, as their risk of relapse in the postpartum 
period may be high. They need an appropriate mental health birth plan and 
monitoring for the peripartum period, with advice around avoiding sleep 
deprivation. 
Mental health medications should not be stopped without review by a doctor 
and risk–benefit analysis. Consultation with a perinatal psychiatrist should be 
considered. 
Women should have continuity of, and culturally appropriate, mental health 
care. During pregnancy and the postpartum period there may be more 
than one mental health team involved – in such cases there should be one 
identified individual who coordinates care.
Doctors who refer women for termination of pregnancy should actively follow 
up these women to ensure they have their free post-termination of pregnancy 
check, which should specifically include assessment of mental health status. 
Acute mental health episodes
Any of the following identified at any time suggests a serious mental illness 
and requires urgent (same day) assessment by mental health services, 
including early consultant psychiatrist review and consultation with perinatal 
mental health services:
• suicidal ideation (new or increasing thoughts) and/or thoughts to 
harm baby or others
• suicide attempts 
• psychotic symptoms
• recent significant change in mental state including fluctuating or 
emergence of new symptoms
• pervasive guilt or hopelessness
• ongoing beliefs of inadequacy as a mother
• a sense of estrangement or disconnection from the infant.
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Maternal Mental Health Birth Plan (example) 
MATERNAL MENTAL HEALTH PRE-BIRTH PLAN FOR:
Name: ___________ NHI: ________ EDD: ____/____/____ Date: ____/____/____
KEY CONTACTS: (List all including contacts details for mental health professionals)
Name:      Phone: 
BACKGROUND INFORMATION AND RATIONALE FOR PRE-BIRTH PLAN:
Brief social and psychiatric history. Risk of postpartum psychosis.
AREAS OF CONCERN: 
Mental Health 
Current mental health and what care has been provided. Current medications, planned changes, and safety in 
pregnancy and breastfeeding.
Alcohol and Other Drugs 
Current and previous use.
Medical
Current medical conditions (non-mental health). 
Social Situation
Family support – partner, extended family. Child protection services involvement, family violence.
Neonatal 
Any additional monitoring or neonatal input that may be recommended.
PRE-BIRTH PLAN
ANTENATAL:
Details of antenatal care and secondary consultations.
Details of psychiatric care.
LABOUR/BIRTH:
Support persons during labour (who will be present).
Details of preferences for labour and birth. Use of PRN medications.
Any history of trauma. Previous birth experiences.
POSTPARTUM – HOSPITAL:
Consider single room/support person staying.
Preference to breastfeed/bottle feed. 
Extended admission for additional support, monitoring of mental health, and establishment of breastfeeding. 
POSTPARTUM – COMMUNITY:
Support and follow-up.
In the event that (Name) becomes unable to care for herself or her baby, the following things are to 
occur:
Signs and symptoms that (Name) is becoming unwell:
Things that (Name) can do to remain well:
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Appendix A: Summary of Key PMMRC Recommendations 
and Progress 2006–2014 Data
Recommendation PMMRC 1st – 10th reports Progress to date (2018)
Perinatal mortality
Methodology
That the Perinatal Society of Australia and New Zealand perinatal 
death classification (PSANZ-PDC) system be modified to allow the 
classification of babies dying with placental pathology outside of 
unexplained antepartum death.
Update 2018
The revision of the PSANZ-PDC system is complete. Improvements 
allow for the identification of babies dying with significant placental 
pathology.
The new version has been used for the classification of cause of 
perinatal death as of 1 January 2018.
These can be found at: https://sanda.psanz.com.au/assets/Uploads/
Section-7-PSANZ-Classification-of-perinatal-deaths-V3-23032018.pdf.
Ethnicity
Clinicians and LMCs should be encouraged to collect accurate 
ethnicity details at the time of booking. 
The Primary Care Ethnicity Data Audit Toolkit has been produced 
and was implemented June 2015. See http://www.health.govt.nz/
publication/primary-care-ethnicity-data-audit-toolkit.
Update 2017
The Maternity Clinical Information System was intended to assist 
clinicians and LMCs to collect accurate standardised data, including 
ethnicity. The roll out of the Maternity Clinical Information System 
in DHBs has been problematic. A governance group is considering 
what shape this will take in the future.
Disparities
There is a need to recognise the independent impact of 
socioeconomic deprivation on perinatal death, specifically 
on preterm birth, which after congenital anomaly is the 
leading cause of perinatal death. Addressing the impact 
of poverty requires wider societal commitment as has been 
highlighted in the recent health select committee report on 
improving child health outcomes. The PMMRC supports the 
implementation of the recommendations. This report can be 
found at: http://www.parliament.nz/resource/en-nz/50DBSCH_
SCR6007_1/3fe7522067fdab6c601fb31fe0fd24eb6befae4a.
There are a number of cross-agency initiatives that are underway to 
respond to, and reduce, the impact of socioeconomic deprivation on 
perinatal death and child health. These include: 
• The Healthy Families New Zealand Initiative. See http://
www.health.govt.nz/our-work/preventative-health-wellness/
healthy-families-nz 
• The Child Poverty Monitor. This was first published in 2013 
and provides data on a set of indicators that assess aspects 
of child poverty in New Zealand and their implications 
for child wellbeing. It is supported by the Office of the 
Children’s Commissioner, Child and Youth Epidemiology 
Service (University of Otago), and the JR McKenzie Trust. 
See http://www.nzchildren.co.nz/
• The Vulnerable Children Act 2014. On 1 July 2014 the 
Vulnerable Children Act was passed into law. The Act is a 
significant part of a range of comprehensive measures to 
protect and improve the wellbeing of vulnerable children 
and strengthen the child protection system. The chief 
executives of five government agencies are accountable for 
acting together to develop and implement a plan to protect 
our children from harm, working with families, whānau and 
communities.
• The Children’s Action Plan. The Children’s Action Plan 
operationalises the Vulnerable Children Act. Children’s 
teams have been set up across the country to work with 
vulnerable children, and across a range of local iwi and 
Māori, health, education, welfare and social organisations.
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Recommendation PMMRC 1st – 9th reports Progress to date (June 2017)
• Social Sector Trials. These have been established to test 
innovative ideas to improve social, health and educational 
outcomes in communities around New Zealand. One of the 
trials has a specific health focus. See http://www.health.
govt.nz/our-work/preventative-health-wellness/social-sector-
trials 
• Well Child/Tamariki Ora. The Ministry of Health is 
investigating how to more effectively integrate the Well 
Child/Tamariki Ora programme and GP practice services 
to be more attractive and responsive to women and families 
who are socially deprived or have socially complex needs.
Possible causes for the increase in perinatal related death of babies 
born to Pacific women, Māori women, women under the age of 
20 or over the age of 40 and women who live in areas of high 
socioeconomic deprivation should be researched. This information 
is necessary in order to develop appropriate strategies to reduce 
these possibly preventable deaths.
The Ministry of Health expects that perinatal mortality will be 
annually reviewed as part of the local maternity quality and safety 
programmes. Findings from the review process will assist DHBs and 
the wider maternity sector to identify and address local issues and 
risk factors.
Further research is warranted to understand the higher rate of 
perinatal related mortality in the Counties Manukau region.
An independent review of perinatal mortality in their region was 
commissioned by Counties Manukau DHB in late 2012. The 
recommendations from this review are being implemented in an 





The Ministry of Health, DHBs and professional colleges should 
collaboratively explore barriers to early booking with a view to 
increase the number of women who book with an LMC before 10 
weeks gestation. A national media campaign should be considered.
All DHBs are aware of the need to take actions that will increase the 
number of women who book before 10 weeks gestation. Barriers to 
early booking are being investigated and actions will be embedded 
in each respective DHB Maternal Quality and Safety Programme. 
Many DHBs are promoting media and social media campaigns 
such as the ‘Find Your Midwife’ website, which supports women 
to find and book with an LMC. See the following website for more 
information: www.findyourmidwife.co.nz.
The regional programme ‘5 Things to Do in the First 10 Weeks’ 
has been effective and widely supported. Key messages from this 
campaign are to: 
• engage early with an LMC 
• take folic acid and iodine
• make decisions about screening tests
• eat well and be active 
• avoid alcohol, recreational drugs and smoking.
The Ministry of Health advises that media campaigns and initiatives 
should be targeted at local level for best results.
Strategies to improve awareness of antenatal care services and 
increase access among women who are isolated for social, cultural 
or language reasons should be developed.
Some initiatives have been developed to improve access to 
antenatal care services for women who are isolated for social, 
cultural or language reasons. These include:
• The Language Line. See http://ethniccommunities.govt.nz/
story/using-language-line
• The TAHA Well Pacific Mother & Infant Service, which 
launched a smart phone application that provides 
information on pregnancy and parenting. See www.
tapuaki.org.nz.
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Recommendation PMMRC 1st – 9th reports Progress to date (June 2017)
Perinatal mortality
That all maternity care providers identify women with modifiable 
risk factors for perinatal related death and work individually and 
collectively to address these.
Strategies to address modifiable risk factors include:
a. improving uptake of periconceptual folate
b. pre-pregnancy care for known medical disease such as 
diabetes
c. access to antenatal care
d. accurate height and weight measurement in pregnancy 
with advice on ideal weight gain
e. prevention and appropriate management of multiple 
pregnancy
f. smoking cessation
g. antenatal recognition and management of fetal growth 
restriction
h. prevention of preterm birth and management of threatened 
preterm labour
i. following evidence-based recommendations for indications 
for induction of labour
j. advice to women and appropriate management of 
decreased fetal movements.
All DHBs should report the availability and uptake of relevant 
services in their annual clinical report to ensure that these strategies 
are embedded and to identify areas for improvements.
DHBs are implementing strategies to address modifiable risk factors, 
and the Ministry of Health will also require DHBs to report on these 
strategies in their annual Maternity Quality and Safety Programme 
reports.
DHB strategies include early screening and encouraging women to: 
• engage early with an LMC 
• take folic acid and iodine 
• eat well and be active 
• avoid alcohol, recreational drugs and smoking.
Examples of DHB programmes include ‘5 Things to Do in the First 10 
Weeks’ and ‘As Soon As Pregnant (ASAP)’, which both promote the 
importance of:
• booking with a midwife as soon as you are pregnant 
• avoiding smoking, alcohol and recreational drugs 
• taking folic acid and iodine
• making a decision about screening tests
• eating well and staying active.





The ‘Healthy Babies, Healthy Futures’ programme provides ethnically 
specific workshops, text messaging and support for new mothers, 
pregnant women and their families. See https://www.healthpoint.
co.nz/download,546672.do.
Some DHBs have established a GP liaison role within the hospital, 
which encourages pre-pregnancy and first trimester primary care. 
A pregnancy information pack has been developed to give to 
women at their first presentation to any health professional. This 
pack contains information about a wide variety of pregnancy issues, 
including folate, smoking, diet and immunisation. 
Offer education to all clinicians so they are proficient at screening 




c. alcohol and other substance use.
Family violence. All DHBs have measures in place for screening of 
family violence when women are admitted to hospital. They offer 
regular education sessions and training workshops to midwives and 
clinicians to help them identify, screen and refer women experiencing 
family violence. The shaken baby prevention programme has also 
been rolled out at a number of DHBs.
The Violence Inervention Programme supports health sector family 
violence programmes throughout New Zealand. See http://www.
health.govt.nz/our-work/preventative-health-wellness/family-violence.
The PMMRC will be collaborating with the Family Violence Death 
Review Committee to further identify strategies to improve screening 
for family violence in the maternity setting.
Smoking. Smoking cessation programmes are a national health 
priority. The Ministry of Health, DHBs and a wide range of non-
governmental organisations have made significant progress on 
leading New Zealand towards being smokefree by 2025. 






Alcohol and other substance use. DHBs offer regular education 
sessions and training workshops to midwives and clinicians to help 
them identify, screen and refer women with alcohol and substance 
use.
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Recommendation PMMRC 1st – 9th reports Progress to date (June 2017)
That multi-disciplinary fetal surveillance training be mandatory for 
all clinicians involved in intrapartum care.
a. This training includes risk assessment for mothers and 
babies throughout pregnancy as well as intrapartum 
observations.
b. The aims include strengthening of supervision and support 
to promote professional judgement, interdisciplinary 
conversations and reflective practice.
Some DHBs reported that mandatory attendance at multi-disciplinary 
fetal surveillance training was required for all core staff. Other DHBs 
have responded that multi-disciplinary fetal surveillance training is 
occurring but is not compulsory.
LMCs and obstetric staff are encouraged to attend/undertake the 
online programme or workshop.
Other initiatives include education meetings where cardiotocograph 
(CTG) recordings from emergency caesareans or abnormal CTGs 
are reviewed as part of reflective practice, and all staff who provide 
intrapartum care are encouraged to undertake a ‘fresh eyes’ 
approach to CTG interpretation.
There is observational evidence that improved detection of fetal 
growth restriction, accompanied by timely delivery, reduces 
perinatal morbidity and mortality. The PMMRC recommends 
(amended from previous PMMRC reports) that assessment of fetal 
growth should incorporate a range of strategies including:
a. assessment and appropriate referral for risk factors for fetal 
growth restriction at first antenatal visit and throughout 
pregnancy 
b. accurate measurement of maternal height and weight at first 
antenatal assessment
c. ongoing assessment of fetal growth by measuring fundal-
symphysial height in a standardised way, recorded at each 
antenatal appointment, preferably by the same person
d. plotting of fundal height on a tool for detection of fetal 
growth restriction, such as a customised growth chart, from 
26 weeks gestation
e. if fetal growth restriction is confirmed by ultrasound, 
appropriate referral and assessment of fetal and maternal 
wellbeing and timely delivery are recommended. The 
New Zealand Maternal Fetal Medicine guideline (2013) 
describes criteria for the management of small for 
gestational age (SGA) pregnancies after 34 weeks.
The PMMRC supports the Ministry of Health initiative to explore the 
evidence and validate the use of customised growth charts in New 
Zealand, and to investigate the appropriate way to incorporate 
these into the national maternity record.
Update 2017
The Growth Assessment Protocol (GAP) (based on GROW) from the 
UK Perinatal Institute is being progressed. The Perinatal Institute is 
making the GAP application freely available to clinicians; however, 
they need to be trained and accredited to use it. 
The Ministry of Health is working on ensuring funding is also 
available for evaluation of the GAP. 
Public health initiatives
A high body mass index (BMI) at booking is an independent risk 
factor for stillbirth. Public health initiatives to prevent obesity prior to 
pregnancy should be supported.
From 2015, the Ministry of Health will report high maternal BMI 
as one of the New Zealand Maternity Clinical Indicators. This is 
expected to support DHBs and maternity services to plan for the 
care of obese pregnant women, as well as identify DHBs that should 
prioritise strategies that support healthy weight gain in pregnancy. 
Other initiatives that support this recommendation include:
• Eating for Healthy Pregnant Women/Ngā Kai Totika mā 
te Wahine Hapū. This is a public health resource and was 
updated in 2014. See https://www.healthed.govt.nz/
resource/eating-healthy-pregnant-womenng%C4%81-kai-
totika-m%C4%81-te-wahine-hap%C5%AB 
• A Ministry of Health web page provides information about 
healthy weight gain during pregnancy and provides links 
to helpful resources. See http://www.health.govt.nz/your-
health/healthy-living/pregnancy/healthy-weight-gain-during-
pregnancy
• The Healthy Families NZ initiative. This initiative encourages 
families to live healthy lives – by making good food choices, 
being physically active, sustaining a healthy weight, being 
smokefree and drinking alcohol only in moderation. It 
is funded by the Ministry of Health and commenced in 
September 2014. See http://www.health.govt.nz/our-
work/preventative-health-wellness/healthy-families-nz.
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• Investment in workforce development. In July 2013 the 
government announced it is investing $2.28 million in 
a new workforce development programme for health 
professionals who care for pregnant women and babies. 
The training programme will be implemented by Gravida 
and aims to give frontline health workers the latest evidence-
based research into how pregnancy and early life events 




In order to reduce perinatal related mortality associated with 
multiple pregnancies, the following is advised. 
a. All women undergoing assisted reproduction be offered 
single embryo transfer. 
b. The use of clomiphene for fertility treatment requires 
monitoring of hormonal response with ultrasound to 
determine the number of follicles. 
c. LMCs note that the referral guidelines recommend transfer 
of clinical responsibility for care of all women with multiple 
pregnancies to obstetrician-led care. 
The recommendations have been promoted through the Ministry of 
Health’s Maternity Quality and Safety Programme.
Clomiphene is being replaced with other medications such as 
letrozole, which has a much lower risk of multiple pregnancy.
The Guidelines for Consultation with Obstetric and Related Medical 
Services (Referral Guidelines) list multiple pregnancies as a reason 
for transfer of clinical responsibility with a clear pathway for 
determining a plan of care that may or may not involve the LMC.
Audit of congenital anomalies
All primary care providers (if first contact of a pregnant woman 
with the health service) should offer first trimester screening and 
facilitate expeditious registration.
The National Screening Unit offers online education for practitioners 
who provide services within the antenatal and newborn screening 
programmes. These can be accessed at: https://www.nsu.govt.nz/
health-professionals/antenatal-screening-down-syndrome-and-other-
conditions 
See ‘Practice Point: Antenatal Screening for Down Syndrome and 
Other Conditions’ (PMMRC 2016, p 57).
The importance of timely registration has been promoted through the 
National Maternity Monitoring Group (NMMG). The 2015 NMMG 
Annual Report can be accessed at: http://www.health.govt.nz/
publication/national-maternity-monitoring-group-annual-report-2015.
Achieving optimal use of periconceptual folate by young women in 
New Zealand requires a policy for fortification of bread.
The Ministry of Health advice to women planning to become 
pregnant is to take folic acid supplements and continue to do so 
when pregnant. There is voluntary fortification of bread by some 
manufacturers.
The National Screening Unit review the cost benefit of the current 
algorithms in the first and second trimester screening programme 
so they are calibrated for maximal sensitivity for all chromosomal 
abnormalities.
The National Screening Unit has commenced a project to provide 
feedback to radiology practitioners on the quality of nuchal 
translucency and crown rump length measurements. This project 
includes best practice guidelines for nuchal translucency and crown 
rump length measurements. Further information, including guidelines 
and videos, can be found at www.nsu.govt.nz. Further analysis is 
occurring on investigating new technology (non-invasive prenatal 
testing) to be included in publicly funded screening.
The National Screening Unit review false negative screening tests. The National Screening Unit is reviewing the cases not detected 
through screening (false negatives). This analysis includes a review 
of information provided for screening, including the completeness of 
information on request forms provided to the laboratory, the impact 
of changes to the measurements and any trends in demographic 
information of women.
The National Maternal Fetal Medicine Network regularly audit time 
from referral to review to ensure that the majority of women are 
seen within seven days as recommended.
The New Zealand Maternal Fetal Medicine Network completed an 
audit at Auckland DHB in 2015, which confirmed that almost all 
women who had their referral triaged for review in less than seven 
days were seen in this timeframe.
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Sudden unexpected death in infancy (SUDI)
National guidelines should be developed for safe sleeping 
arrangements in postnatal wards to improve ward safety and 
to model safe sleeping practices that parents can follow after 
discharge.
The Ministry of Health will be updating its publication Preventing 
Sudden Unexpected Death in Infancy in 2017. See http://www.
health.govt.nz/your-health/pregnancy-and-kids/first-year/helpful-
advice-during-first-year/safe-sleep.
The Ministry of Health has published guidance on observation of 
mother and baby in the immediate postpartum period in 2012. 
This guidance supports safe sleeping in postnatal wards: http://
www.health.govt.nz/publication/observation-mother-and-baby-
immediate-postnatal-period-consensus-statements-guiding-practice.
Guidance on safe sleeping and the Pēpi-pod Sleep Space 
Programme is also available on the Change for Our Children 
website. See http://www.changeforourchildren.co.nz/pepi_pod_
programme.
Access to perinatal investigation and supporting parents
The Ministry of Health should require DHBs to ensure all providers of 
maternity services provide support to parents, families and whānau 
who have experienced perinatal and maternal loss, including 
providing access to information, counselling and clinical follow-up.
The Ministry of Health requires DHBs to provide appropriate 
services to support parents, families and whānau who have 
experienced perinatal and maternal loss, including providing 
access to information for counselling and clinical follow-up. See 
http://www.nsfl.health.govt.nz/apps/nsfl.nsf/pagesmh/444.
The 2015 Survey of Bereaved Women found that 74 percent 
of women were satisfied or very satisfied with the care they 
received. Most women surveyed stated that they had received 
enough information, care and support. The full survey can be 
found at: https://www.health.govt.nz/system/files/documents/
publications/2015-survey-of-bereaved-women-sep15.pdf.
The low uptake of post-mortems amongst families who experience 
perinatal loss should be investigated.
The 2015 Survey of Bereaved Women looked at the information 
provided to women and their decisions about post-mortem 
examination.
The full report can be found at: https://www.health.govt.nz/
system/files/documents/publications/2015-survey-of-bereaved-
women-sep15.pdf.
The reasons for the difference in rates of optimally investigated 
perinatal deaths between DHBs needs investigation.
DHBs with post-mortem rates less than 50 percent were asked 
to provide a progress update on their implementation of this 
recommendation.
DHBs reported that geographical distances, the length of time 
families are separated from their babies, and family cultural beliefs 
can all be barriers to parents agreeing to a post-mortem.
Further information to help families and whānau who are trying to 





Improved communication between primary and secondary services 
is required. A variety of means should be used such as women-held 
maternity notes, integrated notes systems and electronic transfer of 
information.
Both the NMMG and the Maternity Quality and Safety Programme 
are working towards improved communication between primary 
and secondary services.
Update 2017
The Maternity Clinical Information System was intended to assist 
clinicians and LMCs to collect accurate standardised data. The roll 
out of the Maternity Clinical Information System in DHBs has been 
problematic. A governance group is considering what shape this 
will take in the future.
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Maternal mental health
Maternal mental health services should be integrated into maternity 
services.
Under the Ministry of Health’s Rising to the Challenge: Mental 
Health and Addiction Service Development Plan 2012–2017, the 
Ministry will work with providers to support service improvement 
and will report on implementation progress over the next five years. 
The Rising to the Challenge document is available online:
http://www.health.govt.nz/publication/rising-challenge-mental-
health-and-addiction-service-development-plan-2012-2017.
Access should be provided to a mother and baby unit in the North 
Island.
Following on from the Healthy Beginnings report, a three-bed 
mother-and-baby unit was opened in the Child and Family Unit in 
Starship Hospital in Auckland. This is a valuable resource in the 
treatment of acutely unwell mothers with their babies (Ministry of 
Health 2012b). 
Services have also been developed and extended across the 
continuum of care, including increased resourcing of community 
mental health perinatal services, and extension of respite and non-
governmental organisation services. This includes 24-hour perinatal 
phone advice for general mental health services managing acute 
presentations of mothers.
Termination of pregnancy services should undertake holistic 
screening for maternal mental health and family violence and 
provide appropriate support and referral.
The services providing termination of pregnancy to women advise 
that they comply with the Standards of Practice for the Provision 
of Counselling laid down by the Abortion Supervisory Committee. 
These are monitored as part of re-licensing. See http://www.
abortionservices.org.nz/docs/guides98.pdf.
It was noted that there were minimal opportunities in relation to 
training in the field of post-termination of pregnancy counselling 
practice.
Maternal mortality
Seasonal or pandemic influenza vaccination is recommended 
for all pregnant women regardless of gestation and for women 
planning to be pregnant during the influenza season.
a. Vaccination is also recommended for maternity care 
providers to reduce the risk to the women and babies 
under their care.
b. The PMMRC recommends that the Ministry of Health 
consult with women and maternity care providers to 
address barriers to the uptake of influenza vaccination in 
pregnancy and implement strategies to increase access to 
and awareness of the benefit of vaccination.
Immunisation against influenza is specifically promoted to pregnant 
women and available to all pregnant women free of charge.
The Ministry of Health immunisation team annually provides 
information and resources to clinicians and the public to support this 
recommendation. 
The Health Promotion Agency immunisation programme theme for 
2016 was Protecting Baby Begins at Pregnancy. Further information 
is available at: https://www.healthed.govt.nz/resource/protecting-
baby-starts-pregnancy.
A survey was recently conducted amongst pregnant women and 
women who had given birth in the last 12 months to understand 
their knowledge and attitudes towards influenza. The survey 
included attitudes to immunisation against influenza and whooping 
cough, and enablers and barriers to immunisation in pregnancy. 
See the following website for more information: http://www.health.
govt.nz/publication/immunisation-pregnant-women-audience-
research-pregnant-women.
A website has also been developed to help midwives, nurses and 
childbirth educators to quickly and easily find useful information 
and resources about immunisation in New Zealand. See http://
learnonline.health.nz/.
All pregnant women with epilepsy on medication should be 
referred to a physician.
a. Women with a new diagnosis of epilepsy or a change in 
seizure frequency should be referred urgently.
b. The PMMRC recommends a review of epilepsy in the 
Guidelines for Consultation with Obstetric and Related 
Medical Services (Referral Guidelines).
Update 2018
The Guidelines for Consultation with Obstetric and Related Medical 
Services (Referral Guidelines) (Ministry of Health 2012a) are under 
review. This work will include reviewing up-to-date evidence related 
to maternal epilepsy and will be completed by June 2019.
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Team approach to care
Women with complex medical conditions require a multidisciplinary 
approach to care, including a multidisciplinary management plan 
for the pregnancy, birth and postpartum period. This plan must be 
communicated to all relevant caregivers. Each woman requiring 
such care should be assigned a key clinician to facilitate her 
care. Pregnant women who are admitted to hospital for medical 
conditions not related to pregnancy need to have specific pathways 
for perinatal care.
The Ministry of Health expects maternity services (LMCs and DHBs) 
to ensure all women in New Zealand have access to continuity of 
maternity care, and for DHBs to ensure 95 percent of pregnant 
women in their region receive continuity of primary maternity care. 
As outlined in the New Zealand Maternity Standards, DHBs are 
also expected to provide or accommodate continuity of specialist 
secondary or tertiary care where possible. 
DHBs are required to staff appropriately under the primary, 
secondary and tertiary maternity facilities and services 
specifications.





Information about support for pregnant women and their babies 





Women who are unstable or clinically unwell should be cared for 
in the most appropriate place within each unit in order for close 
observation to occur. When observations are abnormal, clear 
documentation, early review by a senior clinician and development 
of a detailed management plan are required.
DHBs support this recommendation and advise that unstable or 
clinically unwell women are cared for in the most appropriate place 
within their hospital. They also indicated that detailed management 
plans are developed if observations are abnormal.
The Guidelines for Consultation with Obstetric and Related Medical 
Services (Referral Guidelines) were developed for LMCs and DHBs. 
The aim is to improve the safety and quality of maternity care and 
to ensure women are referred by their LMC to the most appropriate 
level of care for their particular condition.
Update 2018
The Guidelines for Consultation with Obstetric and Related Medical 
Services (Referral Guidelines) are under review. This work will be 
completed by June 2019.
Investigation of maternal deaths
In maternal deaths, where the coroner declines jurisdiction, a post-
mortem should be offered as part of full investigation of cause of 
death.
DHBs have advised that in cases of maternal death where the 
coroner declines jurisdiction, a post-mortem is offered as part of full 
investigation of cause of death.
Neonatal encephalopathy 
Widespread multidisciplinary education is required on the 
recognition of neonatal encephalopathy. This should include:
a. recognition of babies at increased risk by their history 
b. signs suggestive of encephalopathy
c. knowledge of clinical pathways to induced cooling if 
required.
Update 2018
The Accident Compensation Corporation (ACC) NE Taskforce has 
produced four national initiatives to look at reducing the incidence 
of neonatal encephalopathy. These are as follows:
• Fetal Growth Assessment Protocol (GAP)
• Fetal heart monitoring education
• Newborn observation chart and Newborn Early Warning 
Score (NEWS)
• Fetal cord blood lactate testing.
Working Groups have been established comprising relevant experts 
and representatives to deliver the projects. The NE Taskforce will be 
providing clinical governance for the implementation activities of 
the Working Groups.
See ‘Practice Point: Recognising the Baby at Risk of Neonatal 
Encephalopathy’ in the ninth report (PMMRC 2015, p 147).
PERINATAL AND MATERNAL MORTALITY REVIEW COMMITTEE: 12th ANNUAL REPORT 159
Recommendation PMMRC 1st – 9th reports Progress to date (June 2017)
That all DHBs review local incident cases of neonatal 
encephalopathy (Sarnat stages 2 and 3). 
The findings of these reviews should be shared at multidisciplinary 
local forum and form the basis of quality improvements as 
appropriate.
Most DHBs have advised they review local incident cases of 
neonatal encephalopathy, which are conducted at a multi-
disciplinary level to identify areas of learning and improvement. 
The Ministry of Health has advised the Maternity Quality and Safety 
Programme coordinators of this recommendation.
Local review at place of birth occurred in 63 percent of babies with 
NE born in 2016.
For more details, see “Local review of neonatal encephalopathy at 
place of birth 2016” on page 75. 
Strategies to reduce neonatal encephalopathy include continually 
improving the standard of neonatal resuscitation by all health 
professionals involved in providing peripartum care.
Neonatal resuscitation is an annual continuing education 
requirement for all midwives.
The New Zealand Resuscitation Council provides training for 
clinicians to deliver newborn life support courses in their region or 
organisations. See http://www.nzrc.org.nz/training/.
ACC has facilitated a cross-Ministry initiative to look at reducing the 
incidence of treatment injury by developing a strategy to address 
the issues raised by the NEWG.
Arterial and venous cord gas analysis should be performed on 
all babies born with an Apgar score <7 at one minute, and if 
neonatal encephalopathy is clinically suspected in the immediate 
hours after birth, early consultation with a neonatal paediatrician is 
recommended in order to avoid a delay in commencing cooling. 
The Ministry of Health expects this recommendation will become 
part of ongoing professional development and will be discussed and 
reported within each DHB maternity quality and safety programme. 
See “Management of Umbilical Cord Blood Results” on page 85.
In cases of neonatal encephalopathy (Sarnat stages 2 and 3): 
• all babies with encephalopathy should undergo 
investigation to predict prognosis, including formal 
neurological examination, cerebral magnetic 
resonance imaging (MRI) and, if available, formal 
electroencephalography (EEG)
• all parents of an affected child should have a formal 
discussion with the neonatologist/paediatrician providing 
care in order to review the prognosis and ongoing care of 
their child.
Most DHBs have advised that parents of babies with moderate or 
severe neonatal encephalopathy (Sarnat stages 2 and 3) have a 
formal discussion with the neonatologist/paediatrician providing 
care to review the prognosis and ongoing care of their child.
Update 2017 
All six Level 3 Neonatal Units advised that they use a formal tool 
to assist with the discharge examination for babies diagnosed with 
NE, either the Dubowitz examination or a modification of this. 
The practice was less consistent in the Level 2 Units. The barriers 
identified to the use of a formal tool included training in the use of 
the tool and interpretation of the findings given small numbers of 
babies diagnosed with NE in their DHBs.
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Perinatal mortality 
Birth information
Continued support and funding is required for DHBs and LMCs for 
collection of complete perinatal mortality statistics.
This recommendation has been integrated into core work by the 
Ministry of Health.
All babies, whether stillborn or live born, should be assigned a 
National Health Index (NHI) at the time of birth.
All DHBs are now issuing NHIs to stillborn babies at time of birth.
Early booking
All women should commence maternity care before 10 weeks. This 
enables:
• opportunity to offer screening for congenital abnormalities, 
sexually transmitted infections, family violence and maternal 
mental health, with referral as appropriate
• education around nutrition, smoking, alcohol and drug use 
and other at-risk behaviour
• recognition of underlying medical conditions, with referral 
to secondary care as appropriate
• identification of at-risk women (maternal age, obesity, 
maternal mental health problems, multiple pregnancy, 
socioeconomic deprivation, maternal medical conditions). 
This recommendation has been integrated into core work by the 
NMMG.
Teenage mothers (<20 years old)
LMCs should be aware that teenage mothers are at increased risk 
of stillbirth and neonatal death due to preterm birth, fetal growth 
restriction and perinatal infection. Maternity services need to 
address this risk, paying attention to: 
• maternity care before 10 weeks
• smoking cessation, prevention of preterm birth, screening 
for fetal growth restriction
• antenatal education
• undertaking research on the best model of care
• engagement with the Ministry of Education regarding 
education in the school setting.
This recommendation has been integrated into core work by the 
NMMG.
Disparities 
Clinicians and LMCs should be aware that Pacific women, Māori 
women, women under 20 or over 40 years of age, and those 
women who live in areas of high socioeconomic deprivation are at 
higher risk of a perinatal death.
The Ministry of Health expects that this awareness will be promoted 
within each DHB’s maternity quality and safety programme.
Contributory factors and potentially avoidable perinatal deaths
Key stakeholders providing health and social services to women at 
risk should work together and identify:
• reasons for barriers to accessing maternity care
• interventions to address barriers. 
Clinical services and clinicians have the following responsibilities: 
• continuing education
• local review linked to quality improvement
• up-to-date policies and guidelines that are implemented and 
audited
• culture of teamwork
• culture of practice reflection on patient outcomes linked to 
quality improvement 
• staff arrangements ensuring timely access to specialist 
services.
Ministry of Health to develop a plan to translate these 
recommendations into clinical practice.
This recommendation has been integrated into core work by the 
NMMG.
Previous PMMRC recommendations that have been implemented 
PERINATAL AND MATERNAL MORTALITY REVIEW COMMITTEE: 12th ANNUAL REPORT 161
Recommendation No further update
Antepartum haemorrhage
All women with bleeding during pregnancy, regardless of the 
apparent cause, should be monitored more closely for fetal growth 
and preterm birth.
This recommendation has been integrated into core work by the 
Ministry of Health.
Multiple pregnancies
All women with a multiple pregnancy should be offered an 
early specialist consultation, including ultrasound diagnosis of 
chorionicity prior to 14 weeks gestation. 
Women with high-risk monochorionic multiple pregnancies require 
fortnightly scans and specialist care.
This recommendation is promoted through the Ministry of Health’s 
Maternity Quality and Safety Programme. All DHBs recognise that 
monochorionic multiple pregnancies require early specialist care 
and are high risk. 
Advice is available through the New Zealand Maternal Fetal 
Medicine Network. See http://www.healthpoint.co.nz/public/new-
zealand-maternal-fetal-medicine-network/?solo=otherList&index=5.
Sudden unexpected death in infancy (SUDI) 
The Ministry of Health should prioritise the preparation and 
dissemination of a comprehensive statement for parents and 
caregivers on risk factors and methods of prevention of SUDI to be 
provided to pregnant women.




Support is required for national reporting of maternal deaths. The Ministry of Health funds DHBs in their reporting of mortality 
data and collection of complete perinatal mortality statistics.
Maternal mental health
Clinicians and LMCs should be encouraged to conduct antenatal 
screening and document any mental health history to identify 
women who are at increased risk of mental illness.
Midwives attend a mandatory Practice Day once every three years 
as part of the Midwifery Council’s Recertification Programme. One 
of the key topics included within the current Practice Day is maternal 
mental health. The focus of this education has been on the midwifery 
role of screening, identifying and referring women with mental 
health concerns. 
This recommendation has been revised and included in the practice 
point on maternal suicide: 
• Maternal mental health screening should be included as 
part of standard antenatal care.
See “Practice point: Psychosocial health and maternal suicide” on 
page 149.
Women with a previous history of serious affective disorder or 
other psychoses should be referred for psychiatric assessment and 
management even if well. 
Clinicians are reminded that the most common cause of maternal 
death in New Zealand is suicide.
This recommendation has been revised and included in the practice 
point on maternal suicide. 
• Maternal mental health screening should be included as 
part of standard antenatal care.
• Women with a previous history of serious affective disorder 
or other psychoses should be referred for psychiatric 
assessment and management even if they are currently well.
See “Practice point: Psychosocial health and maternal suicide” on 
page 149.
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The committee notes the publication of the Healthy Beginnings report 
in January 2012 and supports the recommendations with particular 
regard to the establishment of mother and baby units in the North 
Island and the importance of screening for a history of mental health 
disorders.
A comprehensive perinatal and infant mental health service 
includes:
• screening and assessment
• timely interventions including case management, transition 
planning and referrals 
• access to respite care and specialist inpatient care for 
mothers and babies 
• consultation and liaison services within the health system 
and with other agencies; for example, primary care and 
termination of pregnancy services. 
Midwives attend a mandatory Practice Day once every three years 
as part of the Midwifery Council’s Recertification Programme. 
One of the key topics included within the current Practice Day is 
maternal mental health. The focus of this education has been on the 
midwifery role of screening, identifying and referring women with 
mental health concerns. 
This recommendation has been revised and included in the practice 
point on maternal suicide: 
• Maternal mental health screening should be included as 
part of standard antenatal care.
See “Practice point: Psychosocial health and maternal suicide” on 
page 149.
Seatbelts during pregnancy
There is a need for greater public awareness of the importance 
of wearing a seatbelt during pregnancy. All pregnant women 
should know that three-point seatbelts should be worn throughout 
pregnancy, with the lap strap placed as low as possible beneath 
the ‘bump’, lying across the thighs, and the diagonal shoulder strap 
placed above the ‘bump’, lying between the breasts.




Health care practitioners should follow the evidence-based 
management of hypertension in pregnancy recommended by the 
Society of Obstetric Medicine of Australia and New Zealand.
This can be accessed at: https://somanz.org/documents/
HTPregnancyGuidelineJuly2014.pdf. 
The Ministry of Health is funding the development of a 
multidisciplinary clinical guideline for the treatment of hypertension 
in pregnancy. This was a recommendation from the NMMG.
Postpartum haemorrhage
Acute obstetric units should develop a massive transfusion protocol 
to respond to major obstetric haemorrhage.
A national guideline for the treatment of postpartum haemorrhage 
has been developed and distributed to professional colleges and 
DHBs. This can be accessed at: http://www.health.govt.nz/
publication/national-consensus-guideline-treatment-postpartum-
haemorrhage.
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ACC  Accident Compensation Corporation
aEEG  Amplitude-integrated electroencephalogram
AFE  Amniotic fluid embolism
AGA  Appropriate for gestational age
AGREE  Appraisal of Guidelines for Research and Evaluation 
AOR  Adjusted odds ratio
APH  Antepartum haemorrhage
BBA  Born before arrival
BDM  Births, Deaths and Marriages
BMI  Body mass index (kg/m2)
CI  Confidence interval
CTG  Cardiotocograph
CYMRC Child and Youth Mortality Review Committee
DHB  District health board
EEG  Electroencephalograph
FPA  Family Planning Association
GAP  Growth Assessment Protocol
GP  General practitioner
hCG  Human chorionic gonadotropin
HDC  Health and Disability Commissioner
HISO  Health Information Standards Organisation
ICD-10  ICD-MM tenth revision 
ICD-MM International Classification of Diseases – Maternal Mortality
IPPV  Intermittent positive pressure ventilation
LGA  Large for gestational age
LMC  Lead maternity carer
MAT  New Zealand National Maternity Collection
MBRRACE-UK Mothers and Babies: Reducing risk through audits and confidential enquiries across the  
  UK
MDAC  Maternal Deaths Assessment Committee
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MELAA  Middle Eastern, Latin American, or African
MMR  Maternal mortality ratio
MMRWG Maternal Mortality Review Working Group
MMWG Maternal Morbidity Working Group
MRI  Magnetic resonance imaging
NDC  Neonatal death classification
NE  Neonatal encephalopathy
NEWG  Neonatal Encephalopathy Working Group
NHI  National Health Index
NICE  National Institute for Health and Care Excellence
NMDS  National Minimum Dataset
NMMG  National Maternity Monitoring Group
NZDep  New Zealand Index of Deprivation 
OR  Odds ratio
PDC  Perinatal death classification
PMMRC Perinatal and Maternal Mortality Review Committee
PSANZ  Perinatal Society of Australia and New Zealand
PSANZ-NDC PSANZ neonatal death classification
PSANZ-PDC PSANZ perinatal death classification
RANZCOG Royal Australian and New Zealand College of Obstetricians and Gynaecologists
Sands  Stillbirth and Newborn Death Support
SB  Stillborn
SGA  Small for gestational age
SIDS  Sudden infant death syndrome
SIGN  Scottish Intercollegiate Guidelines Network
SUDI  Sudden unexpected death in infancy
TOP  Termination of pregnancy
UK  United Kingdom
USS  Ultrasound scan
VTE  Venous thromboembolism































Appendix D: Key datasets and definitions in the PMMRC 12th report
(for further information see ‘Methodology and Definitions for PMMRC Reporting’ document on the PMMRC website (www.hqsc.govt.nz/our-programmes/
mrc/pmmrc/publications-and-resources/publication/3367/)
Chapter Analyses Key definitions Numerator dataset Denominator dataset
3 Neonatal mortality special topic
5 Perinatal mortality
Deaths only (analyses without 
denominator)
PMMRC
Customised birthweight centile (gestation in days)
NA
4 Neonatal Encephalopathy Cases only PMMRC NA
6 Maternal mortality Deaths only PMMRC NA
RATES
3 Neonatal mortality special topic Neonatal mortality rate per 1000 live births
per 1000 ongoing pregnancies (in utero)
PMMRC MAT
5 Perinatal mortality Stillbirth rate;
Termination of pregnancy rate;
Perinatal related mortality rate
per 1000 total births
per 1000 ongoing pregnancies (in utero)
PMMRC MAT
4 Neonatal Encephalopathy NE rate per 1000 births
per 1000 term births (>=37 weeks gestation)
PMMRC MAT
6 Maternal mortality Maternal mortality ratio per 100,000 maternities (babies from 
20 weeks gestation or 400g if gestation 
unknown)
PMMRC MAT
3 Neonatal mortality special topic
4 Neonatal Encephalopathy
5 Perinatal mortalities
Analyses of data contained in MAT 
but not in PMMRC e.g. neonatal 
survival
MAT: Limited to PMMRC cases merged with MAT MAT
3 Neonatal mortality special topic
4 Neonatal Encephalopathy
5 Perinatal mortalities
Rates: parity, smoking, BMI, 
gestation at registration, customised 
birthweight centile
MAT: Limited to PMMRC cases merged with MAT and 
mothers who were registered for care with an LMC*
Gestation (in weeks) and birthweight for calculation of 
birthweight centile (PMMRC); all other variables MAT
MAT: Limited to mothers 
who were registered for 
care with an LMC*
Gestation (in weeks) 
from MAT
4 Neonatal Encephalopathy Rates: place of birth MAT: Limited to PMMRC cases merged with MAT MAT
MULTIVARIABLE ANALYSIS
3 Neonatal death special topic Multivariable analysis Limited to PMMRC cases merged with MAT; Limited 
to mothers who were registered for care with an LMC*
Gestation, birth weight, plurality, parity, baby sex from 
PMMRC
MAT: Limited to mothers 
who were registered for 
care with an LMC*
MAT=New Zealand Maternity Collection of births from 20 weeks gestation NA not applicable LMC lead maternity carer
* either a midwife, Obstetrician or GP claiming from the Section 88 Primary Maternity Services Notice; limited to births from 2008
